Transcriptional regulation of the mouse and human interleukin-5 genes in T-lymphocytes by Wang, Jun
TRANSCRIPTIONAL REGULATION OF THE MOUSE 
AND HUMAN INTERLEUKIN-5 GENES 
IN T-LYMPHOCYTES
By
Jun Wang
A thesis submitted for the degree of
Doctor of Philosophy
of
The Australian National Unoversity
Division of Biochemistry and Molecular Biology 
John Curtin School of Medical research 
The Australian National University
November 2001
STATEMENT
The research described in this thesis was solely and entirely conducted by the author 
unless specifically stated otherwise in the text.
Jurv Wang
November 2001
This work is dedicated to my parents who gave me great 
encouragement and support, especially to my mother who passed 
away during my PhD; also to my wife, Yafei, for her constant and 
unfailing support and to my son, Kevin, who despite his youth gave 
me great support.
ACKNOWLEDGEMENTS
I am most grateful to Professor Ian Young for his invaluable advice, encouragement 
and constant support throughout the course of my work.
I would like to thank Dr Francis Shannon and Dr David Tremethick for their advice 
and scientific discussions.
I am indebted to all members in the laboratory of Professor Ian Young for promoting 
a congenial atmosphere and for their assistance whenever it was needed.
I also thank all individuals in Biological and Chemical Services in John Curtin 
School of Medical Research.
ABSTRACT
The transient transfection systems were established in both mouse (D10W) 
and human (HSB-2) T cell lines, providing model systems for analysis of the 
molecular mechanisms regulating IL-5 gene expression. Mouse IL-5 promoter 
activity was induced 36-fold by stimulation with PMA/cAMP in D10W cells whereas 
stimulation with PMA/cAMP/ionophore was required for 6-fold induction of the 
human IL-5 promoter in HSB-2 cells. Both inductions were abolished when the 
putative transcription factor binding sites for AP-1, Ets/NFAT or GATA in the 
proximal promoter regions of the respective IL-5 genes were mutated. 
Transactivation studies showed that the transcription factor AP-1 (c-Jun and c-Fos) 
strongly activated both the mouse and human IL-5 promoters in the absence of 
stimulation. In unstimulated cells, AP-1 synergistically transactivated the mouse IL-5 
promoter in combination with Etsl and cooperated with both Etsl and GATA-3 to 
activate the human IL-5 promoter. Electrophoretic mobility shift assays showed that 
recombinant AP-1 and Etsl proteins specifically bound to their respective sites in the 
mouse IL-5 promoter. The transactivation activities of the transcription factors were 
shown to be mediated through the AP-1, Ets/NFAT and GATA binding sites in the 
proximal promoter region of the respective genes. The transactivation activity of Etsl 
plus its unique ability to synergize with AP-1 strongly suggested that Etsl rather than 
Elfi or NFATp or NFATc was involved in gene induction at the Ets/NFAT sites of 
the mouse and human IL-5 proximal promoters. GATA-3 and GATA-4 had strong 
transactivational activity with the human IL-5 promoter and both cooperated well 
with Etsl and AP-1. However, GATA-3 is the Th2 specific factor and therefore most 
likely to be involved in IL-5 expression.
Activation of the ERK MAP kinase pathway was sufficient to induce IL-5 
activation in the absence of stimulation. The JNK pathway gave less gene induction 
and the p38 pathway gave very little activation. However, in stimulated cells, 
activation of each of the three MAP kinase pathways gave strong induction of IL-5 
gene expression. These inductions were dependent on the AP-1, Ets/NFAT and 
GATA binding sites within the proximal promoter region of the mouse IL-5 gene. 
Taken together, these studies suggest that the proximal regions of both the human and 
mouse IL-5 promoters are critical for induction of the IL-5 gene. In addition, 
cooperative interactions between AP-1, Etsl and GATA-3 are obligatorily required 
for IL-5 expression and may be part of a higher order transcriptional complex in 
activated T lymphocytes analogous to the enhanceosome of the IFN-ß gene. 
Preliminary studies showed two sites of binding for HMGI(Y) in the proximal 
promoter and suggest that it may participate as an architectural transcription factor. 
The results support the proximal promoter region as the major inducible switch 
regulating IL-5 gene expression in T cells
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Chapter 1 General Introduction
1.1. Introduction
T lymphocytes coordinate the cellular immune response. Resting T lymphocytes 
are activated when their T cell receptor encounters foreign antigen presented in 
association with self-histocompatibility molecules on the surface of specialised antigen- 
presenting cells (Unanue and Allen, 1987). This specific activation via the T cell receptor 
in conjunction with other cell surface receptors leads to second messenger cytoplasmic 
activity which in turn ultimately affects transcription of particular sets of genes in the T 
cells (Weiss et al., 1986). The immunoregulatory effector molecules, known collectively 
as cytokines, are a major class of genes switched on by this signaling event.
Interleukin-5 (IL-5) is one of the key cytokines produced by activated T 
lymphocytes that are involved in the regulation of immune and inflammatory responses. 
IL-5 appears to play central role in the regulation of the eosinophilia and contributes to 
several human diseases, including asthma (Sanderson et al., 1988). In both atopic and 
non-atopic asthma, elevated IL-5 levels have been detected in peripheral blood and in the 
airways (Hamid et al., 1991; Walker et al., 1991; Robinson, et al., 1992). Understanding 
the regulation of this inducible cytokine may ultimately be valuable in treating certain 
pathological conditions in humans involving eosinophilia. Therefore, there is 
considerable interest in the identification of the transcriptional mechanisms regulating the 
expression of IL-5.
1
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1.2. Molecular Biology of IL-5
1.2.1. Interleukin-5 gene and its structure.
The interleukin-5 gene is located on chromosome 11 in mouse and chromosome 5 
in human. The exon/intron structure of the IL-5 genes in the mouse, human and rat is 
very similar having 4 exons and 3 introns. A similar gene structure arrangement is also 
found in other cytokine genes like IL-2, IL-4, GM-CSF and IFNy. The 3 introns of the 
mouse IL-5 gene are 829, 1875 and 79 bp in length. The first 2 introns are significantly 
longer than those in the human gene which has introns of 208, 950 and 105 bp 
respectively. The relative positions of the introns within the coding regions are identical 
in the two genes and all introns begin with GT and end in AG. A potential TATA box is 
located 29 bp (human) and 30 bp (mouse) upstream from the start of transcription 
(Sanderson et al., 1988). The amino acid sequence of IL-5 is highly conserved between 
human and mouse. (78% homology). The IL-5 gene is part of a cytokine cluster on 
chromosome 11 in mouse and chromosome 5 in human with the 1L-3, IL-4, 1L-13 and 
GM-CSF genes (see below), suggesting these genes may be derived by duplication from 
a common ancestral gene (van Leeuwen et al., 1989). There is a significant homology 
between the IL-5 and GM-CSF genes from -53 to -39 in the proximal promoter region 
(Campbell et al., 1988; Mizuta et al., 1988). This element has been referred as CLEO 
(conserved lymphokine element 0) and it is also present in the IL-4 and G-CSF genes 
(Miyatake et al., 1991). The highly conserved CLEO element, the chromosomal clustering 
of the IL-5, IL-4 and GM-CSF genes and their inducible expression in T lymphocytes 
raises the possibility of coordinate regulatory mechanisms in their regulation.
2
Chapter 1 General Introduction
1.2.2. Structure of the IL-5 protein
IL-5 is a homodimeric glycoprotein connected by two cysteine residues 
(Minamitake et al., 1990). The X-ray structure of IL-5 was first solved using the 
bacterially derived protein (Milburn et al., 1993) and was subsequently solved for 
recombinant protein derived by expression from baculovirus infection of Sf9 cells 
(Tavernier et al., 1995) and from Drosophila cells (Johanson et al., 1995). The structure 
reveals a novel two-domain structure, with each domain consisting of a four-a-helix 
bundle. The four-helix bundles in IL-5 are composed of three helices from one subunit, 
with the fourth being provided by the other subunit, producing a dimerization 
organization which is unique to date to IL-5 (Chaiken and Williams, 1996). An important 
feature of the IL-5 is the pair of Cys residues which are involved in the formation of 
intermolecular disulfide bridges. The disulfide bond assignment of recombinant IL-5 
shows that the intermolecular disulfide bonds linking the two subunits occur in a head-to- 
tail fashion where the Cys44 residue from each chain forms a disulfide with the Cys86 
residue from the other (Minamitake et al., 1990; Proudfoot et al., 1991). These Cys 
residues appear to be essential for IL-5 function, since their removal by site-directed 
mutagenesis abolished biological activity of IL-5 (McKenzie et al., 1991b).
Native IL-5 was isolated initially from mouse T-cell supernatants and was shown to 
be a glycoprotein which exists as a homodimer (McKenzie et al., 1987). The protein was 
shown to have an apparent molecular mass of 45 kDa, but the cloning of the cDNA 
sequence showed that the protein component is composed of two amino acid chains with 
a molecular mass of 13 kDa for each polypeptide monomer (Kinashi et al., 1986). Human 
IL-5 has a similar monomeric polypeptide which had 70% sequence similarity to the 
mouse protein (Azuma et al., 1986; Campbell et al., 1987). The expression of the cDNA 
in eukaryotic systems has shown that it is a disulfide-linked homodimer with apparent
3
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molecular mass of 40 to 50 kDa with O-linked glycosylation at Thr4 and N-linked 
glycosylation at Asn29 (Minamitake et al., 1990), implying that about half of the IL-5 
consists of carbohydrate. However, the carbohydrate component does not appear to be 
essential for IL-5 activity, since the recombinant expression of the cDNA encoding the 
human sequence in E. coli produces fully active protein, as does the expression in 
baculovirus-infected Sf9 cells in the presence of tunicamycin (Tavernier et al., 1989). The 
non-essentiality of glycosylation for biological activity is not unique to IL-5. GM-CSF is 
even more active as the unglycosylated protein than the glycosylated form (Burgess, 
1988).
1.2.3. IL-5 receptor
The IL-5 receptor (IL-5R), a member of the Type 1 cytokine receptor superfamily, 
consists of an IL-5-specific subunit, the IL-5 receptor a  chain (IL-5Ra), and a second 
subunit, IL-5 receptor ß chain (IL-5Rß) (Takaki et al., 1990; Tavernier et al., 1991; 
Takaki et al., 1991; Murata et al., 1992; Takaki et al., 1993). The lL-5Ra cDNA encodes 
a 420 amino acid protein consisting of a leader sequence, an extracellular domain, a 
transmembrane domain, and a cytoplasmic domain (Murata et al., 1992). Both mouse and 
human IL-5Ra also occur in a soluble form (Takaki et al., 1990, Murata et al., 1992).
The extracellular portion of IL-5Ra is composed of three fibronectin type-III-like 
modules (Takaki et al., 1990; Murata et al., 1992). The two membrane proximal modules 
contain the conserved superfamily structures; four conserved cysteines in the middle 
domain and the WSXWS motif (Bazan et al., 1990) in the membrane proximal domain. 
The cytoplasmic domain of IL-5Ra has no significant homology with signaling 
molecules such as kinases, phosphatases, nucleotide binding proteins, and the src
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homology domain. It has regions rich in proline (Pro-Pro-X-Pro) following the 
transmembrane domain (Takaki et al., 1990) that are well conserved between IL-5Ra and 
the receptors for IL-3, GM-CSF, prolactin, and growth hormone.
The IL-5Ra subunit binds IL-5 ligand with low affinity in the mouse but with 
relatively high affinity in the human. The IL5Rß subunit does not bind IL-5 alone, but 
associates with IL-5Ra to enhance the affinity for IL-5 binding (Tominaga et al., 1992). 
The IL-5Rß also enhances the efficiency of IL-5 internalization, which explains the 
reduction in surface expression of high-affinity IL-5R following IL-5 stimulation. The 
IL-5Rß is absolutely necessary for signal transduction (Mita et al., 1993). There is no 
significant association between IL-5Rß and soluble IL-5Roc, which explains the ability of 
soluble IL-5Ra to act as an antagonist. The IL-5Rß subunit is identical to the ß-chains of 
the IL-3 and GM-CSF receptors and is known as the ß-common chain (Lopez et al., 
1992). Recent studies on the structure of the complete extracelluar domain of the ß- 
common chain identify a novel interlocking dimer structure (Carr et al., 2001). The 
sharing of the ß-chain among the receptors for the IL-3, IL-5, and GM-CSF genes 
suggests a common signaling mechanism among these cytokines and may explain the 
overlapping role of these cytokines in the development of granulocytes, as well as the 
cross-competition observed for these cytokines when binding to their receptors.
1.2.4. Transmembrane signaling by IL-5
Receptor-driven signaling processes typically originate from the juxtamembranous 
region of the receptor. The molecular mechanism by which IL-5 binding to its receptor 
elicits diverse responses in subsets of leukocytes remains an enigma. Accumulating 
evidence suggests that phosphatidyl inositol turnover, calcium mobilization and
5
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activation of protein kinase A are not essential for IL-5-induced differentiation signals 
(Yamaguchi et al., 1989). Although tyrosine phosphorylation is usually one of the earliest 
biochemical events in the signal transduction cascade induced by growth factors whose 
receptors possess endogenous enzymatic activity (Ullrich and Schlessinger et al., 1990), 
the cytoplasmic domains of IL-5Ra and the ßc subunit, like a number of other cytokine 
receptors, have no homology with tyrosine kinases. Nevertheless, IL-5 does induce rapid 
tyrosine phosphorylation of cellular proteins (Morla et al., 1988; Murata et al., 1990), and 
enhances the transcription of nuclear proto-oncogenes (Conscience et al., 1986). The 
suppression of IL-5-induced proliferation with a tyrosine kinase inhibitor (Sato et al., 
1994) indicates that activation of tyrosine kinases is indispensable in IL-5 signal 
transduction.
One of the earliest events that occur after IL-5 binds to its receptor is the rapid 
tyrosine phosphorylation of ßc and several cellular substrates including She and Vav. The 
tyrosine phosphorylated She can activate the Ras pathway by binding to an adapter 
protein called Grb2 through its SH2 domain (Pelicci et al., 1992; Egan et al., 1993). Grb2 
also binds through its SH3 domain to a proline-rich motif of Sos, a nucleotide exchange 
protein. Sos then activates Ras, which is a GTP binding protein that functions 
downstream of tyrosine kinases in the growth signaling pathway (Smith et al., 1986; 
Satoh et al., 1991; Duronio et al., 1992). Downstream of Ras is a serine/threonine kinase 
called Raf which activates the unique bifunctional kinase MEK that can phosphorylate 
both tyrosine and serine/threonine. The known substrate for MEK is the serine/threonine 
kinase MAP kinase. Once activated, MAP kinase triggers nuclear transcription factors 
that lead to the induction of several gene products including proto-oncogenes. Activation 
of the Ras cascade is dependent on both the cytoplasmic region of the IL-5Roc and the 
region between Leu626 and Ser763 of ßc (Gorman et al., 1992). The induction of
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tyrosine phosphorylation and nuclear proto-oncogene expression is critical for cytokine 
signal transduction (Conscience et al., 1986). Expression of c-Fos, c-Jun, and c-Myc 
proto-oncogene mRNA is rapidly induced upon stimulation with IL-5 (Takaki et al., 
1994). This proto-oncogene expression is not induced in cells transfected with IL-5Ra 
mutants that lack either the proline-rich motif or a sequence just downstream of the 
proline-rich region in the cytoplasmic domain (Takaki et al., 1994).
Janus kinases (JAK) are a family of cytoplasmic protein tyrosine kinases including 
JAK-1, JAK-2, JAK-3, and TYK-2 and recent studies have revealed that the JAK family 
cf kinases couples ligand binding to cytokine receptors with tyrosine phosphorylation of 
cellular proteins (Ihle, 1995). JAK-2 is rapidly tyrosine phosphorylated in response to IL- 
5 (Kouro et al., 1996). A significant but lesser extent of tyrosine phosphorylation of JAK- 
1 is also observed in response to IL-5 (Kouro et al., 1996). The membrane-proximal 
proline-rich sequence of the cytoplasmic domain of IL-5 Ra, which is also conserved in 
tie a  chains of IL-3Ra and GM-CSFRa, is essential for tyrosine phosphorylation of 
JAK-2 (Cornelis et al., 1995). Treatment of human peripheral blood monocytes or 
basophils with IL-3, IL-5, or GM-CSF activates DNA binding proteins which are 
tyrosine-phosphorylated (Lamer et al., 1993). An IL-3 and GM-CSF responsive STAT 
protein has been identified as STAT-5 (Mui et al., 1995), which is one of the substrates 
lor JAK-2 kinase. IL-5 also induces STAT-5 activity (Kouro et al., 1996; Mui et al., 
1995; Ogata et al., 1997), which is mediated by both JAK-2 and to a lesser extent JAK-1. 
Activation of JAK-2 and STAT-5 has been shown in eosinophils in response to IL-5 
(Ogata et al., 1998; Pazdrak et al., 1995). The activation of STAT-5 in response to IL-3, 
IL-5 and GM-CSF suggests a common signaling pathway through the IL-3R, IL-5R, and 
GM-CSFR, all of which share ßc. These studies suggest different JAK-STAT signaling 
pathways for B cells and eosinophils.
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1.3. Biological function of IL-5 
1.3.1. Eosinophils
Eosinophilia involves four different processes: differentiation of progenitor cells 
and proliferation of eosinophils in bone marrow; interactions between eosinophils and 
endothelial cells that involved rolling, adhesion, and migration of eosinophils; 
chemoattraction directing eosinophils to a specific location; and activation and 
destruction of eosinophils (Rothenberg, 1998). Eosinophils are produced in bone marrow 
from pluripotent stem cells. The latter cells differentiate first into hybrid precursors with 
properties of basophils and eosinophils and then into a separate eosinophil lineage (Boyce 
et al., 1995). There is strong evidence that an excess of eosinophils and their products are 
involved in the pathogenesis of allergic disease such as bronchial asthma (Hoidal, 1990). 
Eosinophils have been associated with neoplasia in various types of tumour-associated 
eosinophilia (Lowe et al., 1981) and are believed to be involved in host defence against 
helminth infections (Hagan et al., 1985).
The most obvious feature of asthma is bronchoconstriction associated with an acute 
attack. However, the major underlying cause of an asthma attack is chronic pulmonary 
inflammation characterised by decreased mucociliary clearance, edema, epithelial 
damage, and broncho-alveolar eosinophilia (Mahanty and Nutman, 1993). There is 
increasing evidence that eosinophils are involved in the pathophysiology of asthma, as 
shown by the ability of eosinophil products such as major basic protein, eosinophilic 
cationic protein, and eosinophil peroxidase to cause damage to lung epithelium both in 
vitro and in vivo (Kay et al., 1995). Three cytokines, IL-3, IL-5 and GM-CSF, are 
particularly important in regulating the development of eosinophils.
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1.3.2. Regulation of eosinophils by Th2 lymphoctes and mast cells
Mast cells participate in the initial events after exposure to allergen, but their 
importance in orchestrating eosinophilia is uncertain. After IgE-triggered activation, mast 
cells may promote inflammation of the airways with eosinophils by producing 
proinflammatory mediators (e.g., IL-1 and TNFa) and eosinophil-directed cytokines 
(e.g., IL-4 and IL-5). These substances, in turn, induce chemokines that attract 
eosinophils. However, mast cells do not appear to be required in some animal models of 
allergic disease. In allergen-sensitized mice with a deficiency of mast cells and allergen- 
sensitized mice with a targeted deletion of the gene for IgE, recruitment of eosinophils 
into the lungs is not impaired after allergen challenge (Mehlhop et al., 1997; Hamelmann 
et al., 1997; Brusselle et al., 1994). In contrast, helper T lymphocytes are essential for the 
late-phase allergic response, because they produce three cytokines that promote allergic 
responses: IL-4 and IL-13, both of which regulate IgE and VCAM-1 production, and IL- 
5. The helper cells that orchestrate this type of response are Th2 cells. In contrast, Thl 
cells produce IFNy and TNFß (Mosmann and Coffman, 1989; Robinson et al., 1992). 
Genetic factors and the conditions of antigen exposure determine the relative 
contributions of mast cells and T cells in the regulation of eosinophils (Galli, 1997).
1.3.3. IL-5 and Eosinophils
Among the cytokines which can support eosinophilopoiesis, IL-5 is unique in its 
ability to specifically promote the terminal differentiation and maturation of 
eosinophil/basophil lineage-committed progenitors (Clutterbuck et al., 1989). In addition, 
IL-5 prolongs eosinophil survival by delaying apoptotic cell death (Yamaguchi et al., 
1988). IL-5 also primes and stimulates eosinophil chemotactic activity (Sehmi et al., 
1992), and enhances eosinophil effector function (Yamaguchi et al., 1988). A pivotal role
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for IL-5 in chronic allergic inflammation has been confirmed by the capacity of
neutralizing anti-IL-5 mAb to inhibit antigen- or virus-induced airway
hyperresponsiveness and eosinophil infiltration in the airways of mice, guinea pigs and
primates (Nagai et al., 1993; Kung et al., 1995; Chand et al., 1992; Mauser et al., 1995;
Egan et al., 1995^These findings suggest that IL-5 antagonists or drugs blocking IL-5 
Leckie et al., 2000
production may provide a new therapeutic approach to these allergic disases.
Of the three cytokines (IL-3, GM-CSF and IL-5), IL-5 is the most specific for the 
eosinophil lineage and is responsible for selective differentiation of eosinophils 
(Sanderson, 1992). In asthma patients, high levels of IL-5 mRNA in the bronchial 
mucosa is detected (Hamid et al., 1991). IL-5 protein is also detectable in the 
bronchoalveolar lavage (BAL) fluid from symptomatic asthma patients (Ohnishi et al.,
1993) . IL-5 also stimulates the release of eosinophils from bone marrow into the 
peripheral circulation (Collins et al., 1995). The critical role of IL-5 in the production of 
eosinophils is best demonstrated by genetic manipulation in mice. Overproduction of IL- 
5 in transgenic mice results in profound eosinophilia (Sanderson, 1992; Takatsu et al.,
1994) and deletion of the IL-5 gene causes a marked reduction of eosinophils in blood 
and lungs after an allergen challenge (Foster et al., 1996) or after helminth parasite 
infection ( Kopf et al., 1996) In allergic lung inflammation tissue, eosinophilia was 
shown to depend on the cooperation of IL-5 with IL-4 and IL-13 (Grunig et al., 1998). 
IL-4 and IL-13 promote eosinophil extravasation, at least in part, by upregulating the 
expression on endothelial cells of vascular cell adhesion molecule (VCAM)-l, a major 
adhesion molecule for eosinophils, which express the receptor VLA-4 (very late antigen- 
4) on their membranes (Schleimer et al., 1992). IL-4 and IL-13 stimulate the production 
of eotaxin by several cell types (Rothenberg et al., 1995). In conjunction with IL-5, 
eotaxin is crucial for eosinophil chemotaxis (Collins et al., 1995; Mould et al., 1997) and
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its receptor, CCR3, is considered as a potential target for anti-allergic therapies. The 
overproduction of one or more of the these cytokines occurs in humans with eosinophilia. 
Diseases involving eosinophilia without increases in other blood-cell lineages are usually 
accompanied by an overproduction of IL-5 (Sanderson, 1992). The mechanisms of 
cytokine overproduction may involve a response of T-helper lymphocytes of the Th2 type 
in patients with allergic conditions or parasitic diseases (Mosmann and Coffman, 1989; 
Robinson et al., 1992), the malignant expression of T-cell clones that produce IL-5 in 
some patients with lymphoma (Cogan et al., 1994) or the activation of gene transcription 
due to a chromosomal translocation in some patients with leukemia (Grimaldi and 
Meeker, 1989; Liu et al., 1993 ).
1.3.4. IL-5 and parasite infections
The primary function of eosinophils is believed to be host defence against infection 
by relatively large organisms such as parasitic helminths. This is based on the finding that 
eosinophils degranulate on to and kill helminths in vitro in the presence of antibody and 
/or complement; they move from the blood and aggregate in the locality of helminths in 
vito; large numbers of eosinophils are often seen in close association with both intact 
and damaged helminths in vivo; and they clearly degranulate in the vicinity of surface of 
heminths in vivo (Butterworth, 1984).
A variety of studies have been carried out in which monoclonal antibodies (mAbs) 
thd neutralize IL-5 have been administered to mice. This treatment greatly reduced the 
de'elopment of eosinophilia upon infection with parasitic helminths, but had little effect 
on the survival or reproduction of a number of nematodes and trematodes (Coffman et al., 
1939; Sher et al., 1990; Betts and Else, 1999; Rotman et al., 1996). However, in a
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minority of studies with other parasite species, anti-IL-5 antibody treatment exacerbated 
the infection. The survival and distribution of parasites in certain tissues was increased in 
primary infections of mice with the rat parasites Strongyloides venezuelensis or 
Angiostrongylus cantonensis (Korenaga et al., 1994; Sasaki et al., 1993) in which 
eosinophils were ablated. Anti-IL-5 mAb treatment compromised both the killing, by 
eosinophils, of Onchocerca volvulus infective larvae implanted in diffusion chambers of 
vaccinated mice and the clearance of microfilariae of Onchocerca linealis from 
immunized mice (Folkard et al., 1996). Similarly, killing of third-stage larvae of 
Strongyloides stercoralis, the parasite that infects humans, within diffusion chambers in 
immunized mice was ablated by IL-5 mAb treatment (Rotman et al., 1996).
Transgenic mice constitutively overexpressing IL-5 display constitutive high blood 
and tissue eosinophilia (Dent et al., 1990; Tominaga et al., 1991). These mice were 
infected experimentally with parasites and studies showed that parasite burdens were 
dramatically decreased (Yoshida et al., 1996; Dent et al., 1999; Shin et al., 1997), 
indicating an IL-5-dependent host-protective effect. Many of the Nippostrongylus 
brasiliensis worms that did establish in the intestine of the transgenic mice failed to thrive 
and produce eggs (Dent et al., 1999). However, worm burdens in secondary 
Nippostrongylus brasiliensis infections of normal and IL-5 transgenic mice were similar, 
indicating no essential role for IL-5 in immunological memory in this infection (Dent et 
al., 1999). Worms in the IL-5 transgenic mice were killed more rapidly which correlated 
with greatly intensified eosinophil infiltration into the cerebrospinal fluid of transgenic 
mice and increased parasite antigen-specific serum IgGl and IgA (Daly et al., 1999). IgA 
is reported to be the most effective stimulator of degranulation of human eosinophils 
(Fujisawa et al., 1990).
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Recently, studies with IL-5-deficient (Kopf et al., 1996) and IL-5Ra-deficient 
(Yoshida et al., 1996) mice provided further evidence that IL-5 plays an important role in 
host defence against some parasites. The IL-5Ra is exclusive to the IL-5 receptor, and is 
expressed in eosinophils and CD5+ B-l cells which are responsive to IL-5. IL-5- and IL- 
5Ra-deficient mice harbour very small populations of normal eosinophils and fail to 
develop an eosinophilopoietic response when infected with any of the helminths tested 
(Ovington et al., 1997). IL-5Ra-deficient mice have reduced levels of serum IgM and 
IgG3 and mucosal secretory IgA. The effect of infection of these mice with a large 
variety of parasites such as Mesocestoides corti (Kopf et al., 1996), Hymenolepis 
diminuta and Fasciola hepatica (Ovington et al., 1997), Trichinella spiralis (Vallance et 
al., 1999), Strongyloides ratti (Ovington et al., 1998), Toxocara canis (Takamoto et al., 
1997), Angiostrongylus cantonensis (Yoshida et al., 1996; Sugaya et al., 1997) has been 
determined. Worm burdens and distributions in primary infections IL-5-deficient mice 
with Mesocestoides corti were similar to wild-type mice although reduced pathology in 
Toxocara canis infections was observed (Kopf et al., 1996; Takamoto et al., 1997). In the 
infections of IL-5-deficient mice with Trichinella spiralis, reduced smooth muscle 
hypercontractility and a delay in expulsion of intestinal adults were also observed 
although worm burdens were similar (Vallance et al., 1999). IL-5-deficient mice infected 
with Strongyloides ratti showed reduced host defence against this intestinal nematode 
(Ovington et al., 1998). These studies in mice give insight into in vivo functions of IL-5 
and eosinophils.
1.3.5. IL-5 and graft rejection
Eosinophil infiltration has been reported to be a specific indicator of adverse 
prognosis in renal (Kormendi and Amend, 1988) liver (Foster et al., 1989) and lung
13
Chapter 1 General Introduction
(Kondo et al., 1991) transplantation. IL-5 expression in biopsies from human liver 
allografts correlates with histopathological evidence of acute rejection (Martinez et al., 
1992). Both IL-5 transgenic mice and neutralizing IL-5 antibodies have been used to 
investigate the role of eosinophils in transplant rejection. IL-5 antibody treatment fully 
delayed allogeneic heart graft rejection and facilitated tolerance induction with anti-T-cell 
monoclonal antibody therapy. Despite the disappearance of the heavy eosinophilic 
infiltrates observed in untreated recipients, IL-5 inhibition did not modify the rejection of 
pig pancreatic islets in mice, suggesting that eosinophils are essentially innocent 
bystanders in this model (Simeonovic et al., 1997). IL-5 neutralization only slightly 
affected the survival of fully mismatched heart allografts in CD8+ T-cell-depleted mice 
recipients although the eosinophilic infiltration of the grafts was strictly IL-5 dependent 
(Braun et al., 2000). Studies with mice in which skin-graft rejection is triggered by a 
single MHC class II incompatibility showed that the CD4+ T-cell response in this model 
is Th-2 biased and associated with massive eosinophilic infiltrates, which depend on IL-5 
production (Le Moine et al., 1999a). Although IL-5 neutralization significantly prolonged 
graft survival it was unable to prevent rejection in wild-type animals, as CD4+ T cells use 
two pathways to induce graft damage in this model (Le Moine et al., 1999a). The first 
pathway depends on FasL-Fas signaling whereas the second pathway involves IL-5 and 
eosinophils. Indeed, when skin transplantation was performed using FasL-deficient mice 
as recepients or Fas-deficient mice as donors, IL-5 neutralization completely prevented 
graft rejection (Le Moine et al., 1999a). This suggests that the role of IL-5-eosinophil 
pathway in transplant rejection becomes crucial when the cytotoxic CD8+ T-cell pathway 
is not operative and the FasL-Fas pathway of CD4+ T-cell-mediated rejection is blocked.
IL-5 neutralization, by injection of an anti-IL-5 antibody or the use of IL-5- 
deficient mice as recipients, established a crucial role for eosinophils in the induction of
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fibrosis. However, IL-5-deficient mice develop transplant arteriosclerosis, indicating that 
the vascular lesions did not depend on eosinophils (Le Moine et al., 1999a). IL-4 
appeared to be a crucial mediator of vasculopathy ( Le Moine et al., 1999b).
1.3.6. Role of IL-5 in B-cell development
IL-5 is a synonym of T-cell replacing factor, B-cell growth factor II, IgA enhancing 
factor, eosinophil differentiation factor, and eosinophil colony-stimulating factor ( 
Kinashi et al., 1986; Takatsu et al., 1994 ). IL-5 induces DNA synthesis in mouse chronic 
leukemic B cells and dextran-sulfate-stimulatcd splenic B cells (Hitoshi et al, 1990). In 
mice expressing the IL-5 transgene, the B-l cell population is markedly increased with 
concomitant hypergammaglobulinemia and autoantibody production (Tominaga et al., 
1991). IL-5- and IL-5Roc-deficient mice show decreased numbers of B-l cells and 
peripheral eosinophils concomitant with low serum concentrations of IgM and IgG3 
(Yoshida et al., 1996; Kopf et al., 1996). IL-5 acts on appropriately activated B cells to 
induce IgGl and IgA production (Takatsu et al., 1994). Thus evidence has accumulated 
in mouse systems for both an IL-5-sensitive developmental pathway for B-l cells and a 
role for IL-5 in the terminal differentiation of mature B-l cells and appropriately 
activated B-2 cells (Takatsu et al., 1994). In addition, a role for IL-5 in promoting CH 
gene recombination has been demonstrated by synergy with IL-4 which induces 
recombination in mouse B cells activated with anti-IgD dextran (Mandler et al., 1993). 
IL-5 is therefore a potent cytokine to induce terminal differentiation of activated mouse B 
cells and a priming factor to induce accessibility to other cytokines.
In contrast to mouse B cells, evidence of a role for IL-5 in human B-cell growth 
and differentiation has been controversial (Huston et al., 1996; Clutterbuck et al., 1987).
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No effects on proliferation and Ig production were found when IL-5 was tested for 
functional activity on purified human B cells from peripheral blood or spleen using anti- 
IgM antibodies (Clutterbuck et al., 1987). Conversely, other studies subsequently 
reported the potential of human B cells to respond to IL-5. As with mice, IL-5 
responsiveness of human B cells depends on the activation signal used. Detection of 
message for IL-5Ra in resting B cells upon the stimulation of B cells with the novel 
bacteria B-cell mitogen Moraxella catarrhalis and Ig synthesis of B cells stimulated with 
mitogen and IL-5 have provided direct evidence that human B cells are able to respond to 
IL-5 (Huston et al., 1996)
1.4. Expression of the IL-5 gene
1.4.1. Gene clustering and coordinated expression of cytokine genes
There is now well-documented evidence that eosinophilia is primarily regulated by 
the production of IL-5, but also by the expression of IL-4 and by the recently described 
IL-13 (Sanderson et al., 1992, Minty et al., 1993, Zurawski et al., 1994). A number of 
other cytokines, including IL-3, GM-CSF, IL-9, and IL-10 influence the immediate 
inflammatory responses elicited during allergic reactions. It is noted that a number of 
these genes, including IL-3, IL-4, IL-5, IL-13, and GM-CSF, are located in a cluster on 
mouse chromosome 11 and human chromosome 5 (van Leeuwen et al., 1989; Mckenzie 
et al., 1993). With the exception of IL-13 (which has five exons), the genes within this 
cluster share a common intron/exon structure consisting of four exons and three introns 
(Mckenzie et al., 1993). The human IL-13 gene is upstream and probably within 20 kb of 
the IL-4 gene (Morgan et al., 1992). Physical linkage has also been demonstrated 
between the IL-4 gene and IL-5 gene in human and mouse, with approximately 310 kb
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separating them in human (Chandrasekharappa et al., 1990) and approximately 110 to 
180 kb in mouse (Lee et al., 1989). The human IL-3 and GM-CSF genes are extremely 
close linked and map in the region of 600 to 1000 kb from IL-5 (Le Beau et al., 1989). 
Recent studies using cross-species sequence comparisons followed by characterization of 
conserved regions in yeast artificial chromosome transgenic mice have identified a 
coordinate regulator of IL-4, IL-13 and IL-5 expression (Loots et al., 2000). The 
structural relationship and clustering of the IL-13, IL-4, IL-5, IL-3, and GM-CSF genes 
suggest that they have evolved through ancestral gene duplication. Although these 
cytokines may show coordinate expression, it is evident that they are also individually 
regulated (Naora and Young, 1995).
1.4.2. Role of the cytokines produced by Thl and Th2 cells
Native CD4+ helper T cells recognize specific major histocompatibility complex 
(MHC)-peptide combinations on antigen-presenting cells (APCs) via interactions with the 
T-cell receptor (TCR), providing the first signal required for activation. The second, 
costimulatory signal, is provided by accessory molecules expressed on APCs, such as the 
B7 family of proteins. B7 proteins are the ligands for the CD28 and CTLA-4 
costimulatory molecules that are expressed on T cells. The combination of these two 
signals induces IL-2 synthesis and secretion, IL-2 receptor expression, clonal expansion 
and differentiation of precursor CD4+ T cells into effector T helper (Th) cells (Rincon 
andFlavell, 1997).
Activated CD4+ T cells are classified into two distinct subsets (Thl and Th2) based 
on their biological functions, which in turn, depend on the cytokines they express. Thl 
cells produce inflammatory cytokines, such as TNF-ß and IFN-y, and enhance cellular
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immunity. Th2 cells produce a different group of cytokines- IL-4, IL-5, IL-6, IL-10, and 
IL-13, and help B cells secrete antibodies. The differentiation of native T cells into the 
Thl or Th2 phenotype has important biological implications in terms of susceptibility or 
resistance to a particular disease.
The cytokines themselves play the most critical role in T helper cell polarization. 
The two critical cytokines that control Thl and Th2 differentiation are IL-12 and IL-4, 
respectively. These two cytokines enhance the generation of their own Th subset and 
simulaneously inhibit the generation of the opposing subset (Macatonia et al., 1993; 
Manetti et al., 1993; Powrie and Coffman, 1993; Trinchieri, 1993). These events are 
likely to occur at a precursor stage (Thp) because, once established, Thl and Th2 cells are 
stable (Scott, 1991; Murphy et al., 1996). The requirement for IL-12 and IL-4 has been 
demonstrated unequivocally by the phenotype of mice that lack these cytokines, their 
receptors, or the effector molecules downstream of receptor signaling. IL-12, secreted by 
APC, activates the STAT4 signaling pathway, and mice lacking IL-12 or STAT4 do not 
have Thl cells (Kaplan et al., 1996; Magram et al., 1996; Thierfelder et al., 1996). Two 
other cytokines that influence Thl development are IL-18, whose receptor is related to 
the IL-1 receptor family (Okamura et al., 1995), and IFN-y (Scott, 1991; Meraz et al., 
1996). IFN-y activates the STAT1 pathway (Meraz et al., 1996). Mice lacking IL-18 or 
STAT1 have defective in vivo Thl responses (Meraz et al., 1996; Takeda et al., 1998). In 
contrast, mice that lack IL-4, IL-4 receptor or STAT6, the downstream signaling 
molecule for the IL-4 receptor, fail to develop Th2 cells in response to most stimuli 
(Kuhn et al., 1991; Kopf et al., 1993; Shimoda et al., 1996; Takeda et al., 1996; Noben- 
Trauth et al., 1997). The biological function of IL-13 partially overlaps with IL-4 
because, in some instances, IL-13 drives Th2 development and IgE synthesis in an IL-4- 
independent fashion (Minty et al., 1993; Punnonen et al., 1993 Emson et al., 1998;
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McKenzie et al., 1998). IL-13 is especially important in the asthmatic response (Wills- 
Karp et al., 1998; Wills-Karp, 2001)
The Thl/Th2 differentiation step requires new protein synthesis and gene 
expression. An understanding of the transcriptional mechanisms that are involved in the 
differentiation and /or activation of Thl and Th2 cells might provide potential targets for 
therapeutic intervention.
1.4.3. Signaling pathways involved in IL-5 regulation
In order to establish whether IL-5 is regulated by mechanisms shared with other 
coordinately expressed cytokines in Th2 cells, the effect of variety of activators and 
inhibitors of known signaling pathways on the expression of IL-5 and five other 
cytokines was studied in the Th2 clone DIO (Naora et al., 1994a; Naora and Young, 1995 
). Using northern blot analysis it was shown that, whereas none of the six cytokine 
mRNAs could be detected in unstimulated DIO cells, the lectin Con A was effective in 
inducing all of the cytokine genes. This agent is believed to stimulate a number of 
glycosylated cell surface molecules including the TCR-CD3 complex which triggers 
activation of two parallel second messenger pathways involving PKC activation and Ca2+ 
mobilization. The Ca2+signal appears to be largely mediated via a CsA-sensitive pathway 
in DIO cells and this pathway was shown to be essential for TCR-CD3-induced 
expression of the IL-3, IL-4, and GM-CSF genes. The Ca2+ signal was optimally induced 
by the Ca2+ ionophore A23187 which produces sustained elevation of intracellular Ca2+ 
levels. In contrast, the TCR-CD3-stimulated expression of the IL-5, IL-6, and IL-10 
genes was relatively resistant to CsA. Furthermore, these three genes were induced by 
PMA stimulation alone, suggesting that the PKC signaling pathway may independently
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regulate these genes. The IL-5, IL-6, and IL-10 gene were also selectively induced by 
stimulation of the IL-1 receptor and by forskolin. Studies by other workers with a subline 
of DIO (Munoz et al., 1990) have indicated that stimulation of the IL-1 receptor induces 
PKC activation and increased intracellular cAMP flux. Since forskolin activates 
adenylate cyclase it would appear that the IL-5, IL-6, and IL-10 genes can be induced by 
PKC- and cAMP-dependent pathways in DIO cells.
1.5. Transcriptional regulation of cytokine genes
1.5.1. Basal transcriptional machinery
In the eukaryotic cell, messenger RNA (mRNA) synthesis of most genes is 
controlled by the enzyme RNA polymerase II. Although the eukaryotic RNA polymerase 
II is able to catalyze mRNA synthesis, it is not sufficient by itself to initiate transcription. 
Instead, a host of general transcription factors (GTFs), including TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH, work in a concert with RNA polymerase II to bring about 
promoter recognition and accurate transcriptional initiation (Zawel et al., 1995). The 
complete set of GTFs is usually sufficient to direct a basal level of transcription in vitro 
from strong promoters. Based on the TATA box (-TATA-DNA sequence), eukaryotic 
gene promoters are divided into two groups: 1) TATA-containing promoters that have 
the -TATA- sequence upstream of the transcriptional induction site and possess strong 
promoter activity; and 2) TATA-less promoters that do not have a -TATA- sequence 
upstream of the transcriptional induction site and express relatively weak promoter 
activity . So far, all cytokine gene promoters are TATA-containing promoters.
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Transcription from a cytokine gene promoter is tightly controlled by the combined 
actions of positive and negative sequence-specific DNA-binding nuclear factors. 
Activators are transcription factors that can enhance promoter activity. Chromatin- 
associated proteins such as HMG proteins and histone proteins also play an important 
role in transcriptional regulation. For transcription to occur, a complex array of signals 
must be integrated at the gene promoter to initiate RNA production.
1.5.2. Regulation of the basal transcriptional machinery
One paradigm that has been established as a result of in vitro biochemical studies 
with RNA polymerase II is the importance of protein-protein interactions between 
activator proteins and components of the basal transcriptional machinery. Site-specific 
transcriptional activators or repressors, which recognize and bind to specfic DNA 
sequences in the genomic DNA, target distinct components of the basal transcriptional 
machinery. For example, the nuclear factor Spl can specifically interact with a subunit of 
the general transcription factor TFIID (Pugh and Tjian, 1991; Pugh and Tjian, 1990). 
TFIID is a large complex in the basal transcription machinery that contains at least nine 
subunits, including the TATA binding protein (TBP) and another eight or more 
transcription-associated factors(TAFs). The Spl-specific subunit of TFIID has a 
molecular mass of 110 kDa and interacts with the glutamine-rich activation domain of the 
Spl protein (Tanese et al., 1991). Therefore, when Spl binds to a promoter in which the 
110 kDa subunit is required for the activity of TFIID (Tanese et al., 1991), Sp-1 may 
facilitate assembly of the basal transcription machinery and enhance promoter activity. If 
the 110 kDa subunit is not necessary for promoter activity, Spl may not regulate the 
activity of the promoter even if it can bind to the promoter DNA. This specific interaction
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provides a model of how a specific DNA-binding nuclear factor regulates assembly and 
function of the basal transcription machinery.
In some cases, the site-specific nuclear factor cannot physically contact a 
component of the basal transcriptional machinery, but may indirectly interact with the 
basal transcriptional machinery through an intermediate nuclear factor known as a 
"cofactor". For example, CREB (CRE binding protein) is a nuclear factor that recognizes 
the cyclic AMP response element (CRE) in many gene promoters (Foulkes and Sassone- 
Corsi, 1996 ). However, in the absence of a nuclear factor such as CBP (CREB binding 
protein), the DNA-bound CREB cannot exert its cis-acting function on the promoter 
because it can not directly interact with the basal transcriptional machinery (Chrivia et al., 
1993; Kwok et al., 1994 ). CBP is a non-DNA-binding nuclear factor that is able to bind 
to CREB through protein-protein interactions. However, CBP can also interact physically 
and functionally with the general transcription factors TFIIB and TBP (Janknecht and 
Hunter, 1996). In this case, DNA-bound CREB influences assembly of the transcription 
initiation complex through the CBP protein; thus, CBP acts as a cofactor that mediates 
signals between specific nuclear factors and the basal transcriptional machinery.
1.5.3. Chromatin remodeling in cytokine gene expression
I.5.3.I. Role of chromatin structure
Genomic DNA is packed into nucleosomes, which then form higher order 
chromation structures. Chromatin remodeling is accompanied by changes in nucleosomal 
positioning which is ATP dependent. It has been suggested that cytokine gene loci, 
including IL-2, IL-4, IL-12, IL-13, IFNy and GM-CSF, undergo changes in chromatin 
structure that allow access to gene-specific transcription factors, likely mediated in part
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through acetylation of histones. Distal control regions such as enhancers and LCRs (locus 
control regions) have been shown to regulate accessibility to gene loci by regulating 
chromatin structure (Ernst and Smale, 1995). The location of regions that control these 
changes have been identified in cytokine genes using both assessment of CpG 
methylation status and DNase I hypersensitivity assays since transcriptionally active 
chromatin is hypomethylated and is more accessible to nucleases (Agarwal and Rao, 
1998; Kadonaga, 1998; Agarwal et al., 1999). The most complete information on the role 
of chromatin remodeling in the regulation of cytokine genes is available for IL-4 and 
IFN-y •
I.5.3.2. Evidence for chromatin remodeling in cytokine genes
Several observations suggested that the IL-4 gene was regulated at the level of 
chromatin structure. First, in vitro analyses had indicated that only 157 bp of the proximal 
IL-4 promoter was required for tissue-specific expression in Th2 cells. In vivo, the 
proximal 800 bp of the promoter was required to confer significant Th2-selective 
expression of an IL-4 promoter-reporter transgene (Wenner et al., 1997) However, not 
even 3 kb of sequence upstream the promoter were sufficient to achieve expression 
equivalent to the endogenous IL-4 gene, suggesting the presence of additional elements 
for optimal expression (Todd et al., 1993). Second, differentiated effector Th2 cells 
produce IL-4 more rapidly and at higher levels than naive Thp cells, implying that the IL- 
4 regulatory regions are more accessible in effector, but not in naive T cells (Reiner and 
Seder, 1999).
In both mouse and human chromosomes, the Th2 cytokine genes IL-4, IL-5 and IL- 
13 are clustered together within 150 kb, consistent with the notion that these genes 
compose a single chromosomal locus that may be controlled by long-range modulation of
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chromatin structure. Evidence supporting this model was obtained using both methylation 
and DNase I hypersensitivity assays was obtained by identifying regions in the IL-4/IL13 
locus that responded to stimulation through the TCR. Differentiated Th2 cells and 
established Th2 clones had an accessible chromatin structure as evidenced by the 
presence of five clusters of hypersensitive (HS) sites over the IL-4 locus. Naive T helper 
cells, in contrast, like Thl cells, possessed only one of the five HS sites. After 48 hours of 
antigen activation, naive Thp cells rapidly acquired the chromatin phenotype of 
differentiated Th2 cells, implicating these regions in gene regulation (Agarwal and Rao, 
1998). The Th2-specific transcription factor GATA-3 produced the same changes when 
transduced into differentiated Thl cells or STAT6-deficient cells, indicating that GATA- 
3 acts to remodel this locus downstream of STAT6 (Ouyang et al., 2000). Factors like 
GATA-3 and STAT6 may directly remodel chromatin structure to allow TCR-induced 
factors like c-Maf and NFAT to access their specific binding sites in the IL-4 locus and 
promote rapid transcription of IL-4 (Agarwal and Rao, 1998). NFAT proteins may also 
directly alter chromatin configuration. Mice that lack both NFATp and NFATc largely 
overproduce Th2 cytokines and display a highly allergic phenotype (Ranger et al., 1998) 
suggesting that NFAT proteins may help regulate the balance between the active/inactive 
state of the IL-4/IL-5/IL-13 locus during the initiation of Th2 differentiation.
Although chromatin remodeling may also be important for the IFN-y gene, less is 
known about this locus than the IL-4 locus. Tissue (Thl)-specific DNase I HS regions 
have been identified in both the first and third introns of the IFNy gene (Young et al., 
1994; Agarwal and Rao, 1998), and these assays also demonstrated alteration of the IFN- 
y locus in native Thl cells compared with Th2 cells (Agarwal and Rao, 1998). The 
methylation patterns of the IFNy locus have also been analyzed during T-cell 
differentiation. IFN-y-producer cells like Thl and CD8+ T cells display hypomethylation
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that appears to be a stable, long term inheritable trait (Young et al., 1994; Fitzpatrick et 
al., 1999), whereas the same locus is methylated in Th2 cells. The assembly of Thl- 
specific transcription factors may remodel the chromatin in a configuration that facilitates 
access to other factors required to transcribe the IFN-y gene.
1.5.3.3. Role of the HMGI(Y) in cytokine gene expression
The mammalian HMG I(Y) family of proteins consists of three members: HMG I, 
HMG Y and HMG I-C. HMG I and HMG Y are encoded by the same gene and are 
generated through alternative RNA splicing, whereas a separated gene encodes HMG I-C 
(Bustin and Reeves, 1996). The HMG I proteins bind specifically to the minor groove of 
AT-rich regions of DNA via three short basic repeats containing the core motif GRGRP 
or PRGRP (Huth et al., 1997). The HMG I(Y) proteins can affect gene expression in 
different ways, including alteration of DNA conformation through DNA bending and 
distortion, increase of supercoiling of plasmid DNA (Nissen and Reeves, 1995), binding 
to entry/exit regions of nucleosomes (Reeves and Nissen, 1993), change of rotational 
setting of DNA on nucleosomes (Reeves and Nissen, 1993), enhancement or inhibition of 
transcription factor binding (Bustin and Reeves, 1996), binding to transcription factor 
consensus sites on gene promoters (Bustin and Reeves, 1996), or stabilization of 
enhancesome complexes on gene promoters (Yie et al., 1999).
There is increasing evidence that HMG I(Y) plays an important role in cytokine 
gene transcription. Many of the inducible cytokine genes contain a number of closely 
spaced HMG I(Y) binding sites overlapping or adjacent to other transcription factor 
binding sites in their promoter or enhancer regions. The multiple abilities of HMG I(Y) to 
alter DNA structure, modulate transcription factor binding and also to bind to 
nucleosomes may contribute to its influence on these gene promoters/enhancers. The
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IFN-ß promoter was the first cytokine gene promoter where HMG I(Y) was shown to be 
involved in transcription. IFN-ß is induced by virus infection in mammalian cells, and the 
transcription factor complexes involved have been studied in detail. HMG I(Y) appears to 
have an important role in the activation of IFN-ß transcription by facilitating the 
assembly of an enhanceosome at several organizational levels. HMG I(Y) can bind to 
four sites on the IFN-ß promoter and promotes the binding of NF-kB and ATF/c-Jun 
complexes to the PRDII and PRDIV sites, respectively (Du et al., 1993; Thanos and 
Maniatis, 1992, 1995). The relative arrangement of the transcription factor and HMG 
I(Y) binding sites appears to be critical for the enhancement of factor binding by 
HMGI(Y). The specific directional binding as well as the molecular cooperativity of the 
two HMG I(Y) molecules bound to the promoter are critical for enhanceosome assembly 
(Yie, et al., 1997). HMG I(Y) binding has been shown to alter the DNA structure of the 
IFN-ß promoter by unbending an intrinsic bend in the promoter (Falvo et al., 1995). 
Direct contact between HMG I(Y) and the transcription factors is also required for the 
completion of enhanceosome assembly (Yie et al., 1997, 1999).
In the case of the IL-2 gene, functional studies using antisense expression for HMG 
I(Y) RNA showed that HMG I(Y) was a positive activator of the IL-2 promoter (Himes et 
al., 1996, 2000). In vitro studies showed that HMG I(Y) could affect the binding of many 
of the transcription factors involved in IL-2 transcription including NFAT, NF-kB and 
AP-1 (Himes et al., 1996, 2000; Shang et al., 1999). The non-DNA binding mutant of 
HMG I(Y) acted as a dominant-negative protein inhibiting the activity of the IL-2 
promoter (Himes et al., 2000). This implies that the DNA binding capacity of HMG I(Y) 
is important for transcriptional activity. Experiments on the IFN-ß promoter have also 
shown that both DNA binding and HMGI(Y):transcription factor interactions are 
important for the formation of a functional IFN-ß enhanceosome (Yie et al., 1999).
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HMG I(Y) has also been shown to play an important role in IL-4 gene expression. 
There are several HMG I(Y) binding sites in the IL-4 promoter (Chuvpilo et al., 1993). 
These sites are associated with functional binding sites for NFAT or NFAT/AP-1 
complexes and Oct proteins (Chuvpilo et al., 1993). It has been shown that HMG I(Y) 
inhibits the binding of NFAT factors to one specific region of the IL-4 promoter (Klein- 
Hessling et al., 1996). When the HMG I(Y) binding site was mutated, leaving the NFATp 
binding site intact, an increase in IL-4 promoter activity was observed. The relative levels 
of NFATp and HMG I(Y) may be important in determining the functional outcome of the 
interaction between NFATp and HMG I(Y).
HMGI(Y) has been shown to inhibit transcription from the germline 
immunoglobulin epsilon (Ige) gene (Kim et al., 1995). It is interesting that this gene is 
induced by IL-4 and thus may share some similarity with the IL-4 promoter itself. It was 
found that IL-4 treatment of cells could lead to serine phosphorylation of HMG I(Y) 
(Wang et al., 1995), which could, in turn, lead to an increase in transcription from those 
genes that are repressed by HMGI(Y) such as IL-4 or Ige. On the other hand, promoters 
of genes such as IL-2 or GM-CSF, that are activated HMG I(Y), may have decreased 
activity after HMG I(Y) phosphorylation (Shannon et al., 2001).
1.5.4. IL-5 gene regulation
I.5.4.I. Activation of the IL-5 gene
The expression of IL-5 is closely linked with the production of eosinophils. These 
blood and tissue leukocytes are produced in a limited range of immune responses, 
indicating a unique control of the production of IL-5 in the T-cell response to antigen. 
Clearly this control is regulated at the level of gene expression. Considering the tight
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inducible control of IL-5 expression, as well as the similarity in the development of 
eosinophilia in different species, it might be expected that the specific regulatory 
elements involved in its expression would be highly conserved. It is interesting in this 
context that the flanking regions of the human and mouse genes have very limited 
homology. The region -80 to -20 is highly conserved, but upstream and 3' regions give 
little indication of common elements that might be involved in the specific regulation of 
the gene. The conserved proximal region appears critical for inducible expression, but as 
discussed below, other elements outside this region are probably also required for overall 
regulation.
Activation of T-cells requires both interaction of the T-cell receptor (TCR) complex 
with antigens in association with the major histocompatibility complex and co­
stimulation generated by the CD28 signalling pathway. Activation of the TCR results in 
an increase in intracellular calcium concentration and activation of protein kinase C 
(PKC) (Perlmutter et al., 1993). In vitro activation of T cells can be achieved by 
stimulating the TCR with anti-CD3 mAb. The TCR-CD3 pathway is sensitive to CsA and 
FK506. Stimulation of the TCR alone, however, is insufficient to fully activate most T 
cells and a second signal provided by antigen presenting cells (APC) is also required 
(Rincon and Flavell, 1994). This costimulatory signal can be generated through the CD28 
signaling pathway (Jenkins et ah, 1993). Interestingly CD28 signal transduction is 
resistant to CsA but is sensitive to rapamycin (Lai and Tan, 1994). Commonly used 
agents which mimic T cell activation are PMA and ionomycin (a Ca2+ ionophore used to 
raise intracellular Ca2+ levels).
A widely used cell line for studies on IL-5 regulation is the T cell leukemia line EL- 
4. IL-5 expression has been shown to be strongly stimulated by the combination of PMA
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and cAMP in these cells (Lee et al., 1993; Lee et al., 1994a). Thus it appears that optimal 
induction of the mouse IL-5 gene in EL-4 cells requires two signals, one generated by 
PMA which activates PKC (Nishizuka, 1986) and the other by cAMP which exerts its 
action through the PKA pathway (Lee et al., 1993). It is important to note that while 
cAMP markedly enhances the expression of IL-5, it has an inhibitory effect on expression 
of IL-2, IL-3, and GM-CSF (Lee et al., 1993, Chen and Rothenberg., 1994; Derigs 
et al., 1990) and also no effect on IL-4 (Novak and Rothenberg, 1990).
Studies of IL-5 gene activation compared with a number of other cytokine genes 
have also been carried out with the mouse Th2 clone D10.G4.1 (Naora et al., 1994b, 
Naora et al., 1994a). The regulation of the IL-5 gene was shown to be primarily at the 
level of transcription and to involve de novo protein synthesis. Expression of the IL-5, IL- 
6 and IL-10 genes induced by ConA was resistant to CsA whereas IL-3 and IL-4 
expression was completely inhibited. In keeping with this, the IL-5, IL-6 and IL-10 genes 
were not induced by Ca2+ ionophore in contrast to the IL-3 and IL-4 genes. The IL-5, IL-6 
and IL-10 genes were induced by IL -la , PMA and forskolin (an activator of adenylate 
cyclase) and Abs to CD2 and CD45. The effect of inhibitors suggested that IL-5 gene 
expression was dependent on PKC and PKA activation (Naora et al., 1994a). Similar 
comparative studies were carried out using EL-4 (Naora et al., 1994b).
Cell systems suitable for studying human IL-5 regulation have been limited and the 
mouse EL-4 line has been used in the study of human IL-5 regulation (Gruart-Gouilleux 
et al., 1995). The human Jurkat T cell line has also been used in some cases (Blumenthal 
et al., 1999) but has the disadvantage that it does not express IL-5 when stimulated and 
therefore must be lacking part of the regulatory apparatus for normal IL-5 induction. The 
human leukemia T cell line HSB-2 is a potential model for regulation studies. Activation
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of the human IL-5 gene in these cells can be achieved with PMA/ionomycin stimulation 
and expression is repressed by CsA and FK506 (Rolfe et al., 1997). IL-5 expression in 
this cell line is therefore similar to that in normal T cells (Rolfe et al., 1992). Recently, 
the PER-117 human T cell leukemia line has been shown to be a useful model for IL-5 
regulation studies (Mordvinov et al., 1999) but this cell line has not been generally 
available.
1.5.4.2. Transcription regulation of the mouse IL-5 gene
Studies on the regulation of the mouse IL-5 gene have used a variety of promoter 
constructs of varying lengths carrying up to3859 base pairs of upstream sequence. To 
simplify discussion, it is useful to define the proximal promoter region as the region-1 to -88. 
This region seems to have particular significance in IL-5 gene induction and is the main 
focus of the work described in this thesis.
Previous studies in this laboratory using stable transfection of D10W cells (a faster 
growing derivative of the Th2 clone D10.G4.1) showed that a reporter construct carrying 
1170 bp upstream sequence could be induced over 100-fold when the cells were 
stimulated by PMA/cAMP and was repressed by dexamethasone (Tan, 1998; Young et 
al., 1999). Deletion studies showed that the proximal promoter region gave similar high 
levels of inducibility which was Th2 specific (Tan, 1998; Young et al., 1999). No major 
positive control elements upstream of the proximal promoter region were detected by 
deletion studies. The expression directed by the proximal promoter region was found not 
to be repressible by dexamethasone indicating upstream elements involved in this 
property. In contrast to the results of Tan (1998), a variety of elements in the upstream 
region or at the 3' end of the gene have been reported by other laboratories as affecting 
IL-5 expression but there is considerable disagreement over the results. Most are positive
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elements. These include: mPREl-IL5 (-90/-79, Schwenger et al., 1998); IL-5RE-B (-96/- 
76, Stranick et al., 1998); IL-5P (-117/-92, Lee et al., 1995) which binds NFATp, c-Fos 
and c-Jun; IL-5PRE (-224/-81, Stranick et al., 1995); mPRE2- IL5 (-470/-459, 
Schwenger et al., 1998); mDRE (3' end of gene, Salerno et al., 2000) which binds Octl 
and Oct2. Some negative elements have also been reported including: NRE-II (-300/-261, 
Stranick et al., 1995); NRE-I (-431/-392, Stranick et al., 1995); CTF/NF1 (-940/-928, 
Bourke et al., 1995). As yet there is little consensus on the importance of the upstream 
elements in regulating IL-5 expression.
There is more consensus and, in general, more data available for the role of the 
regulatory elements in the proximal promoter region. The proximal promoter region of 
the IL-5 gene carries a region which is highly conserved in the human and mouse IL-5 
and GM-CSF genes, and to a lesser extent in the IL-3, IL-4 and G-CSF genes (Campbell 
et al., 1988; Miyatake et al., 1991). This region is referred to as the CLEO (conserved 
lymphokine element 0) element (Miyatake et al., 1991) which is located at -53 to -39 in 
the mouse IL-5 promoter. CLEO has been shown to be a positive regulatory element in 
both IL-5 (Naora et al., 1994a; Lee et al., 1995; Bourke et al., 1995) and GM-CSF 
(Masuda et al., 1993; Fraser et al., 1994). The CLEO element is essential for the induction 
of the GM-CSF promoter by PMA and Ca2+ ionophore through a calcineurin-mediated 
pathway (Miyatake et al., 1991; Nimer et al.,1990; Tsuboi et al., 1994). Deletion analysis 
of the mouse IL-5 promoter in EL-4 cells showed the CLEO element was critical for IL-5 
expression. Mutations in this element almost completely abolished expression in response 
to PMA and PMA/cAMP (Lee et al., 1995). Similarly, the importance of this element was 
demonstrated by the establishment of stable transfectants in EL-4 and DIO cells. 
Mutation of CLEO markedly reduced expression of the gene in DIO cells induced by 
PMA or ConA (Naora et al., 1994b) and in EL-4 cells when induced by PMA (Bourke et
31
Chapter 1 General Introduction
al., 1995). Support for the role of CLEO in DIO cells has also come from the work of 
Stranick et al., (1998). In these studies, proteins binding to the CLEO element were 
generally found to be inducible with little binding activity in nuclear extracts from 
unstimulated cells. Proteins of similar mobility were noted in an EL-4 subline which did 
not produce IL-5, as well as in the human Jurkat cell line which does not produce IL-5. 
Thus induction of the protein complexes binding to the CLEO element appears to be 
essential for expression but is not specifically related to the expression of the IL-5 gene 
(Karlen et al., 1996). However, Stranick et al., (1995) reported that the protein complexes 
binding to the CLEO element were expressed constitutively and that the CLEO element 
contributed to but was not essential for IL-5 reporter expression in antigen-stimulated 
D10.G4.1 cells.
The CLEO element has been recognized to consist of putative AP-1 and Ets/NFAT 
binding sites which are adjacent. Binding to the AP-1 site has been relatively well studied 
but binding to the Ets/NFAT site has not been detected. The major inducible proteins 
binding to the AP-1 region of the mouse IL-5 CLEO element have been reported to be 
JunB and JunD in DIO cells (Zhang et al., 1997), c-Fos , JunB and JunD in EL-4 cells 
(Siegel et al., 1995), and c-Fos, JunB and NFAT in EL-4 cells (Karlen et al., 1996). More 
recently it has been demonstrated that the immediate 5' end of the CLEO element carries 
an Oct site which overlaps with the AP-1 site (Salerno et al., 2001).
There are several reports suggesting the importance of a GATA site (-71 to -66) 
located upstream of the CLEO element in regulating IL-5 expression. These include 
studies in EL-4 cells (Siegel et al., 1995; Lee et al., 1995) and in D10.G4.1 (Zhang et al., 
1997, 1998; Lee et al., 1998; Stranick et al., 1998). Siegel et al., (1995) and Zhang et al., 
(1997) showed that GATA-3 rather than GATA-4 bound to GATA element. GATA-3 has
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been shown to be specifically expressed in Th2 cells and to be important in the 
expression of Th2-specific cytokines (Zheng and Flavell, 1997; Zhang et al., 1998). The 
proximity of the GATA element to CLEO suggests the possibility that these elements and 
the factors interacting with them work in concert in regulating IL-5 gene induction.
I.5.4.3. Transcriptional regulation of the human IL-5 gene
Van Straaten et al., (1994) showed that Con A or PMA but not Ca2+ionophore could 
stimulate IL-5 expression in human peripheral T cells. The expression of IL-5 could also 
be blocked by inhibition of protein synthesis. These results show a strong similarity with 
studies of mouse IL-5 gene expression (Naora and Young, 1995). The CLEO element and 
GATA site in the proximal promoter region of the IL-5 gene is highly conserved between 
mouse and human. However, studies with the human IL-5 promoter in mouse EL-4 cells 
showed that deletion to -67, which would delete the GATA site, had no effect on IL-5 
expression (Gruart-Gouilleux et al., 1995). Also, studies of human IL-5 expression in 
mouse DIO cells demonstrated that deletion to -80 increased the constitutive expression 
and removed inducibility (Stranick et al., 1997), suggesting that the CLEO element, which 
is left intact, is not responsible for inducible expression. Such results are in contrast to the 
demonstrated roles of CLEO and the proximal GATA site in mouse IL-5 expression. On 
the other hand, Yamagata et al., (1995, 1997) showed that the GATA site has a 
significant effect on human IL-5 expression when tested in the ATL-16T cell line which 
expresses IL-5 constitutively and also demonstrated a role for the CLEO element. The 
transactivator protein Tax appeared to stimulate expression via the CLEO element 
(Yamagata et al., 1997; Blumenthal et al., 1999). One puzzling feature of these studies, 
which remains controversial, is the demonstration of a selective role for GATA-4 in 
binding to the GATA site and functioning in IL-5 gene expression. Studies with Jurkat T
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cells suggested that Etsl or Ets2 could function at the Ets/NFAT site of the CLEO 
element (Blumenthal et aL, 1999).
The above studies either used the mouse cell line EL-4 or human cell lines which 
do not express the IL-5 gene in a fashion analogous to normal T cells. More recently, the 
human T cell leukemia line PER-117 has been shown to be a suitable model for IL-5 
expression studies (Mordvinov et al., 1999) and data obtained supporting the involvement 
of CLEO in human IL-5 expression (Thomas et al., 1999). Binding of Oct factors to the 
region -67 to -30 of the human IL-5 promoter, which includes the CLEO element, was 
demonstrated (Gruart-Gouilleux et al., 1995), suggesting a role for this group of 
transcription factors in the activation of IL-5. Octl and Oct2 have been reported to be 
involved in human IL-5 gene activation in the PER-117 cell line. One of the binding sites 
is the CLEO element (Thomas et al., 1999).
There have also been several regulatory elements reported which are outside of the 
proximal promoter region of the human IL-5 gene. These include the positive elements: 
REII (-123/-100, Stranick et al., 1997) which binds NFAT and AP-1, REIH (-17-/-130, 
Stranick et al., 1997) and one at -312/-227 (Gruart-Gouilleux et al., 1995) which binds 
Oct, and the negative elements: BR3 (-90/-79, Mordvinov et al., 1999) which binds Octl 
and YY1, a GATA site (-400, Schwenger et al., 2001) which binds GATA-3 acting as a 
repressor and hPRE2-IL-5 (-459/-447, Schwenger et al., 1999) which binds NFAT and 
YY1.
1.6. Aims of the research
It is clear from the above summary that there is still disagreement about the 
molecular mechanisms involved in regulation of the IL-5 gene. Some of these
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disagreements may come from studying IL-5 regulation in cell lines which do not express 
the endogenous IL-5 gene such as Jurkat cells, or which express IL-5 in an abnormal 
fashion such as the human T-cell leukemia cell line ATL-16T. The study of human IL-5 
constructs in mouse cell lines is also not desirable. The mouse thymoma EL-4 cell line 
has been widely used to study IL-5 regulation but it is not a T-cell clone and it is 
therefore desirable to confirm results in Th2 cells such as D10.G4.1. IL-5 has been shown 
to play an important role in the pathogenesis of allergic diseases such as asthma. 
Therefore there is a considerable interest in identifying the molecular mechanisms 
controlling the IL-5 expression. Studies in mouse T cell lines provide a valuable starting 
point for identification of the basic control mechanisms relevant to IL-5 gene expression 
which should then be followed up in human T cells if the findings are to be applicable to 
human allergic conditions.
There have been relatively few functional studies on the identification of 
transcription factors which are specifically involved in both human and mouse IL-5 gene 
activation even though several potential regulatory elements have been shown to be 
important in IL-5 expression. In addition, there has been little clarification of the factors 
which function at the Ets/NFAT site in the CLEO element. Also little is known about the 
MAP kinase pathways activating the IL-5 transcription.
In this study, the mouse DIO Th2 clone cell and the human HSB-2 T cell leukemia 
line were used to study the transcriptional activation mechanisms of the mouse and 
human IL-5 genes, respectively. Both cell lines exhibit inducible expression of the IL-5 
gene and appear to be good models for studying IL-5 gene regulation.
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Specific aims of the research:
1) To establish transient transfection systems in both mouse D10W cells and human 
HSB-2 cells using the sensitive luciferase reporter gene.
2)  . To determine the optimum conditions for inducible expression of reporter genes 
in D10W and HSB-2 cells
3) To investigate the transcription factors functioning at the transcriptional elements 
of the IL-5 promoter proximal region and to study possible synergistic effects between 
them using transactivation assays. In addition, to clarify the activity of GATA-3 
compared with GATA-4 and whether Ets or NFAT family members function at the CLEO 
element.
4) To study the role of MAP kinase pathways in induction of IL-5 gene expression.
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Chapter 2 Materials and Methods
2.1. Preparation of bacterial cells
2.1.1. E. coli DH5aF'IQ
The main bacterial cell used in this thesis was E. coli DH5aF'IQ. This strain 
from Life Technologies Inc., USA, is a derivative of Hanahan’s strain DH5 
(Hanahan, 1985). The /acZAM15 locus is a partial deletion of the ß-galactosidase 
gene that allows cx-complementation between the portion of the ß-galactosidase gene 
carried by the pUC or M13-based plasmid and the portion on the chromosome of the 
E. coli host cell, allowing the blue/white screening of clones. The recAi and endAl 
alleles greatly enhance the ability to retain recombinant plasmids. The F' episome 
contains a kanamycin-resistance marker (zzf::Tn5), allowing DH5otF'IQ to be 
maintained on rich medium (LB or YT) containing kanamycin without loss of the F' 
episome. The strain also expresses large amounts of the lacl repressor due to the laclq 
locus, thus allowing IPTG induction of cloned sequences under the control of the lac 
promoter.
2.1.2. Electro-competent bacterial cells
A single colony of DH5a bacterial cells was inoculated into 50 ml of LB 
medium and the culture shaken at 250 rpm at 37°C overnight. 10 ml of overnight 
culture was used to inoculate 1000 ml of LB medium and the culture grown with 
shaking at 37°C until the OD600 reached between 0.5 and 1.0. The cells were then 
chilled on ice for 30 minutes and centrifuged at 4°C for 15 minutes at 5000 rpm. The
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supernatant was removed and the cells were washed once with 1000 ml of cold MQ 
water, once with 500 ml of cold MQ water and once with 20 ml of cold water before 
final resuspension in 3 ml of cold 10% glycerol. Forty pi aliquots of the suspension 
were dispensed into sterile Eppendorf tubes on ice and stored at -70°C.
2.1.3. Transformation of electro-competent bacterial cells
Ten ng of DNA was mixed with 40 pi of electro-competent cells in an ice-cold 
micro-cuvette (2 mm path length), The cells were transfected by electroporation using 
the Bio-Rad Gene Pulser II set at 2.5 KV, a capacitance of 25 pF and with 200 Ohms 
resistance. The transformed cells were immediately incubated in 1 ml of LB at 37°C 
for an hour to allow recovery before selection on LB agar plates containing the 
appropriate antibiotic (usually ampicillin at 100 pg/ml).
2.2. Recombinant DNA techniques
2.2.1. Mini preparation of plasmid DNA
DNA was prepared using the WIZARD DNA Minprep Kit (Promega). 
according to the manufacturer's instructions. Briefly, cells from an overnight bacterial 
culture in medium supplemented with antibiotic (eg 100 pg/ml ampicillin) were 
harvested by centrifugation, and lysed by alkaline lysis. The lysate was neutralised 
and the cellular debris removed by centrifugation. The supernatant was passed 
through a silica-based matrix that allowed binding of the DNA. The DNA was 
subsequently eluted using T10E, buffer (10 mM Tris-HCl, 1 mM EDTA, pH8.0).
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2.2.2. Large scale preparation of plasmid DNA
Large amounts of DNA were prepared using the QIAGEN Maxiprep Kit 
according to the manufacturer's instructions. For low yielding plasmids, an 
amplication procedure was carried out prior to using the kit. A single colony of 
bacterial cells was used to inoculate 20 ml of LB medium supplemented with 100 
pg/ml ampicillin and grown overnight at 37°C with shaking at 250 rpm. 10 ml of 
overnight culture was used to inoculated 300 ml of fresh LB medium supplemented 
with 100 pg/ml ampicillin and the culture grown with shaking at 37°C until the OD 
600 was between 0.5 and 1.0. Chloramphenicol (170 pg/ml), a protein synthesis 
inhibitor, was then added and the culture grown under the same conditions overnight. 
The cells were harvested by centrifugation at 4000 rpm and lysed by alkaline lysis. 
After removal of the cell debris by centrifugation, the crude DNA was applied to an 
anion-exchange resin under conditions of low salt. RNA, proteins and low molecular 
weight components were removed by a medium salt wash. The plasmid DNA was 
eluted by a high salt buffer, concentrated and desalted by isopropanol precipitation.
2.2.3. Quantitation of nucleic acids
The amount of DNA or RNA in solution was quantitated by measuring its 
optical density (OD) at 260 nm and the concentration calculated using the 
relationship that at 260 nm, an OD of 1 is equivalent to 50 pg/ml of double stranded 
DNA and 40pg/ml of single stranded RNA. The ratio between the OD reading at 260 
nm and 280 nm (OD260/OD280) was used to give an estimate of the purity of the 
nucleic acid preparation. Pure preparations of DNA and RNA have OD260/OD280 ratios
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of 1.8 and 2.0 respectively, with lower readings being obtained if there is protein or 
phenol contamination (Sambrook et al., 1989).
2.2.4. Restriction enzyme digestion of DNA
Restriction endonucleases were supplied by New England Biolabs or 
Boehringer Mannheim. DNA digestion was performed according to the 
manufacturer's protocols and in the buffer specified for each enzyme. The DNA 
concentration in the final reaction volume was kept at between 50 to 100 ng/pl. 
Bovine serum albumin (BSA) was routinely included in the reaction at 0.1 mg/ml.
2.2.5. Electrophoresis of DNA
Agarose gel electrophoresis was used to separate and purify DNA fragments 
generated by restriction enzyme digestion of plasmid DNA. Electrophoresis was 
carried out using a voltage gradient of between 1-5 V/cm and using 1 x TAE buffer 
containing 40 mM Tris-acetate, ImM Tris-HCl pH 8.0. Prior to loading, the DNA 
samples were mixed with 0.1 volume of 10 X loading buffer containing 0.25% 
bromophenol blue, 0.25% xylene cyanol, and 40% sucrose.
2.2.6. Purification of DNA fragments
After agarose gel electrophoresis, the DNA fragment of interest was purified 
using the Bresaclean Kit (Bresatec Inc., Australia) according to the manufacturer's 
instructions. Briefly, the electrophoresed DNA fragment was extracted from an 
agarose gel using a chaotropic salt (Nal) and absorbed to a silica matrix. The matrix 
was washed to remove impurities. The silica-DNA pellet was resuspended in TjqE,
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and incubated at 50°C for two minutes. The eluted DNA was recovered by 
centrifugation.
2.2.7. Dephosphorylation of DNA termini
Following restriction enzyme digestion, the DNA was purifed using Bresaclean 
Kit (Bresatec, Australia). The pellet was then dissolved in a buffer containing 50 mM 
Tris-HCl pH8.5, 0.1 mM EDTA and 1 U of calf intestinal alkaline phosphatase (CIP) 
per 2 pmol of DNA ends was added then the mixture incubated at 37°C for 15 
minutes. After that, an equal amount of CIP was added and the incubation continued 
at 55°C for 45 minutes. The reaction was terminated by the addition of SDS, EDTA 
pH8.0 and Proteinase K to final concentrations of 0.5%, 5 mM and 100pg/ml 
respectively and the mixture incubated at 55°C for a further 30 minutes. The DNA 
was then purified using the Bresaclean Kit. The DNA was then ready for ligation.
2.2.8. DNA ligation
Generally, a 5-fold molar excess of insert DNA to vector DNA was used in 
cohesive end ligation reactions. For blunt-end ligation a 10- to 20-fold molar excess 
of insert DNA was used. The ligation reaction was carried out in a 10 pi volume 
containing 30 mM Tris-HCl pH.8, 10 mM MgCl2, 10 mM DTT, ImM ATP and 1-3 
Weiss units of T4 DNA ligase (Promega). The reactions were incubated at 16°C for 
16 hours before termination of the reaction by heating at 65°C for 15 minutes.
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2.2.9. PCR analysis of recombinant plasmid clones
Colonies were picked and transferred to 50 pi of MQ water with a sterile 
toothpick and the suspensions incubated at 65°C for 10 minutes to lyse the bacterial 
cells. Each colony was also used to inoculate a numbered grid plate. Five pi of lysate 
was amplified in a 20 pi reaction containing 5 pmol of each of two flanking primers 
(sense primer on the inserted DNA; anti-sense primer on the vector sequence), 0.2 
mM of dNTPs, 1.5 mM MgCl2, 10 mM Tris-HCL, 50 mM KC1, 0.1 units of Taq 
DNA polymerase (Promega). The PCR reaction was carried out in a Thermal cycler 
(Corbett, FTS-1) using the following conditions: denaturation at 94°C for 10 seconds, 
annealing at 65°C for 10 seconds, and extension at 72 °C for 1 minute. This cycling 
was repeated 35 times, and at the end of the procedure, the PCR products were 
analysed by agarose gel eletrophoresis.
(I) Primer pairs used for screening mouse IL-5 promoter mutants 
Sense primer 5’-ATGGGCGTCTCTAGAGAGATCC-3’
Anti-sense primer 5'-TTATGCAGTTGCTCTCCAGCG-3'
(II) Primer used for screening human IL-5 promoter mutants
Sense primer 5'-GCAAATGTGGGGCAATGATG-3'. This primer binds to the
human IL-5 promoter region'and was used to directly sequence the colonies obtained 
(-160 to -140)
from the mutagenesis.
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2.2.10. Mutagenesis of DNA
The QuickChangeTM Site-directed Mutagenesis system (Stratagene) was used. 
This system uses PfuTurbo DNA polymerase and a thermal temperature cycler. 
PfuTurbo DNA polymerase replicates both plasmid strands with high fidelity and 
without displacing the mutant oligonucleotide primers. Briefly, the basic procedure 
uses a supercoiled double-stranded DNA vector with an insert of interest and two 
synthetic oligonucleotide prim ers containing the desired m utation. The 
oligonucleotide primers, each complementary to opposite strands of the vector, are 
extended during temperature cycling using PfuTurbo DNA polymerase. Incorporation 
of the oligonucleotide primers generates a mutated plasmid containing staggered 
nicks. Following temperature cycling, the product is treated with Dpn I. The Dpn I 
endonuclease (target sequence: 5'-Gm6ATC-3') is specific for methylated and 
hemimethylated DNA and is used to digest the parental DNA template and to select 
for the mutation-containing synthesized DNA. DNA isolated from almost all 
Escherichia coli strains is dam  methylated and therefore susceptible to Dpn 1 
digestion. The nicked vector DNA incorporating the desired mutations is then 
transformed into D H 5a competent cells.
Primers for mutagenesis
Primers used for site-directed mutagenesis of the AP-1, Ets and GATA binding 
sites of the human IL-5 promoter are listed below:
Ets site mutant:
5'-G ATTGTT AG A A ATT ATTC AT ggaaTC A A AG AC AG AC A AT A A ATTG-3'
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AP-1 site mutant:
5'-CTCTATCTGATTGTTAGAAATccTatATTTCCTCAAAGACAGAC-3' 
GATA site mutant:
5'-CC ATT ATT AGGC ATTCTCT AagTG ATTGTT AGA A ATT ATTCATTTC3'
Primers used for site-directed mutagenesis of the AP-1, Ets/NFAT and GATA 
sites of mouse IL-5 promoter are listed below:
Ets site mutant:
5'-G ATTGTT AGC A ATT ATTC AT ggaaTC AG AG AGAG A AT A A ATTGCT-3 
AP-1 site mutant:
5'-CTCTATCTGATTGTTAGCAATccTatATTTCCTCAGAGAGAGAA-3' 
GATA site mutant:
5'-CCTTT ATT AGGTGTCCTCT AagTG ATTGTT AG A A ATT ATTC ATTTC-3'
Mutagenesis procedure
M utagenesis was carried out using the QuickChangeTM  Site-directed 
Mutagenesis system (Stratagene) according to the manufacturer's instructions. 
Briefly, the reaction mixture consisted of 125 ng of each of two complementary 
primers containing the desired mutation as listed above, 50 ng of double stranded 
plasmid template, 50 pM dNTPs, 1.5 mM MgC12, 10 mM Tris-HCl pH9.0, 50 mM 
KC1, and 2.5 units PfuTurbo DNA polymerase in a final volume of 50 pi. The
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following program was used: 1 cycle of 30 seconds at 95°C; 18 cycles of 30 seconds 
at 95°C (denaturation), 1 minute at 55°C (annealing), 14 minutes at 68°C (extension); 
and 1 cycle of 7 minutes. After mutagenesis reaction,10 units of Dpn I was added, the 
reaction mixture incubated at 37 °C for 1 hour and then 1 pi of reaction mixture was 
used for transformation. After transformation, individual colonies or pools of colonies 
were picked and screened by PCR. Mutants were sequenced to verify that the desired 
mutation had been introduced into the target gene.
2.3. Electrophoretic mobility shift assays (EMSA)
2.3.1. Preparation of oligonucleotide probes
Oligonucleotide probes corresponding to various transcription factor binding 
sites on the proximal promoter region of IL-5 were synthesised by the Biomolecular 
Resource Facility, JCSMR. The primers corresponding to those regions are listed 
below. Complementary primers were annealed by combining equimolar amounts of 
the primer pairs and incubating at 65°C for 10 min. The primers were further heated 
at 100°C for 5 minutes and the mixture allowed to slowly cool to room temperature in 
the water bath and stored at -20°C.
2.3.2. Labelling of oligonucleotide probes
One pmol of primer was labelled with 20 pCi of y-32P ATP (3000 Ci/mmol, 
GeneWorks, Australia) in a 10 pi reaction with 0.1 units of polynucleotide kinase 
(BioLabs) in provided buffer. The reaction was incubated at 37°C for 30 minutes. The 
labelled primers were separated from unincorporated nucleotides on an 8%
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acrylamide (acrylamide-bisacrylamide, 29:1) 1 x Tris-borate-EDTA (TBE) gel. The 
gel was autoradiographed (Kodak) for 1 minute and the fragments were excised from 
the gel and eluted in an elution buffer containing 0.5 M ammonium acetate, 10 mM 
magnesium acetate, 1 mM EDTA, pH 8.0 and 0.1% SDS by incubation overnight at 
37°C with shaking. The radiolabelled primers were ethanol-precipitated, the pellets 
washed with 70% ethanol and dried under vacuum followed by resuspension in 12 pi 
T jqEj pH 8.0. The radioactivity of lpl of the DNA was measured using a liquid 
Scintillation Analyser (Packard, 1900CA) and the primers diluted to 300000 cpm/pl.
The following oligonucleotide probes were used for EMSA:
Proximal promoter region of the mouse IL-5 gene:
-60 in
I " f
5,-TTAGCAATTATTCATTTCCTCAGAGAGAG-3t 
AP-1 Ets/NFAT
PI: wt mIL-5 promoter 5'-TTAGCAATTATTCATTTCCTCAGAGAGAG-3' 
P2: IL-5 AP-1 mutant 5'- TTAGCAATccTatATTTCCTCAGAGAGAG-3’
P3: IL-5 Ets mutant 5'-TTAGCAATTATTCATggaaTCAGAGAGAG-3'
P4: AP-1 consensus 5'-CGCTTGATGACTCAGCCGGAA-3'
P5: Ets consensus 5'-GATCGAGAGCGGAAGCGCGCGATC-3'
P6: Ets consensus mutant 5'-GATCGAGAGCaGAAGCGCGCGATC-3'
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P7: non-specific sequence 5'-CTCATACACACAGTACGCTGCAACT-3'
2.3.3. Binding assay
Binding reactions were performed in a final volume of 25 pi containing lpg of 
poly (dl.dC), 25 mM Hepes pH 7.9, 25 mM NaCl, 10% glycerol, ImM EDTA, ImM 
DTT, 0.025% NP-40). The recombinant proteins and 15000 cpm (1.25 ng) of labelled 
DNA probes were added to the reaction mixtures on ice and then they were incubated 
for 10-15 minutes at room temperature. After addition of 3 pi of loading dye 
containing 0.25% bromophenol blue, 0.25% xylene cyanol, 40% sucrose, the samples 
were loaded directly onto a pre-electrophoresed 4.5% non-denaturing polyacrylamide 
0.5 x TBE gel and electrophoresed at 15V/cm at 4°C. The gels were dried and 
exposed to X-ray film (Kodak) at room temperature overnight.
In competition experiments, 100-fold molar excess unlabelled oligonucleotides 
which correspond to the same binding site or other unrelated binding sequences were 
added to the reactions.
2.4. Preparation of reporter and expression constructs
2.4.1. pXPG luciferase reporter construct
pXPG plasmid was generated by incorporating a novel high-copy origin of 
replication and a modified luciferase gene into a pXPl-derived vector that efficiently 
blocks read-through transcription in eukaryotic cells (Bert et al., 2000). pXPG 
encodes the luciferase gene derived from pGL3 that lacks a peroxisomal targeting 
sequence, thereby allowing accumulation of luciferase protein in the cytoplasm rather
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than in subcellular organelles of transfected eukaryotic cells. pXPG has distinct 
advantages over pGL3, because it contains SV40 polyadenylation signals that appear 
to be more efficient at blocking read-through transcription than the synethetic 
polyadenylation signal present in pGL3. pXPG contains a novel mutation near the 
origin of replication that increases plasmid copy number in E.coli. This mutation 
alters the -10 sequence in the RNA II promoter of the ColEl origin of replication 
from TAATCT to TAATAT. This sequence is a closer match to the consensus -10 
element, suggesting that the mutation increases copy number by increasing the rate of 
transcription of the RNA II replication promoter. Unlike pUC, which reverts to low 
copy number at 30°C, the pXPG mutation supports a higher copy number at both 
37°C and 30°C (Bert et al., 2000).
2.4.2. Mouse IL-5 luciferase reporter construct
The -1170mIL-5Luc reporter construct used in this work contains 
approximately 1170 bp of sequence preceding the transcription initiation site of the 
mouse IL-5 promoter. A Sad  fragment from -1170SynCATmIL-5 construct which 
encompasses the -1174 to +26 of the 5'-unstranslated region of the mouse IL-5 gene 
was cloned into the Sad  site of the pXPG luciferase reporter construct. The mutations 
of AP-1, Ets/NFAT and GATA sites of IL-5 promoter were made in this construct.
The -88mIL-5Luc construct which carries the proximal 88 bp of the mIL-5 
promoter was generated by PCR. Addition of a Kpn I site on the sense primer and a 
Bam HI site on the anti-sense primer allowed the fragment to be subcloned into the 
pXPG luciferase reporter plasmid. The construct was verified by sequencing.
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2.4.3. Human IL-5 luciferase reporter construct
The -1.2khIL-5Luc construct which carries 1200 bp of the upstream region of 
the human IL-5 promoter was provided by Boehrimger-Ingelheim. This vector is 
based on pXPl which was described previously (Nordeen, 1988).
2.4.4. Mammalian expression constructs
2.4.4.1. pEFIRES-p expression plasmid
pEFIRES-p consists of the human elongation factor l a  (EF-la) promoter 
driving transcription of a chimaeric intron, multiple cloning site, internal ribosome 
entry sites (IRES) and the puromycin N-acetyltransferase (pac) resistance marker 
gene as a single mRNA species. This plasmid combines the advantages of a 
bicistronic message with EF-la promoter to drive high level protein expression. 
Details of this plasmid have been described elsewhere (Hobbs et al., 1998).
2.4.4.2. Expression plasmid for mouse GATA-3
2056 bp cDNA encoding GATA-3 was released by EcoR I from pGM mc5bB 
(Ko and Engel, 1993). This fragment was cloned into the EcoR I site of pEFIRES-p 
expression plasmid.
2.4.4.3. Expression plasmid for mouse GATA-4
1799 bp cDNA encoding GATA-4 was released by EcoR  I from 
pMT2mGATA-4 plasmid (Bielinska and Wilson, 1995). This fragment was cloned 
into EcoR I site of pEFIRES-p expression plasmid.
2.4.4.4. pEFBOS expression plasmid
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pEFBOS carries the SV40 replication origin, human E F-la promoter, the 
stuffer fragment from CDM8 vector and poly (A) adenylation signal from human G- 
CSF. The size of pEFBOS is 5.8 kb and the cDNA to be expressed can be inserted at 
Bst XI site using Bst XI adapters, or at the XZ?a I site using Xba I linkers. Details of 
this plasmid have been described elsewhere (Mizushima and Nagata, 1990).
The c-Jun, c-Fos, Etsl and Elfi expression constructs were made using 
pEFBOS expression vector under the control of the E F-la  promoter and were 
provided by I Kola (Monash University, Australia). The construct for dominant 
negative AP-1 was provided by C. Vinson (National Institutes of Health, Bethesda, 
USA).
NFATp and NFATc expression plasmids were provided by F. Shannon 
(JCSMR, ANU) These two expression plasmids were made using pREP4 expression 
vector derived by RSV promoter. Details of these plasmids were described elsewhere 
(Hoey et al„ 1995).
2.4.4.5. Plasmids for MAP kinase pathways studies
The p4 x AP-l/Ets construct carries four copies of a combined AP-l/Ets 
binding site of polyoma virus enhancer in front of a luciferase gene (Hoffmeyer et al., 
1999) and provided by Ulf R. Rapp (Universität Würzburg, Germany).
The expression vector Raf-BXB-CX encodes activated Raf which lacks the N- 
terminal negative regulatory domain and contains the C-terminal membrane targeting 
17 amino acids of Ki-Ras fused to the kinase domain of c-Raf. This construct is 
driven by the RSV-promoter of pRSPA (Hoffmeyer et al., 1998) and provided by Ulf 
R. Rapp (Universität Würzburg, Germany).
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The expression vector MLK3 is a activator of JNK and provided by Ulf R. 
Rapp (Universität Würzburg, Germany).
The expression vector MKK6E is a specific activator of p38. This vector uses 
the RSV-promoter of pRSPA (Hoffmeyer et al., 1998) and provided by Ulf R. Rapp 
(Universität Würzburg, Germany).
2.5. DNA Sequencing
All plasmid constructs generated in this study were verified by sequence 
analysis. DNA sequencing was performed using the ABI cycle sequencing system 
following the manufacturer's instructions using an Applied Biosystems Model 373A 
Automated DNA Sequencer. The sequencer was operated by the Biomolecular 
Resource Facility, JCSMR.
2.6. Cell culture
2.6.1. D10.G4.1 and D10W cells
The mouse CD3+, CD4+, CD8- T-cell clone D10.G4.1 is a conalbumin- 
specific, H-2 Iak restricted Th2 clone derived from AKR/J mice (Kaye et al., 1983) 
and was obtained from Dr. T. Mosmann (DNAX Research Institute, Palo Alto, CA). 
D10.G4.1 cell growth was induced by allogeneic stimulation every 10-14 days with a 
10-fold excess of irradiated spleen cells from 6-8 week old C57B1/6 female mice as 
accessory antigen presenting cells. D10.G4.1 produces significant levels of IL-5 
mRNA and protein after TCR-mediated stimulation, while IL-5 mRNA or protein can
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not be detected in the resting D10.G4.1 cells (Naora et al., 1994a; Stranick et al., 
1995).
D10W is a spontaneously derived subline of D10.G4.1 produced in this 
laboratory which grows more vigorously and still shows inducible expression of the 
IL-5 gene. IL-5 gene induction is also still repressed by dexamethasone. D10W cells 
appear to be less dependent, but not completely independent of TCR stimulation for 
growth. The conditions used for the growth and maintenance of D10W cells were the 
same as those for D10.G4.1 cells except that stimulation using irradiated spleen cells 
was not carried out.
2.6.2. Human HSB-2 cells
HSB-2 cells express CD2 surface receptors, which are a phenotypic marker of 
T lymphocytes but lacks CD3 and CD25 surface receptors. The induction of IL-5 
mRNA expression in HSB-2 cells occurs in response to stimulation with PMA and 
ionomycin (Rolfe et al., 1997; Valentine and Sewell, 1998) and IL-5 expression is 
repressed by CsA or FK506 as with normal human T cells (Rolfe et al., 1997; Rolfe 
et al., 1992). HSB-2 was provided by W. Sewell (St. Vincent's Hospital, NSW, 
Australia).
2.6.3. Maintenance of tissue culture cells
Mouse Th-2 type D10W cells and human HSB-2 cells were maintained in 
RPMI-1640 medium with the following additives: 10% fetal calf serum, 10 mM 
NaCl; 1 mM sodium pyruvate; 56.2 mM monothioglycerol; 60 pg/ml benzylpenicillin 
(Commonwealth Serum Laboratories [CSL], Australia); 100 pg/ml streptomycin
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(Sigma, St Louis, MO); 2 mM L-glutamine (CSL); 0.05 mM ß-mercaptoethanol 
(Sigma). For D10W, 25 units/ml of IL-2 were added. The IL-2 was prepared from 
Sf9 cells infected with a baculovirus expressing mouse IL-2 and was provided by S. 
Ford (JCSMR). One unit of IL-2 bioactivity is the amount of IL-2 required to support 
half-maximal proliferation of HT-2 cells. The medium was replaced with fresh 
medium containing IL-2 every three days. Both D10W and HSB-2 cells were grown 
at 37°C and 95% relative humidity.
2.7. Transfection assay
2.7.1. Optimization of transfection efficiency
An expression plasmid containing the gene encoding green fluorescent protein 
(GFP) was used to optimize transfection efficiency in D10W and HSB-2 cells. 5 x 106 
D10W or HSB-2 cells were mixed with 5 pg of GFP plasmid in 300 pi of RPMI- 
1640 supplemented with 20% FCS in electroporation cuvettes for 15 minutes at room 
temperature and subjected to voltage pulses ranging from 230 V to 310 V for D10W 
cells (220 V to 320 V for HSB-2 cells) at 975 pF capacitance in a GenePulser 
apparatus (Bio-Rad). Transfected cells were cultured in 5 ml of complete RPMI-1640 
medium for 20 hours. One ml of cells were transferred into FACS analysis tubes and 
stained with PI (Propidium iodide) at 10 pg/ml for 30 minutes, and then subjected to 
FACS assay. Both total number of dead cells and viable cells expressing GFP were 
determined. The conditions giving the best transfection efficiency of D10W or HSB-2 
cells were established.
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2.7.2. Stimulation of the cells
In these studies following chemicals have been used to treat the cells.
Phorbol myristate acetate (PMA) (Sigma): The stock solution of 10 ng/pl was 
made up in DMSO and stored in the dark at -20°C. The final concentration used was 
25ng/ml.
Dibutvryl cyclic AMP (cAMP) (Sigma): The stock solution of 0.1 M was made 
up in MQ water and stored in the dark at -20°C. The final concentration used was 1 
mM.
Ca2+ ionophore (A23187) (Sigma): The stock solution of lOmM was made up in 
DMSO and stored in the dark at -20°C. The final concentration used was ImM.
PD98059 (Calbiochem): a inhibitor of MAP kinase kinase (MEK). The stock 
solution of 20 mM was made up in DMSO and stored in the dark at -20°C.
SB203580 (Calbiochem): a specific inhibitor of p38 kinase. The stock solution 
of 10 mM was made up in DMSO and stored in the dark at -20°C.
2.7.3. Time course of IL-5 luciferase reporter gene expression
Five pg of -1170mIL5Luc or -1.2khIL-5Luc plasmid were transfected into 
D10W or HSB-2 cells according to the established conditions. Transfected cells were 
treated with PMA and cAMP or ionophore after periods of growth ranging from 0 
hour to 24 hours. The cells were harvested and luciferase assays were carried out as 
described below. Suitable times at which to measure for IL-5 reporter gene 
expression in D10W and HSB-2 cells were then determined.
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2.7.4. Transfection
D10W or HSB-2 cells were grown in RPMI-1640 completed medium and sub­
cultured at 5 x 105 cells/ml the day before transfection. The cells were harvested and 
re-suspended in the growth medium described above. 5 xlO6 cells were incubated 
with 20 pg of DNA (5pg of IL-5 reporter plasmids, 5 pg of different expression 
plasmid, and empty plasmid to make up to 20 pg of total DNA) in 300 pi of growth 
medium supplemented with 20% FCS for 15 minutes at room temperature, and 
subjected to electroporation at 270 V and 975 pF capacitance for D10W cells or 280 
V and 975 pF capacitance for HSB-2 cells (Bio-Rad GenePulser). The cells were 
transfered into 5 ml of fresh medium and incubated at 37°C for 20 hours.
Transfected D10W cells were treated with or without PMA and cAMP for 9 
hours. In MAP kinase pathway studies, transfected cells were preincubated with 
MAP kinase inhibitor for 30 minutes before stimulation. Transfected HSB-2 cells 
were treated with PMA, cAMP and ionophore for 9 hours (25 ng/ml PMA, 1 mM 
cAMP and 1 mM ionophore). In the stimulation procedures, DMSO controls were 
carried out.
2.7.5. Luciferase assays
After 9 hours stimulation, the cells were harvested by centrifugation at 1500 
rpm for 5 minutes, washed twice in PBS and then lysed with three rounds of freeze- 
thaw lysis in liquid nitrogen in a lysis buffer containing 10 mM K2HP04, 1 mM 
EDTA and 0.2 mM DTT. The debris was removed by centrifugation at 3000 rpm for 
10 minutes. Protein concentrations of lysates were determined using the Bio-Rad
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protein assay according to the manufacturer's instructions. In the luciferase assays, 15 
pg of protein for D10W cell extracts or 30 pg of protein for HSB-2 cell extracts were 
dispensed into 96 well plates and mixed with 200 pi of assay buffer containing 100 
mM potassium phosphate buffer (combine four parts lOOmM K2HP04 with one part 
100 mM KH2P04), 8 mM MgS04, 2 mM DTT, 0.75 mM ATP and 0.175 mM co­
enzyme A. The reactions were initiated by adding 40 pi of 1 mM D-luciferin. The 
light signal was measured using TopCounter (Packard). The linearity of the assay was 
confirmed for high activity samples by measuring the activity of two-fold dilutions of 
the protein samples. The background of assay was very low and taken away from all 
values. Mean and standard deviation of at least three independent experiments are 
shown in the figures.
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Chapter 3 A Primary Role for AP-1, in Synergy with 
Etsl and GATA-3 in the Inducible Expression of the IL-5 
Gene in Mouse Th2 Lymphocytes
3.1. Introduction
Previous studies in this laboratory showed that the regulation of the mouse IL-5 
gene in the Th2 clone D10.G4.I was primarily at the level of transcription. Induction 
of IL-5 gene expression could be achieved by stimulation of the TCR, by ConA or by 
agents stimulating PKC and PKA (Naora et al., 1994b; Naora and Young, 1995). In 
each case there was an absolute requirement for protein synthesis (Naora and Young, 
1995). Subsequently, stable transfection studies with the IL-5 gene in a normal 
chromatin environment were carried out using CAT reporter genes. A reporter 
construct carrying 3859 bp of the upstream sequence of the mouse IL-5 gene was 
shown to have the same expression characteristics as the endogenous IL-5 gene 
(Bourke et al., 1995). It was found that a shorter construct (-1062mIL-5CAT) also 
showed the same expression properties (Naora et al., 1994a; Bourke et al., 1995). An 
analysis of the proximal promoter region of the mouse IL-5 gene revealed two major 
regions of transcription factor binding sites called mIL-5A (-60 to -40) and mIL-5B (- 
76 to -61) (Naora, 1993). Immediately upstream of the TATA box at positions -41 to 
-55 in the mIL-5A region is the CLEO site (conserved lymphokine element 0) 
(Miyatake et al., 1991). The CLEO element contains an AP-1 like binding site 
adjacent to a putative Ets/NFAT site. There is a putative GATA site within the mlL- 
5B region at -67 to -72. Site-directed mutagenesis showed that each of the three 
transcription factor binding sites was essential for IL-5 expression (Naora et al.,
57
Chapter 3 Mouse Interleukin-5 Gene Regulation
1994a; Tan, 1998; Young et al., 1999). In addition, it was shown that the proximal 
promoter region of the mouse IL-5 gene is responsible for its tissue-specific inducible 
expression in Th2 cells (Bourke et al., 1995; Tan, 1998; Young et al., 1999).
A number of studies on mouse IL-5 gene expression have been carried out in 
other laboratories using transient transfection (see Chapter 1). Although there is 
considerable disagreement in the findings, several studies have supported an 
important role for the CLEO element (Naora et al., 1994a; Lee et al., 1995; Bourke et 
al., 1995; Stranick et al., 1998) and for the adjacent GATA element ( Lee et al., 
1995, 1998; Siegel et al., 1995; Stranick et al., 1998; Zhang et al., 1997, 1998). The 
CLEO element carries an atypical AP-1 site adjacent to a site which could potentially 
involve a member of the Ets or NFAT families. Recently, Oct binding to the CLEO 
site has been demonstrated (Salerno et al., 2001). The Oct site is immediately 
upstream of and slightly overlapping with the AP-1 site. Although GATA-3 is the 
more likely transcription factor to be active at the GATA site due to its selective 
expression in Th2 cells, a selective role for GATA-4 has been reported for human IL- 
5 expression (Yamagata et al., 1995, 1997). One way of further investigating the 
transcription factors involved in IL-5 expression is transactivation studies using 
transient transfection of expression constructs.
The purpose of the work described in this Chapter was to establish a transient 
transfection assay utilizing the luciferase reporter gene system in the Th2 clone 
D10W to enable analysis of the functional role of the GATA, AP-1 and Ets/NFAT 
regulatory elements in the proximal promoter region and to further identify the 
transcription factors that may be involved in the regulation of the IL-5 gene by 
transactivation studies.
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3.1.1. GATA transcription factor
The GATA family of zinc finger transcription factors plays an important role in 
regulating cell lineage differentiation during vertebrate development. Six GATA 
family members have been identified in vertebrate species. These six proteins have 
been classified into two subfamilies based on common amino acid sequence identities 
and patterns of expression (Weiss and Orkin, 1995). Each GATA family member 
contains a conserved C-X2-C-X17-C-X2-C (type IV) zinc finger DNA-binding 
domain that recognizes a consensus sequence motif (WGATAR) located within 
transcriptional regulatory elements that control sets of lineage-specific genes (Ko and 
Engel, 1993; Merika and Orkin, 1993).
GATA-3 was initially cloned as a T-cell-specific transcription factor that bound 
to the Ta3 element of the TCRa gene enhancer (Ho et al., 1991). Deletion of the 
GATA-3 gene produces lethal abnormalities of the central nervous system and 
hematopoietic system (Pandolfi et al., 1995), whereas mice lacking GATA-3 in the 
lymphoid system do not generate T cells because GATA-3-deficient thymocytes 
arrest at the immature double-negative stage (Ting et al., 1996; Hendriks et al., 1999). 
A key discovery was the selective expression of GATA-3 in Th2 cells. Ectopic 
expression of a GATA-3 transgene led to increased levels of Th2 cytokines, whereas 
a dominant-negative GATA-3 transgene inhibited Th2 differentiation (Zheng and 
Flavell, 1997; Zhang et al., 1999). Several reports support a role for GATA-3 in the 
control of IL-5 gene expression through binding to and transactivation of elements in 
the region -70 to -59 of the IL-5 promoter (Siegel et al., 1995; Zhang et al. 1997, 
1998). GATA-3 probably does not directly bind to and transactivate the IL-4 
promoter (Zhang et al., 1997, 1998). Rather, several genomic regions within the IL-
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4/IL-13 locus have GATA-3-dependent enhancer activity (Ouyang et al., 1998) 
suggesting GATA-3 may augment expression of IL-4 or IL-13 via interactions at sites 
distant from the proximal promoter.
In addition to increasing expression of Th2-selective cytokines, GATA-3 
inhibits Thl development independently of IL-4, perhaps in part by inhibition of 
IL12Rß2 expression (Ouyang et al., 1998). Although GATA-3 is a Stat6-inducible 
gene, the developmental program initiated by GATA-3 can operate independently of 
Stat6 (Ouyang et al., 2000). When GATA-3 was expressed in Statö-deficient T cells, 
all components of Th2 development were observed, including induction of Th2 
cytokines, inhibition of Thl cytokines, induction of c-Maf, and the formation of 
DNase I hypersensitive sites in the IL-4 locus. The endogenous GATA-3 gene was 
observed to be induced in these cells, despite the addition of IL-12 to the culture, 
normally a signal that inhibits GATA-3 expression (Ouyang et al., 1998). These 
findings suggest that GATA-3 plays a key role in promoting Th2 differentiation and 
that GATA-3 expression is suppressed in developing Thl cells.
3.1.2. Ets transcription factor
The v-Ets oncogene was originally discovered as part of a fusion protein 
expressed by a transforming retrovirus, and later shown to be transduced from a 
cellular gene (Nunn et al., 1983). The v-Ets protein contains an 84 amino acid 
sequence, the" Ets domain" that has been found in proteins from species ranging from 
Drosophila to humans (Karim et al., 1990). Ets proteins have been implicated in the 
regulation of gene expression during a variety of biological processes, including
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growth control, transformation, T-cell activation and developmental programs in 
many organisms (Macleod and Plumb, 1991). The expanding family includes Etsl 
(Gegonne et al., 1987), Ets2 (Boulukos et al., 1988), Erg (Reddy et al., 1987) Elk-1 
and Elk-2 (Rao et al., 1989), Spi 1/PU.l (Klemsz et al., 1990) Fli-1 (Ben-David et al., 
1991), Elfi (Leiden et al., 1992), the Drosophila E74A and E74B proteins (Burtis et 
al., 1990) and the a-subunit of the GA-binding protein (GABP) (LaMarco et al., 
1991). The Ets family can be classified into subfamilies, based on sequence 
similarities in the Ets domain, the position of the Ets domain in the protein, and 
additional sequences found only in sub-families (Wasylyk et al., 1993). The Ets 
proteins have been found to bind specifically to an invariant core motif C/A GGA 
A/T in the middle of 10 bp of DNA (Wasylyk et al., 1993), suggesting that their 
specificity is conferred by sequences flanking the GGA core. Ets members can 
cooperate with other transcription factors. For example, Etsl can cooperate with c- 
Fos and c-Jun to increase the transcriptional activity of the polyoma virus enhancer 
(Wasyly et al., 1990). This enhancer is used in the MAP kinase studies presented in 
Chapter 5. Other potentially important interactions have been found between Ets-2 
and c-Fos/c-Jun (Basuyaux et al., 1997), Ets-1 and Pit-1 (Bradford et al., 1995), Elfi 
and AP-1 (Wasylyk et al., 1990; Gottschalk et al., 1993; Wang et al., 1994), Elfi and 
the retinoblastoma protein (Wang et al., 1993) and Elk-1 and the serum response 
factor (Hipskind et al., 1991).
Elfi is a lymphoid/myeloid-specific Ets family member which has a DNA 
binding domain that is nearly identical to that of E74, the ecdysone-inducible 
Drosophila transcription factor required for metamorphosis (Thompson et al., 1992). 
Elfi is involved in the positive regulation of several T-cell specific genes, including
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IL-2 (Thompson et al., 1992), IL2Ra (John et al., 1995, 1996), and GM-CSF (Wang 
et al., 1994). Elfi has also been found to be required for repression of the constitutive 
expression of the IL-2R.cc gene in non-activated T lymphocytes (Lecine et al., 1996).
3.1.3. NFAT transcription factor
Nuclear factor of activated T cells (NFAT) is a family of proteins related to the 
NF-kB family. Initially identified as a T cell-specific transcription factor that bound 
to the IL-2 promoter upon antigen stimulation, NFAT activity has now been 
demonstrated in a variety of cell types (Rao et al., 1997). The NFAT family contains 
at least four members: NFATp, NFATc, NFAT3 and NFAT4 (Hoey et al., 1995; 
Masuda et al., 1995). Each of these NFAT proteins contains a series of serine/proline- 
rich repeats at N terminus and a downstream Rel homology domain (RHD). The 
RHD is essential for DNA binding and dimerization with basic region/leucine zipper 
proteins such as the AP-1 family members Jun and Fos (Rooney et al., 1995). In 
resting T cells, NFAT proteins are present in the cytoplasm as phosphorylated forms. 
When T cells are activated, the level of the calcium-activated phosphatase calcineurin 
is elevated, which subsequently results in dephosphorylation of NFAT (Clipstone and 
Crabtree, 1992; Beals et al., 1997). The dephosphorylated NFAT is quickly 
translocated into the nucleus where, in synergy with AP-1, Maf, and NIP45 proteins, 
it transactivates a variety of cytokine genes and other activation genes including IL-2, 
IL-4, and GM-CSF (Cockerill et al., 1993; Rooney et al., 1995; Hodge et al., 1996). 
All NFAT members can bind to and transactivate the same set of NFAT sites derived 
from the IL-2 and IL-4 promoters, although NFATp and NFATc account for the 
majority of the binding activity (Rao et al., 1997; Timmerman et al., 1996). However,
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the expression pattern and tissue distribution of each of the NFAT proteins suggests 
that they subserve different functions. Three of the four NFAT members (NFATp, 
NFATc, and NFAT4) are expressed in lymphoid organs and NFATp and NFATc are 
constitutively expressed at low levels. Only NFATc is up-regulated upon stimulation 
through the T cell receptor (Hoey et al., 1995; Masuda et al., 1995). Additional 
evidence for distinct functions of NFAT proteins comes from the analysis of NFATp- 
and NFATc-deficient mice. NFATp-deficient mice have lymphoid hyperplasia with 
hyperproliferation and elevated levels of IL-4 and IgE. NFATc deficiency causes 
cardiac valvular defects and defects in IL-4-driven responses (Hodge et al., 1996; 
Xanthoudakis et al., 1996; Ranger et al., 1998).
3.1.4. AP-1 transcription factor
AP-1 transcription factors are immediate early response genes involved in a 
diverse set of transcriptional regulatory processes (Angel and Karin, 1991). The AP-1 
complex consists of a heterodimer of a Fos family member and a Jun family member. 
This complex binds the consensus DNA sequence (TGAGTCA) sites found in a 
variety of promoters (Ransone and Verma, 1990). The Fos family contains four 
proteins (c-Fos, FosB, Fra-1, and Fra-2) (Cohen and Curran, 1988; Zerial et al., 1989; 
Nishina et al., 1990), while the Jun family is composed of three members (c-Jun, 
JunB, and JunD) (Bohmann et al., 1987; Ryder et al., 1989). Fos and Jun are 
members of the bZIP (basic zipper) family of sequence-specific dimeric DNA- 
binding proteins (Baxevanis and Vinson, 1993), which have a DNA-binding domain 
consisting of a leucine zipper that is critical for the dimerization of the bZIP proteins 
(Landschulz et al., 1988) and a basic region that is critical for sequence-specific DNA
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binding (Shuman et al., 1990). Although Jun proteins form very stable heterodimers 
with Fos- and ATF-family members, they can also homodimerize among themselves 
(Ziff, 1990). Jun-Jun and Jun-Fos dimers preferentially bind to the TPA-responsive 
element (TRE; this element has the base sequence TGAG/CTCA), whereas Jun-ATF 
dimers or ATF homodimers prefer to bind to the cAMP-responsive element (CRE; 
this element has the base sequence TGACGTCA) (Hai and Curran, 1991). Both 
elements are palindromic and contain the same AP-1 half-site.
3.1.5. Reporter gene systems
Reporter genes provide easy and efficient methods for the indirect measurement 
of relative rates of transcription. Utilizing common DNA cloning methods, a putative 
regulatory region can be coupled to the coding sequence of a reporter gene such that 
expression of the reporter protein product varies according to the regulatory potential 
of the DNA tested. The assays for reporter enzymes have the advantage of high 
sensitivity with low background and, although an indirect measure, the amount of 
protein product is usually directly proportional to the level of transcriptional 
activation. The direct measurement of the level of specific mRNAs for endogenous 
genes can be influenced by RNA stability changes and assays for mRNA are also 
more labor-intensive and difficult to quantify.
The use of reporter systems allows the detailed mapping of specific enhancer 
and silencer regulatory elements in transcriptional control regions. The region of 
DNA containing the full potential for transcriptional activation can be sequentially 
deleted and tested in the reporter system to identify the types of elements present. 
Loss or enhanced activation of reporter activity is easily measured and indicates the
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position of active elements within the DNA. These individual elements can be further 
characterized by inserting one or multiple copies of the element immediately 
upstream of a heterologous basal promoter in the reporter construct. Weak 
constitutive promoters, such as the minimally active fragment of the Herpes Simplex 
Virus thymidine kinase promoter, are usually used for this purpose (Wegner et al., 
1994). An enhancer region, for example, should confer a stimulus-specific or cell- 
specific transcriptional response on the basal promoter with the DNA fragment 
inserted in either orientation. On the other hand, a silencer element would result in an 
inhibition of reporter expression when used with a strong promoter such as a viral 
promoter (Wegner et ah, 1994).
Reporter genes are again useful in the analysis of the transcription factors that 
bind to DNA at specific cis acting elements and control the function of these 
elements. Mutations can be made in specific regulatory elements within 
enhancer/promoter regions which prevent protein binding and the effect on reporter 
expression tested. In addition, transcription factors can be over-expressed or their 
expression inhibited with antisense methods to determine the role of individual 
factors in the activity of a specific element. Finally, reporter systems can provide a 
useful endpoint measurement for receptor structure-function studies and the 
delineation of components within signal transduction pathways.
Numerous reporter systems have been developed to accurately measure 
transcription rates. The two most commonly used systems are based on the 
chloramphenicol acetyltransferase (CAT) gene and the firefly luciferase gene 
(Gorman et ah, 1982). Although both assay systems can provide an accurate and 
linear quantitation of transcription rates, they differ in sensitivity, ease of
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performance, quantifiable range and the stability of proteins within the cells. The 
main advantages of the luciferase system are the nonisotopic assay of 
bioluminescence, the high degree of sensitivity, the absence of endogenous enzyme 
activity in eukaryotic cells, the wide linear range of quantitation and the ease and 
speed of assay. The production of advanced instrumentation such as luminometers 
that read 96 well plates allows an even more rapid and extensive collection of data.
In the present work, the luciferase reporter gene system was used to investigate 
the transcriptional regulation of the IL-5 gene. The pXPG luciferase reporter gene 
vector used in this study has been described in detail (Bert et al., 2000).
3.1.6. Stable versus transient transfection systems
In stable transfection, DNA is permanently integrated into the normal 
chromatin environment of the host cell. Exogenous DNA in a chromosomal 
environment is able to interact with the normal regulatory mechanisms of the cell, 
including DNA replication, nuclear matrix and nucleosomal spacing and positioning 
(Wolff, 1994). It is now clear that chromatin structure plays an important role in the 
regulation of gene expression. Since all cellular genes are packaged into ordered 
chromatin structures, an understanding of the mechanisms by which nucleoprotein 
structure influences transcriptional activation is necessary for a complete 
understanding of gene regulation in higher eukaryotes.
However, structural analysis of stably integrated gene promoters in mammalian 
cells requires the time-consuming generation of multiple stable cell lines or pools, in 
which the integrated genes could be subject to position effects from surrounding 
chromatin. Therefore, the identification and characterization of factors involved in
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gene expression have been addressed primarily through the use of transient 
transfection assays. In this approach, exogenous plasmid DNA, usually 
promoter/reporter constructs and transcription factor expression vectors, is introduced 
into cultured cells and expressed transiently, without replication or integration into
the cellular genome. These studies have resulted in an abundance of information
*
%
about promoter structure and function and have allowed the characterization of 
transcription factor interactions that are part of various cellular regulatory pathways.
The disadvantages of the transient transfection system are that the bacterial 
methylation pattern of the exogenous DNA and the artificial state of the DNA outside 
the normal chromatin environment of the cell may affect the transcription. The 
appropriate genomic enhancers and/or repressors also may not function normally 
outside of their usual chromatin environment. In addition, the large amounts of 
plasmid DNA entering the cell may interfere with the coordinated assembly of the 
transcription apparatus on a particular template by competitively displacing critical 
factors which may be in low abundance.
3.1.7. Transfer of DNA into cells by electroporation
A variety of transfection methods have been utilized to deliver DNA into cells. 
Four of the most commonly used transfection procedures are 1) calcium phosphate 
precipitation (Gorman et al., 1982), 2) DEAE-dextran-mediated transfection (Danna 
et al., 1982), electroporation (Toneguzzo et al., 1986), and 4) liposome-mediated 
transfer (Feigner et al., 1987). Among these methods, electroporation is the most 
widely used. In this method, an electrical pulse delivered by a capacitor is believed to
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transiently disturb membrane integrity creating pores through which the plasmid 
DNA enters the cell. Plasmid uptake has been assumed to occur by passive diffusion, 
although evidence has been obtained suggesting that DNA entry is a rapid 
electrophoretic event (Klenchin et al., 1991).
3.1.8. The eletrophoretic mobility shift assay (EMSA)
The gel mobility shift assay is a simple and sensitive method for determining 
interaction between proteins and DNA. This assay (Fried and Crothers, 1981; Gamer 
and Revzin, 1981) was developed for analysing protein-DNA interactions. In this 
assay, the DNA fragment or synthetic oligonucleotide containing potential 
transcription factor binding sites is radiolabelled. DNA binding proteins are incubated 
with the radiolabelled probes. The protein-DNA complexes are separated from free 
DNA by non-denaturing polyacrylamide gel electrophoresis. Unlike footprinting 
techniques, that rely on the loss of a signal to determine protein-DNA interactions 
(negative assay), the gel mobility shift assay yields a positive signal; the appearance 
of a DNA fragment with an altered mobility. An unexpected property of the gel assay 
is its ability to detect and physically separate alternative conformational states of 
complexes that rapidly equilibrate in solution. However, the gel shift assay does not 
give a direct readout of the DNA nucleotides that the protein is recognizing. For this 
type of information, a higher resolution technique such as DNase I footprinting or 
methylation interference is necessary. A combination of these assays can often be 
used with considerable advantage
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3.2. Results
3.2.1. Establishment of a transient transfection system in D10W cells.
A transient transfection system was established using D10W cells. Since 
electroporation is an efficient, highly reproducible technique, which is suitable for 
suspension cell lines like D10W, this technique was used for transfection. It was 
necessary to determine the electrical parameters for maximum electroporation 
efficiency. The principle of electroporation involves the use of a high voltage pulse 
which causes the temporary formation of pores in the cell and nuclear membranes, 
making them permeable to exogenous DNA. In general, the conditions for delivery of 
DNA into cells result in the death of about half the cells of the population, although 
the extent of cell death associated with maximum electroporation efficiency is 
variable among cell lines. A control plasmid expressing green fluorescent protein 
(GFP) was used to optimize electroporation conditions for D10W cells. The 
percentage of cells transfected at voltages ranging from 230-310 V with a capacitance 
of 975 pF was determined by FACS as described in Materials and Methods. As 
shown in Fig.3.2, at 270 V and 975 pF capacitance, about 50% of the cells were 
killed and 16% of the cells expressed GFP. Using these conditions, a luciferase 
reporter construct (-1170mIL-5Luc) carrying 1170 bases of the upstream region of 
the mouse IL-5 gene was transiently transfected into D10W cells. Subsequent 
stimulation of the cells with PMA and cAMP stimulus which had previously been 
shown to give optimal expression of the IL-5 gene in D10W cells (Bourke et al., 
1995; Tan, 1998; Young et al., 1999) gave significant induction of luciferase 
expression. A time course of expression of -1170mIL-5Luc was determined and it
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Fig. 3.2. Effect of electroporation voltage on D10W cells viability and 
transfection efficiency in single pulse electroporation. Five pg of GFP 
expression construct was transfected into DIOWcells using voltages between 
230-310 V. After 20 hours recovery , transfected cells were stained with PI. 
The number of the cells expressing GFP (a) and cell viabilities (b) were 
determined by FACS analysis (see Materials and Methods).
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was found that maximal induction of the IL-5 reporter construct was achieved after 9- 
12 hours stimulation (Fig.3.3).
3.2.2. Induction of the mouse IL-5 reporter gene by PMA and cAMP 
in D10W cells
Using optimal conditions for electroporation and stimulation, the -1170mIL- 
5Luc construct was transiently transfected into D10W cells. Transfected cells were 
treated with PMA, cAMP or both. PMA alone gave little stimulation whereas cAMP 
alone gave 10-fold induction. The combination of PMA and cAMP gave 36-fold 
induction (Fig.3.4). There was very low expression of the reporter construct in the 
absence of stimulation. The synergism observed between PMA and cAMP agreed 
well with previous findings using stable transfection assays in D10W cells and the 
degree of induction was sufficient to make this a good system for transactivation 
experiments.
3.2.3. Transactivation with expression constructs
Previous studies from this laboratory using stable transfection into the mouse 
Th2 clone D10W (a derivative of D10.G4.1) have indicated that the proximal 
promoter region to -88 controls the inducible expression of the mouse IL-5 gene in 
Th2 lymphocytes (Tan, 1998; Young et al., 1999). This region carries putative 
binding sites for Ets/NFAT (-41 to -47), AP-1 (-48 to -54) and GATA (-67 to -72) 
(Fig.3.1). It was previously shown by mutational studies that each of these sites is 
required for inducible expression of IL-5 reporter gene constructs stably incorporated 
into the genome.
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Fig. 3.3. Time course of mouse IL-5 luciferase reporter gene expression 
in D10W cells in response to PMA and cAMP stimulation. D10W cells were 
transiently transfected with the -1170mIL-5Luc construct. Transfected cells 
were treated with PMA and cAMP and luciferase activity was measured between 
0-24 hours (see Materials and Methods).
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Fig. 3.4 Expression of mouse IL-5 promoter in DlOW cells. The
-1170mIL-5Luc construct was transiently transfected into DlOW cells. 
After 20 hours recovery, transfected cells were stimulated with PMA 
or cAMP, and both PMA and cAMP for 9 hours and uciferase activity 
measured (see Materials and Methods). The results represent the 
average of at least three independent experiments
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Transactivation experiments in transient expression assays using expression 
constructs encoding relevant transcription factors were therefore carried out to 
identify those that could stimulate expression of the IL-5 gene. The most likely 
factors to be involved in binding to the respective sites were AP-1 (AP-1 site), Etsl, 
Elfi, NFATp or NFATc (Ets/NFAT site) and GATA-3 (GATA site). Since a role for 
GATA-4 in the expression of the human IL-5 gene has been reported (Yamagata et 
al., 1995,1997), GATA-4 was also tested. Expression constructs for these 
transcription factors were transiently cotransfected together with the -1170mIL-5Luc 
reporter construct into D10W cells and the transcriptional activity of the IL-5 
promoter was measured with and without stimulation.
As shown in Fig.3.5a, in the absence of stimulation, dramatic transactivation of 
approximately 400-fold over normal unstimulated levels of expression was achieved 
with an AP-1 expression construct. Smaller increases in expression of up to 4-fold 
were obtained with expression constructs for GATA-3 and GATA-4. There was no 
significant transactivation of the IL-5 promoter by Elfi. Etsl. NFATp and NFATc 
gave small increases of up to 2-fold (Fig.3.5a). The effect of stimulation by PMA, 
cAMP or both on the level of transactivation was also tested. In each case, PMA 
stimulation resulted only in a minor increase in transactivation. In contrast, cAMP 
was considerably more effective and strong synergistic stimulation was observed 
when PMA and cAMP were used together (Fig3.6a-d). In the transactivation 
experiments, responses to stimulation by PMA, cAMP or both agents were similar to 
the responses observed with the -1170mIL-5Luc plasmid alone (Fig.3.6a-d), although 
significantly higher values of IL-5 expression were obtained by transactivation. For 
AP-1, the values after transactivation and stimulation with PMA and cAMP were
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Fig. 3.5 Transactivation of expression of IL-5 promoter using expression 
constructs for relevant transcription factors. The -1170mIL-5Luc construct was 
cotransfected with various expression vectors for relevant transcription factors into 
D10W cells. Luciferase activity was measured after 9 hours (see Materials and 
Methods), (a) unstimulated; (b) stimulated with PMA and cAMP. The results 
represent the average of at least three independent experiments.
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250-fold higher than with -1170mIL-5Luc alone (Fig.3.5b). Transactivation by Elfi, 
NFATpand NFATc was also tested following stimulation with PMA and cAMP. 
Like Etsl, these transcription factors could also potentially bind at the putative 
Ets/NFAT site. Elfi and NFATpgave lower levels of transactivation than Etsl and 
NFATc(Fig.3.5b). In these experiments Etsl and NFATc gave similar levels of 
transactivation. However, the involvement of Etsl at the Ets/NFAT site is supported 
by its unique ability to synergize with AP-1 (see below).
In view of the high levels of transactivation of the -1170mIL-5Luc construct 
achieved with AP-1 (c-Fos/c-Jun), experiments were carried out to determine the 
level of transactivation by c-Fos and c-Jun alone. Expression constructs were 
transfected together with -1170mIL-5Luc into D10W cells and the cells stimulated 
with PMA and cAMP. Transactivation by c-Jun was much more effective than by c- 
Fos but transactivation by a combination of the two was by far the most effective 
(Fig.3.7a). The low level of transactivation by c-Fos is consistent with the inability of 
c-Fos to form transcriptionally active dimers. The moderate activity of c-Jun in 
comparison to AP-1 indicates that c-Jun homodimers are less active than c-Fos/c-Jun 
heterodimers in stimulating transcription from the IL-5 promoter.
3.2.4. Repression of the transcriptional activity of the IL-5 promoter 
by dominant negative AP-1
Since the transactivation experiments showed a very strong stimulation by AP- 
1, experiments were carried out to see if normal induction of IL-5 expression could be 
inhibited by dominant negative AP-1 expression constructs. Dominant negative c-Fos 
and c-Jun have been made by fusing an acidic amphipathic extension to the N-
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terminus of the c-Jun and c-Fos leucine zipper domains. The acidic extension of c-Jun 
and c-Fos interacts with the basic region of wild type c-Jun and c-Fos forming a 
coiled-coil extension of the leucine zipper and thus prevents the basic region of wild- 
type c-Jun and c-Fos binding to DNA (Olive et al., 1997)
To test for repression of IL-5 expression, dominant negative c-Fos and c-Jun 
expression plasmid constructs were cotransfected together with -1170mIL-5Luc into 
D10W cells and IL-5 expression induced with PMA and cAMP. Dose-dependent 
repression of the IL-5 promoter activity by a combination of dominant negative c-Fos 
and c-Jun was observed which was very significant at higher levels of transfected 
DNA (Fig.3.7b). The dominant negative c-Fos construct alone also significantly 
inhibited the transcriptional activity of the mouse IL-5 promoter consistent with the 
other evidence obtained of strong involvement of AP-1 in IL-5 gene expression 
(Fig.3.7c).
3.2.5. Etsl and AP-1 synergistically transactivate the IL-5 promoter
Since the Ets and AP-1 binding sites are adjacent in the proximal region of the 
mouse IL-5 promoter and Etsl and AP-1 have been reported to form a complex in T 
lymphocytes (Bassuk et al., 1995), it was of interest to determine if AP-1 could 
synergize with Etsl or any of the other transcription factors potentially able to bind to 
the Ets site. Therefore an expression construct for AP-1 was transiently cotransfected 
in combination with expression constructs for the other relevant transcription factors 
into D10W cells. Without stimulation, AP-1 and Etsl gave strong synergistic 
transactivation of the -1170mIL-5Luc reporter construct elevating expression levels 
to 10 times the additive stimulation of AP-1 and Etsl alone. None of the other
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transcription factors tested, including GATA-3 and GATA-4 synergized strongly with 
AP-1 (Fig.3.8). The demonstrated synergy between AP-1 and Etsl further supports 
the involvement of Etsl in regulating IL-5 expression at the Ets/NFAT site.
3.2.6. Mutation of the putative AP-1, Ets/NFAT and GATA binding 
sites in the proximal promoter region
To investigate whether the transcriptional activity of the IL-5 gene induced by 
PMA and cAMP in transient transfection assays was dependent on the three 
transcription factor binding sites in the proximal promoter region (Fig.3.1), individual 
mutations in the AP-1, Ets/NFAT and GATA sites were generated in the -1170mIL- 
5Luc construct. Transient transfection experiments showed that each mutation 
resulted in very little change in the basal level of expression. However, mutation of 
each of the three transcription factor binding sites resulted in almost complete 
abolition of IL-5 expression in response to PMA and cAMP treatment (Fig.3.9a) 
indicating that the AP-1, Ets/NFAT and GATA binding sites are all required for the 
promoter activity of the IL-5 gene in transient transfection assays. These findings are 
in complete agreement with the results obtained from stable transfection assays with 
the IL-5 gene in a chromatin environment (Tan, 1998; Young et al., 1999)
To determine if the transactivation of IL-5 expression by AP-1, Etsl and 
GATA-3 was also dependent on the AP-1, Ets/NFAT and GATA sites in the 
proximal promoter region, the transactivation experiments were therefore repeated 
using derivatives of the -1 170mIL-5Luc construct carrying mutations at the AP-1, 
Ets/NFAT or GATA sites (Fig.3.1). In each case, the transactivations observed with 
AP-1, Etsl or GATA-3 were reduced to 1% or less by mutation of the relevant
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transcription factor binding sites (Fig.3.9b). In addition, each transactivation was also 
reduced to a low level by mutating either of the other two binding sites. This indicates 
that the normal mechanism of gene induction is involved in the transactivations 
observed and gives further indication that each of the three binding sites is 
obligatorily required for expression of the IL-5 gene.
3.2.7. Transactivation experiments with the proximal promoter 
region
The proximal promoter region to -88 carries the AP-1, Ets/NFAT and GATA 
sites (Fig.3.1). Previous work in this laboratory has shown that this region is 
important in the induction of the promoter and in its tissue-specific expression in Th2 
lymphocytes (Tan, 1998; Young et al., 1999) However, the stably transfected 
proximal promoter construct shows differences in its induction and repression 
characteristics to the construct which carries the upstream region to -1170 (Tan, 1998; 
Young et al., 1999). For example, stably transfected -88mIL-5CAT is fully induced 
by cAMP alone and not repressible by dexamethasone (Tan, 1998; Young et al., 
1999). This indicates the involvement of one or more additional transcription factors 
binding further upstream in normal gene induction and repression. In addition, there 
have been a number of reports from other laboratories of the involvement of upstream 
regulatory element in mouse IL-5 expression. These include: mPREl-IL5 (-90/-79, 
Schwenger et al., 1998); IL-5P (-117/-92, Tsuruta et al., 1995), IL-5PRE (-2247-88, 
Stranick et al., 1995) and mPRE2- IL5 (-470/-459, Schwenger et al., 1998). Some 
negative elements have also been reported including: NRE-II (-300/-261, Stranick et 
al., 1995), NRE-I (-431/-392, Stranick et al., 1995) and CTF/NF1 (-940/-928, Bourke 
et al., 1995).
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Etsl. The -1170mIL-5Luc was cotransfected with the combinations of 
various expression plasmids into D10W cells. Luciferase activity was 
measured(see Materials and Methods). Results represent the average of 
at least three independent experiments.
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In the present work, a proximal promoter construct (-88mIL-5Luc) was used to 
determine whether the induction by PMA and cAMP stimulation and the 
transactivation observed with the -1170mIL-51uc construct were also observed with 
the -88mI15Luc construct and therefore not dependent on transcription factor binding 
sites further upstream.
The pattern of induction of -88mIL-5Luc reporter gene construct by stimulation 
with PMA, cAMP or both was very similar to that achieved with -1170mIL-5Luc 
construct (Fig.3.10). Dramatic transactivation by AP-1 (430-fold above unstimulated 
levels was also observed with the -88mIL-5Luc construct in the absence of 
stimulation (Fig.3.11a). Transactivation by the other expression constructs was much 
less, the strongest being with Etsl (3-fold). When the cells were stimulated with 
PMA and cAMP, AP-1 transactivation gave levels over 5000-fold above those with 
-88mIL5Luc alone (Fig.3.11b). Transactivation by the other expression constructs 
gave much less stimulation than that achieved with AP-1. Moderate synergy was 
observed between AP-1 and NFATp, NFATc (Fig.3.11c). The highest synergy was 
between AP-1 and Etsl (Fig.3.11c) although the level of synergy was much reduced 
compared with the -1170mIL-5Luc construct. It is clear from these results that the 
high levels of activation of the IL-5 gene achieved by transactivation with AP-1 are 
also seen with the -88mIL-5Luc construct.
3.2.8. Binding of recombinant AP-1 and Etsl to the IL-5 promoter
Recombinant AP-1 (c-Fos/c-Jun) and Etsl were expressed in E.coli together 
with an affinity tag (6 N-terminal histidine residues) and purified by affinity 
chromatography. Recombinant AP-1 protein was provided by D. Tremethick
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Fig. 3.10 Expression of proximal promoter of mouse IL-5 in D10W cells.
The-88mIL-5Luc construct was transiently transfected into DlOW cells. 
After 20 hours recovery, transfected cells were stimulated with PMA or 
cAMP, and both PMA and cAMP for 9 hours and luciferase activity was 
measured (see Materials and Methods). The results represent the average of 
at least three independent experiments.
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Fig. 3.11 Transactivation of the proximal promoter region of the mouse IL-5 
gene promoter. The -88mIL-5Luc construct was cotransfected with various indicated 
expression constructs into D10W cells and luciferase activity was measured (see 
Materials and Methods), (a) without stimulation; (b) cells stimulated with PMA and 
cAMP; (c) effect of AP-1 in combination with other transcription factors. The results 
represent the average of at least three independent experiments.
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(JCSMR) and recombinant Etsl was provided by I. Kola (Monash University). The 
EMSA showed that the recombinant AP-1 bound strongly to an oligonucleotide 
encompassing the AP-1 and Ets/NFAT sites of the promoter (Fig.3.12, lane 2). This 
binding was sequence-specific as it was competed away by an excess of the same 
unlabelled oligonucleotide (lane 10) but not by an unrelated oligonucleotide (lane 3). 
Also, mutation of the AP-1 site abolished binding of recombinant AP-1 (lane 6) but 
mutation of the Ets/NFAT site had no effect (lane 8). By contrast, the binding of 
recombinant Etsl to the oligonucleotide encompassing the AP-1 and Ets/NFAT sites 
was much weaker (lane 4) although still detectable. This binding was also shown to 
be sequence-specific using the same criteria used for AP-1 binding above. The 
recombinant Etsl was shown to bind strongly with a consensus oligonucleotide for 
Ets (lane 12) but not when the Ets/NFAT site was mutated (lane 13). Therefore the 
weak binding reflects a property of the Ets binding site of the IL-5 proximal promoter 
under the conditions used. Weak binding of Etsl to the analogous Ets/NFAT binding 
site of the proximal GM-CSF promoter has been observed previously (Thomas et al., 
1997). In the present work, AP-1 and Etsl were also added together but no evidence 
of the formation of an AP-1/Etsl complex was obtained (data not shown).
3.2.9. Effect of HMGI(Y) on IL-5 gene expression
The HMGI(Y) proteins, architectural transcription factors, can bind to the 
minor groove of A/T-rich DNA, and interact directly with several families of 
transcription factors including NF-kB, AP-1 and NFAT (Thanos et al., 1992; Bustin 
et al., 1996; Himes et al., 1996, 2000) There are several reports regarding the 
involvement of HMGI(Y) proteins in the regulation of cytokine gene expression,
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including expression of IFN-ß, IL-4, IL-2 and GM-CSF (Chuvpilo et al., 1993;
Himes et al., 1996; Klei-Hessling et al., 1996'^ie et al., 1997). The IL-5 proximal
Marrugo et al., 1996;
promoter region is rich in A/T base pairs and has some potential binding sites for 
HMGI(Y) with A/T sequences present within the GATA site and adjacent to the AP- 
1 and Ets/NFAT sites. To study if HMGI(Y) can play a role in the regulation of the 
IL-5 gene, transient transfection experiments were carried out. The mouse IL-5 
reporter gene construct was cotransfected with a plasmid expressing HMG I or a 
plasmid expressing antisense HMG I into D10W cells. The expression of antisense 
HMG I RNA slightly enhanced, in a dose dependent manner, IL-5 promoter activity 
in PMA/cAMP-treated D10W cells, (Fig.3.13). The antisense HMGI gave stronger 
effects on expression of the -88mIL-5Luc construct than on the -1170mIL-5Luc. 
Surprisingly, overexpression of HMG I protein also resulted in an increase in IL-5 
promoter activity in response to PMA/cAMP (Fig.3.13). To identify potential binding 
sites for HMG I in the IL-5 promoter region, EMSA and DNase footprinting 
experiments were performed in collaboration with M Bunce using recombinant HMG 
I protein. Two potential HMGI(Y) binding sites were found in the regions -76 to -88 
and -44 to -65 (M. Bunce, unpublished data ). The functional role of the site at -76 to 
-88 was then tested by mutation (Fig.3.14). A transfection experiment showed that 
the mutation of this potential HMGI(Y) binding site resulted in an increase of IL-5 
promoter activity in response to PMA/cAMP stimulation (Fig.3.14). This data 
supported the results of the antisense experiment. Clearly, further work is required to 
investigate the function of HMGI(Y) in this system but these results raise the 
interesting possibility that HMGI(Y) may function as a negative regulator of IL-5 
gene expression and as an architectural transcription factor for the proximal promoter 
region.
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3.3. Discussion
3.3.1. Establishment of a transient expression system for IL-5 in 
D10W cells
In the work described in this Chapter, an IL-5 luciferase reporter construct 
carrying 1170 bases of upstream sequence was prepared and used in transient 
transfection experiments with D10W cells. The D10W cell line is a subline of the Th2 
clone D10.G4.1 derived in this laboratory which grows without spleen cell 
stimulation. Careful optimization of the electroporation conditions using a GFP 
control plasmid enabled 36-fold induction of IL-5 reporter gene expression to be 
achieved using stimulation by PMA and cAMP. Previous attempts to establish such a 
transient expression system in this laboratory using the parent cell line D10.G4.1 and 
an analogous reporter construct employing the CAT reporter gene were not successful 
(Bourke et al., 1995). This was probably because D10.G4.1 is poorly transfectable 
compared to D10W, the CAT reporter gene has a lower sensitivity of detection than 
luciferase and PMA was used for stimulation rather than the much more effective 
combination of PMA/cAMP.
In transient transfection experiments, the -1170mIL-5Luc reporter gene 
construct was found to be slightly inducible by PMA, more so by cAMP, but strongly 
synergistically stimulated by PMA/cAMP (Fig.3.3). These results are closely similar 
to those obtained with stable transfection (Tan, 1998; Young et al., 1999). In contrast 
to stable transfection, the induction of -1170mIL-5Luc construct in transient 
transfection was found not to be repressed by dexamethasone (data not shown), 
suggesting a requirement for a normal chromatin structure for dexamethasone
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repression of IL-5 expression. When a reporter construct deleted to -88 bp was 
transiently transfected into D10W cells, strong induction of expression of the IL-5 
gene was also achieved (Fig.3.10) indicating that this region contains the critical 
regulatory elements involved in the induction of expression of the IL-5 gene. 
Interestingly, the reporter gene construct carrying -88 bp of IL-5 gene, unlike that 
carrying -1170 bp of IL-5 gene, is not repressed by dexamethasone when stably 
transfected into D10W cells (Tan, 1998; Young et al., 1999). Thus, although the 
proximal promoter region is sufficient for efficient induction of the IL-5 gene by 
PMA/cAMP, elements further upstream affect its repressibility by dexamethasone.
3.3.2. Transactivation of the IL-5 promoter
Transactivation by AP-1 (c-Fos/c-Jun) gave 400-fold stimulation of IL-5 
expression in the absence of stimulation (Fig.3.5a) suggesting that in the Th2 clone 
D10W, low endogenous levels of AP-1 limit IL-5 gene expression. This is the first 
demonstration that upregulaton of AP-1 is sufficient to induce the IL-5 promoter 
without stimulation. Further evidence for the normal involvement of AP-1 in IL-5 
gene regulation was provided by the strong inhibitory effect of a dominant negative 
AP-1 expression construct (Fig.3.7b and c). Elevation of AP-1 levels when Th2 
lymphocytes are stimulated may therefore be an important part of the process of IL-5 
gene induction and may explain why IL-5 transcription requires protein synthesis. 
There are two other reported cases where upregulation of AP-1 also appears to be 
involved in gene induction. The cAMP stimulation of dopamine ß-hydroxylase gene 
expression is mediated by AP-1 (c-Fos, c-Jun and JunD) with c-Fos transcription 
being up-regulated by cAMP (Swanson et al., 1998). Also, insulin activation of the
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AP-1 transcriptional complex is mediated by the ERK MAP kinase pathway and 
involves stimulation of expression of c-Fos, Fral and c-Jun (Griffiths et al., 1998)
A number of studies have detected elevation of AP-1 binding to the CLEO site 
of the mouse IL-5 promoter following gene induction (Naora et al., 1994a; Siegel et 
al., 1995; Karlen et al., 1996; Zhang et al., 1997; Tan, 1998; Young et al., 1999). The 
present results indicate the involvement of a Jun/Fos heterodimer at the AP-1 site in 
the IL-5 promoter and show that c-Jun and c-Fos have high functional activity in 
transactivation. Other laboratories have attempted to define the AP-1 family members 
binding to the AP-1 site using supershift EMSA experiments. It has been reported 
that the members of the AP-1 family binding to the IL-5 promoter included JunB, 
JunD, c-Jun and one or more members of the Fos family including c-Fos, FosB, Fral 
or Fra2 using EL-4 nuclear extracts (Siegel et al., 1995) and Karlen et al., (1996) 
showed binding of c-Fos and JunB using nuclear extracts of EL-4. Zhang et al., 
(1997) reported binding of JunB and JunD using nuclear extracts of D10.G4.1.
Transactivation by Etsl and GATA-3, the other two transcription factors likely 
to be involved in IL-5 regulation, was low by comparison with AP-1 but significant 
levels of transactivation were achieved after stimulation with PMA/cAMP. Although 
Etsl was more active than Elfi and NFATp in the transactivation experiments it was 
of comparable activity to NFATc. However, AP-1 synergized strongly with Etsl in 
the absence of stimulation. This synergy was not seen with Elfi, NFATc or NFATp 
which could also potentially bind to the Ets/NFAT site, suggesting an involvement of 
Etsl in normal IL-5 gene induction. Etsl has been shown to be involved in GM-CSF 
regulation, where it can cooperate with AP-1 and NF-kB to synergistically 
transactivate the GM-CSF promoter in Jurkat cells (Thomas et al., 1997). Ets proteins
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can physically associate with AP-1 in activated T cells (Bassuk and Leiden, 1995). 
This Ets and AP-1 interaction is mediated by the binding of the basic domain of Jun 
to the Ets domain of Ets proteins. Jun, in association with Ets, is capable of 
interacting with Fos family members to form a trimolecular protein complex. The 
physical association between Etsl and AP-1 protein is required for the transcriptional 
activity of enhancer elements containing adjacent Ets and AP-1 binding sites (Bassuk 
and Leiden, 1995). Several studies showed that functional interactions between AP-1 
and multiple Ets proteins and EMSA studies have demonstrated that complexes of Ets 
and AP-1 proteins bound to naturally occurring enhancer motifs (Wang et al., 1994; 
Gottschalk et al., 1993; Wasylyk et al., 1990; Bergelson and Daniel, 1994). Bassuk et 
al., (1995) demonstrated direct physical interaction between Ets and Jun proteins 
which helps to explain the molecular basis of the previously observed functional 
cooperativity between these two important families of transcription factors. 
Blumenthal et al., (1999) reported that both Etsl and Ets2 participate human IL-5 
gene regulation in Jurkat cells.
EMSA results showed that recombinant AP-l(c-Jun/c-Fos) strongly binds to the 
AP-1 site within the CLEO element of the IL-5 promoter. This binding was sequence- 
specific. The transactivation and EMSA results demonstrated the critical role of the 
AP-1 site and AP-l(c-Fos/c-Jun) transcription factor in the activation of the mouse 
IL-5 promoter. Specific binding of Etsl protein to Ets/NFAT site in the proximal 
region of IL-5 promoter was also demonstrated although this binding was very weak 
compared to that with a consensus oligonucleotide for Ets. Although the 
transactivation data showed strong synergy between AP-1 and Etsl, no evidence for 
an AP-1/Etsl complex was obtained in the in vitro binding experiments.
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GATA-4 was only slightly less active than GATA-3 in the transactivation 
experiments suggesting that it has the potential to function in IL-5 regulation. The 
GATA family of transcription factors (GATA-1 to GATA-6) bind to the WGATAR 
(W=A/T; R=A/G) sequence through a highly conserved C4 zinc finger domain 
(Laverriere et al, 1994). Based on their expression profile, the GATA proteins may be 
classified functionally as hemopoietic (GATA-1 to GATA-3) or non-hemopoietic 
(GATA-4 to GATA-6). GATA-3 is expressed primarily in T lymphocytes and in the 
embryonic brain and has shown to be important in the development of Th2 cells and 
the expression of Th2 cytokines (Zheng and Flavell 1997; Zhang et al., 1999). 
GATA-3 rather than GATA-4 is expressed by mouse Th2 lymphocytes and so would 
normally be involved in IL-5 expression in mouse T cells. In contrast to these 
findings, selectivity for GATA-4 has been reported for constitutive human IL-5 
expression by the ATL-16T cell line (Yamagata et al., 1997).
The individual GATA elements in the double GATA site in the mouse IL-5 
promoter are present in an inverse orientation with respect to each other and are 
located between -70 and -65 and between -65 and -60. The first sequence conforms 
with WGATAR consensus sequence and the present work shows it is essential for IL- 
5 expression in D10W cells. The second site has an intact GAT core but has a T 
instead of A in the +1 position. Overlapping GATA sites have also been previously 
identified in many erythroid-expressed genes such as the chicken a-globin promoter 
(Evans and Felsenfeld, 1991). Overlapping and /or multiple GATA sites appear to 
confer increased GATA binding activity and may play a key role in differential 
responsiveness to GATA-3 for different genes (Evans and Felsenfeld, 1991; Tsai et 
al., 1991). There are a number of reports supporting a role for the proximal GATA
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elements in mouse IL-5 promoter activity in Th2 cells (Zhang et al., 1997, 1998; Lee 
et al., 1995, 1998; Siegel et al., 1995; Stranick et al., 1998). Present studies provided 
further functional evidence, suggesting that the inverted GATA site is critical for IL-5 
activation and that GATA-3 is involved. Compared to AP-1, transactivation of the IL- 
5 promoter by GATA-3 was low in unstimulated D10W cells, suggesting that 
sufficient endogenous levels of GATA-3 are present in D10W cells to fully support 
IL-5 gene expression.
3.3.3. Role of the HMGI(Y) proteins in IL-5 promoter activity
HMGI(Y) proteins are small nonhistone nuclear proteins that bind the narrow 
minor groove of A:T sequence-rich B form DNA and modify gene transcription by 
bending the DNA and permitting the interaction of the various transcription factors 
with the transcriptional machinery (Bustin and Reeves, 1996). HMGI(Y) has been 
shown to play an important role in the transcription regulation of several cytokine 
genes including IL-2, GM-CSF, IFNß and IL-4 (Thanos et al., 1992; Chuvpilo et al., 
1993; Himes et al.,1996).
HMGI(Y) appears to have an important role in the activation of IFN-ß 
transcription by facilitating the assembly of the IFN-ß enhanceosome at several 
organizational levels. HMGI(Y) binds in vitro to four sites across the IFN-ß promoter 
and promotes the binding of NF-kB and ATF/c-Jun complexes to their binding 
elements (Thanos and Maniatis, 1992, 1995). Studies on IL-2 regulation indicated a 
strong involvement of HMGI(Y) in IL-2 activation. HMGI(Y) binds to many sites 
across the proximal promoter region of IL-2 (Himes et al., 1996). Functional studies 
using antisense expression for HMGI(Y) RNA showed that HMGI(Y) was a positive
84
Chapter 3 Mouse Interleukin-5 Gene Regulation
activator of the IL-2 promoter (Himes et al., 1996). Most of the HMGI(Y) binding 
sites are overlapping or close to known functional transcription factor sites. HMGI(Y) 
could affect the in vitro binding of many of the major transcription factor families 
that drive IL-2 transcription, including NFAT, NF-kB, and AP-1 ( Himes et al., 1996; 
Shang et al., 1999; Himes et al., 2000).
Studies on the role of HMGI(Y) in IL-4 gene expression and IL-4 signal 
transduction have shown the importance of phosphorylation in HMGI(Y) activity. 
There are several HMGI(Y) binding sites in the IL-4 promoter (Chuvpilo et al., 
1993). These sites are associated with functional binding sites for NFAT or 
NFAT/AP-1 complexes and Oct proteins (Chuvpilo et al., 1993). HMGI(Y) inhibits 
the binding of NFAT factors to specific regions of the IL-4 promoter (Klein-Hessiing 
et al., 1996). Not only can HMGI(Y) inhibit the binding of NFATp but if NFATp is 
in excess the opposite effect occurs, implying mutually exclusive binding of these 
two factors.
In the proximal promoter region up to -88 bp of the IL-5 promoter, there are a 
number of regions which could potentially bind HMGI(Y). Preliminary experiments 
have been carried out in collaboration with M. Bunce (JCSMR) and it has been 
shown that recombinant HMGI binds at two sites in the -88 region. In the work 
described in this Chapter, mutation of the site at (-88 to -77) resulted in an increase in 
IL-5 transcriptional activity in agreement with the results of antisense experiments 
(Fig.3.14). These results suggest that like the IL-4 promoter, HMGI(Y) may act as a 
repressor of IL-5 gene expression. However, these results do not agree with the effect 
of overexpression of HMGI which also resulted in increased IL-5 transcription 
(Fig.3.13) indicating a need to more experiments to clarify this issue.
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The absolute requirement for the GATA, AP-1 and Ets/NFAT sites for IL-5 
gene induction and the synergy demonstrated between AP-1 and Ets in the present 
work raises the possibility that mouse IL-5 expression may require the assembly of a 
three dimensional nucleoprotein complex (enhanceosome) analogous to that 
characterized for the IFN-ß gene. Such a complex would be likely to also involve 
architectural proteins like HMGI(Y) as well as co-activators. Verification of the 
possibility that the proximal promoter region of the IL-5 gene participates in 
enhanceosome formation requires further progress in the identification of the 
coactivators and architectural proteins involved and is an interesting challenge for 
future research.
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Chapter 4 Synergistic Transactivation of the Human 
Promoter by Transcription Factors AP-1, Etsl and 
GATA-3 in Human HSB-2 T cells
4.1. Introduction
The work described in Chapter 3, together with studies from other laboratories, 
have given a basic understanding of the regulation of the mouse IL-5 gene at least 
terms of the transcriptional factors and regulatory elements involved. The human IL-5 
promoter has in general been less well studied (Chapter 1), largely because of the lack 
of suitable models. Although it is likely that human IL-5 gene regulation will be 
similar to the regulation of the mouse IL-5 gene and several studies support this 
(Chapter 1), the importance of IL-5 in eosinophilic inflammation in asthma, allergic 
rhinitis, allergic-skin disorders (Rothenberg, 1998) and in gastro-intestinal allergies 
(Rothenberg et al., 2001) makes IL-5 gene regulation important clinically. Until 
recently, there was no suitable T cell line which showed inducible IL-5 gene 
expression. The PER-117 leukemia line (Kees et al., 1994) was recently shown to 
give inducible IL-5 expression (Mordvinov et al., 1999) but it has not been generally 
available. HSB-2, another T cell leukemia line, also potentially provides a model for 
the study of inducible IL-5 expression (Rolfe et al., 1997, Valentine et al., 1998) but a 
good transient expression system in this cell line has not previously been developed. 
IL-5 expression in HSB-2 cells is inducible with PMA and ionomycin and mRNA 
can be detected by PCR-based nuclear run-on asays (Rolfe et al., 1997). IL-5 
expression in these cells is also repressed by CsA and FK506 (Rolfe et al., 1997) and 
thus shows the basic characteristics of human IL-5 regulation in human T cells.
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In the work described in this chapter, a transient expression system for studying 
IL-5 gene regulation was established in HSB-2 cells. Transactivation assays were 
used to study the transcription factors and regulatory elements involved in IL-5 gene 
induction including synergistic effects. The findings were correlated with the 
analogous investigations into mouse IL-5 gene regulation described in Chapter 3.
4.2. Results
4.2.1. Expression of human IL-5 luciferase reporter gene in human 
HSB-2 T cells
In order to develop a sensitive transient reporter gene assay for IL-5 gene 
expression in HSB-2 cells, both transfection efficiency and cell stimulation were 
optimized and the sensitive luciferase reporter gene was used. A plasmid encoding 
GFP under the control of the CMV promoter was used to optimize transfection 
efficiency in HSB-2 cells. The GFP plasmid was transfected by electroporation into 
HSB-2 cells using voltages between 220-320 V and a capacitance of 975 pF. 
Transfected cells were stained with PI (10pg/ml) and analyzed by FACS to determine 
the number of cells expressing GFP and hence the optimum parameters for 
electroporation. As shown in Fig.4.1 the optimum conditions were achieved with 280 
V at 975 pF where 46 % of the cells were viable and 15 % of the cells expressed 
GFP.
The optimized electroporation conditions for HSB-2 were utilized to transfect 
the -1.2khIL5Luc reporter construct into the cells. This construct carries 1.2 kb of 
upstream sequence of the human IL-5 promoter linked to the luciferase reporter gene.
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Fig. 4.1 Effect of electroporation voltage on HSB-2 cell viability and 
transfection efficiency in single pulse electroporation. Five pg of GFP 
expression construct was transfected into HSB-2 cells using voltages 
between 220-320 V. After 20 hours recovery , transfected cells were stained 
with PI. The number of the cells expressing GFP and cell viabilities were 
determined by FACS analysis (seeMaterials and Methods).
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The transfected cells were stimulated with PMA, cAMP and calcium ionophore 
(A23187) individually and in combination. The -1.2khIL-5Luc construct was induced 
1.7 fold by PMA, 1.9 fold by cAMP and 1.2-fold by ionophore. Pairwise 
combinations of these agents gave up to 3-fold induction whereas PMA, cAMP and 
ionophore together induced expression of human IL-5 promoter 5.6-fold in HSB-2 
cells (Fig.4.2).
To determine the time course of induction of the -1.2khIL-5Luc construct in 
HSB-2 cells, the luciferase activity of the transfected cells was measured over 24 
hours. The peak of luciferase activity occurred between 9 and 12 hours (Fig.4.3).
4.2.2. The AP-1, Ets/NFAT and GATA binding sites are required for 
transcriptional activity of the human IL-5 promoter in 
response to PMA/cAMP/ionophore in HSB-2 cells
Sequence analysis of proximal human IL-5 promoter region showed the 
presence of adjacent putative AP-1 and Ets/NFAT sites (-42 to -56) analogous to the 
mouse CLEO binding element and an upstream GATA regulatory element. These 
three sites are highly conserved between the human and mouse IL-5 promoters 
(Fig.4a) and present in the proximal promoter region of human IL-5 gene (Fig.4b). To 
test whether transcriptional activity of the human IL-5 promoter in response to 
PMA/cAMP/ionophore stimulation in HSB-2 cells may depend on these three 
transcription factor binding sites as is the case with the mouse IL-5 promoter 
(Chapter 3), the respective binding sites were mutated, and the effects upon 
PMA/cAMP/ionophore-mediated IL-5 transcription measured. Mutation of each of 
the three sites resulted in little change in the basal level of expression but resulted in
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Fig. 4.2 Transcriptional activation of the human IL-5 promoter in 
HSB-2 cells in response to PMA, cAMP and calcium ionophore. The
HSB-2 cells were transfected with the -1.2khIL-5Luc construct. Transfected 
cells were stimulated with PMA, cAMP and ionophore individually or in 
combination and luciferase activity was measured (see Materials and 
Methods). The results represent the average of at least three independent 
experiments.
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Fig. 4.3 Time course of human IL-5 luciferase reporter gene expression 
in HSB-2 cells in response to PMA, cAMP and ionophore. HSB-2 cells 
were transiently transfected with the-1.2khIL-5Luc construct. Transfected 
cells were treated with PMA/cAMP/ionophore and luciferase activity was 
measured between 0-24 hours (see Materials and Methods).
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almost complete abolition of IL-5 expression in response to PMA/cAMP/ionophore 
treatment (Fig.4.4), indicating that the AP-1, Ets/NFAT and GATA binding sites are 
indispensable for induction of the human IL-5 gene in HSB-2 cells
4.2.3. AP-1, Etsl and GATA-3 transcription factors transactivate the 
IL-5 promoter in human HSB-2 T cells
To examine which transcription factors are involved in the transcription of IL-5 
gene, transactivation experiments were performed using expression plasmids 
encoding relevant transcription factors. The -1.2khIL-5Luc construct was 
cotransfected with various expression plasmids into HSB-2 cells to analyse the effect 
of overexpression of these factors on the transcriptional activity of the human IL-5 
promoter.
To test if AP-1, in the absence of stimulation, can transactivate the IL-5 
promoter in HSB-2 cells, an expression construct for AP-1 was cotransfected together 
with the -1.2khIL-5Luc reporter construct into HSB-2 cells. AP-1 expression resulted 
in an 85-fold increase in transcription of the IL-5 promoter in the absence of 
stimulation. The transcriptional activity was increased to 500-fold by stimulation with 
PM A, to 180-fold with cAMP and to 130-fold with ionophore. The combination of 
PM A, cAMP and ionophore increased the expression of IL-5 promoter to 1000-fold 
(Fig.4.5a).
Transfection with an Etsl expression plasmid resulted in a 15-fold increase in 
transcriptional activity of the IL-5 gene without stimulation (Fig.4.5b). To investigate 
the requirements for Etsl transactivation of IL-5, transiently transfected HSB-2 cells 
were stimulated with PMA, cAMP and ionophore individually or in combination.
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Fig. 4.4 Effects of mutation of the putative AP-1, Ets/NFAT and GATA sites 
of the human IL-5 promoter on its induction. HSB-2 cells were transfected 
with the indicated plasmids and then treated with PMA/cAMP/ionophore and 
luciferase activity was measured (see Materials and Methods). The results 
represent the average of at least three independent experiments.
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PMA treatment alone was able to enhance IL-5 transcription to 35-fold, stimulation 
with cAMP resulted in 20-fold induction, but ionophore reduced activation of the IL- 
5 promoter to 8-fold compared to Etsl transactivation alone. The combination of 
PMA, cAMP and ionophore gave the highest Etsl transactivation (136-fold) 
(Fig.4.5b).
Elfi is one of Ets family of transcription factors which has been shown to be 
involved in GM-CSF gene expression (Wang et al., 1995) and this transcription factor 
could potentially interact at the Ets/NFAT site in the IL-5 promoter. Transactivation 
experiments with Elfi only resulted in 2-fold induction of IL-5 promoter activity 
(Fig.4.5c). Stimulation with PMA, cAMP or ionophore individually had little effect 
on E lfi-mediated IL-5 transcription. However, when transfected cells were treated 
with PMA/cAMP/ionophore, the transcriptional activity of the IL-5 promoter was 
slightly increased (Fig.4.5c). Thus Etsl is considerably more active than Elfi in the 
transactivation of the human IL-5 promoter.
GATA-3 is expressed primarily in T lymphocytes and in the Th2 subclass of T 
helper cells. Functionally important GATA-3-binding sites have been identified in T 
cell receptor genes and the CD8 gene (Ho et al., 1991; Henderson et al., 1994 ). 
GATA-3 has been reported to be involved in Th2-specific expression of the mouse 
IL-5 gene (Zhang et al., 1997) and evidence for its involvement was also obtained in 
the present work (Chapter 3). To investigate the functional role of GATA-3 in human 
IL-5 expression. HSB-2 cells were cotransfected with the -1.2khIL-5Luc construct 
and a GATA-3 expression construct. GATA-3 was able to increase IL-5 promoter 
activity 100-fold in the absence of stimulation (Fig.4.6). When transfected cells were 
treated with PMA, cAMP or ionophore, 500-fold, 300-fold and 360-fold increases in
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Fig. 4.5 Transactivation of the human IL-5 promoter by relevant transcription 
factors. HSB-2 cells were cotransfected with the-1.2khIL-5Luc construct and 
expression vectors encoding different transcription factors. Transfected cells were 
stimulated as indicated in the figure and luciferase activity was measured (see 
Materials and Methods). P+C+I denotes PMA + cAMP + ionophore. (a)AP-l; 
(b) Etsl; (c) Elfi; (d) GATA-3; (e) GATA-4; (f) NFATc; (g) NFATp. The results 
represent the average of at least three independent experiments.
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expression respectively were achieved. Moreover, a 7000-fold increase over basal 
expression levels was obtained by stimulation with PMA/cAMP/ionophore 
(Fig.4.5d).
The selective involvement of GATA-4 in transcription of the human IL-5 gene 
in ATL-16T cells has been reported (Yamagata et al., 1997) although GATA-4 
involvement remains controversial since GATA-3 is the GATA family member 
normally expressed in T cells (Oosterwegel et al., 1992). The effect of GATA-4 on 
the transactivation of the human IL-5 promoter in HSB-2 cells was therefore tested. 
GATA-4 was able to transactivate the IL-5 promoter 80-fold in the absence of 
stimulation (Fig.4.6). PMA-treated cells gave 200-fold induction, while 100-fold 
stimulation was achieved with cAMP and 65-fold stimulation with ionophore. 4000- 
fold induction was obtained with a combination of PMA/cAMP/ionophore (Fig.4.5e). 
These results suggest that even though GATA-4 is not normally expressed in T cells, 
it can function as effectively as GATA-3 in regulating IL-5 expression.
NFAT has been shown to be important in the regulation of a number of 
cytokine genes, including GM-CSF, IL-4 and IL-2 (Rooney et al., 1995; Cockerill et 
al., 1995). Most NFAT binding sites in cytokine promoters are accompanied by 
neighbouring sites that bind other transcription factors such as members of the AP-1 
or its relatives. In the IL-5 promoter, NFAT could potentially be involved in binding 
to the putative Ets/NFAT site adjacent to AP-1 site in the CLEO element. It was 
therefore of interest to study if NFAT can transactivate the IL-5 promoter. Expression 
plasmids for NFATp or NFATc and the -1.2khIL5Luc reporter construct were 
cotransfected into HSB-2 cells. NFATc gave 5-fold transactivation of the IL-5 
promoter in the absence of stimulation (Fig4.6). Treatment with PMA, cAMP or
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Fig. 4.6 Comparison of the transactivation of the human IL-5 promoter 
using expression constructs for different transcription factors without 
stimulation. The-1.2khIL-5Luc construct was cotransfected with various 
expression constructs encoding relevant transcription factors into HSB-2 cells 
(see Materials and Methods).The results represent the average of at least three 
independent experiments.
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ionophore did not enhance the activity of the IL-5 promoter but the three agents in 
combination resulted in a synergistic stimulation of 24-fold (Fig.4.5f). 
Overexpression of NFATp led to 2.5-fold induction (Fig.4.6) and 15-fold induction in 
IL-5 promoter activity was observed when transfected cells were treated with 
PMA/cAMP/ionophore (Fig.4.5g). These results suggest that neither NFATp or 
NFATc is very active in the transactivation of the human IL-5 promoter compared to 
Etsl. It seems likely from the above results that Etsl is the transcription factor 
functioning at the putative Ets/NFAT site in the human IL-5 promoter.
4.2.4. AP-1, Etsl and GATA-3 synergistically transactivate the 
human IL-5 promoter in HSB-2 cells
Since the binding sites for Ets, AP-1 and GATA are relatively close together in 
the proximal region of IL-5 promoter with the Ets and AP-1 sites being adjacent and 
since AP-1, Etsl and GATA-3 individually gave strong transactivation of the IL-5 
promoter in HSB-2 cells, it was of interest to examine if these transcription factors 
can function cooperatively in stimulating IL-5 expression, Expression plasmids for 
AP-1, Etsl and GATA-3 were therefore transfected in different combinations 
together with the -1.2khIL-5Luc into HSB-2 cells. GATA-3 showed synergistic 
transactivation with Etsl (400-fold), with AP-1 (1000-fold) and with Etsl/AP-1 
(2500-fold) in the absence of stimulation (Fig.4.7). Similar synergistic interactions 
were shown between GATA-4 and Etsl and AP-1 (Fig.4.7).
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Fig. 4.7 Synergism between transcription factors in the transactivation 
of the human IL-5 promoter in HSB-2 cells. The -1.2khIL-5Luc construct was 
cotransfected with a combination of various indicated expression plasmids into 
HSB-2 cells and luciferase activity was measured (see Materials and Methods). 
The results represent the average of at least three independent experiments.
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4.2.5. Synergistic cooperation between AP-1, Etsl and GATA-3 is 
dramatically reduced by mutation of their binding sites.
In view of the high level of transactivation of the human IL-5 promoter 
achieved in the absence of stimulation, it was considered important to determine if 
the transactivation was dependent on the three transcription factor binding sites 
shown to be essential for normal inducible IL-5 gene expression (Fig.4.4). 
Transfection experiments were therefore carried out with -1.2khIL-5Luc constructs 
containing mutations of the individual transcription factor binding sites and the effect 
of AP-1, Etsl and GATA-3 transactivation determined in human HSB-2 cells. The 
transactivation activity of GATA-3 on human IL-5 expression was reduced from 100- 
fold to 9.5-fold by mutation of the GATA site. Similarly Etsl transactivation was 
dramatically decreased (14- to 3-fold) by mutation of the Ets site, and mutation of 
the AP-1 site abrogated the AP-1 transactivation from 85- to 5.6-fold (Fig.4.8). All of 
these results indicated that the transactivations observed were dependent on binding 
to the respective transcription factor binding sites in the proximal promoter region. 
Also, in each case, transactivation by each of the three transcription factors was 
dependent on the presence of intact binding sites for all three transcription factors 
(Fig.4.8) as is the case with normal gene induction (Fig.4.4). Similarly the synergistic 
transactivation of 2800-fold produced by overexpression of AP-1, Etsl and GATA-3 
together in unstimulated cells transfected with -1.2khIL-5Luc was completely 
abolished by the mutations in each of the transcription factor binding sites (Fig.4.9).
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Fig.4.8 Effect of mutation of the transcription factor binding elements in 
human IL-5 promoter on transactivation by AP-1, Etsl and GATA-3 in 
HSB-2 cells. The structures of the mutant human IL-5 promoter constructs are 
shown schematically. The mutant constructs were cotransfected with expression 
plasmids for AP-1, Etsl and GATA-3 into HSB-2 cells as indicated in the figure 
and luciferase activity was measured (see Materials and Methods). The results 
represent the average of at least three independent experiments.
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Fig. 4.9 Effect of mutation of the respective transcription factor binding 
sites on the synergistic transactivation of human IL-5 promoter by AP-1, 
Etsl and GATA-3. The HSB-2 cells were cotransfected with wild-type or 
indicated mutant -1.2khIL-5Luc constructs together with expression constructs for 
AP-1, Etsl and GATA-3 and luciferase activity was measured ( see Materials and 
Methods). The results represent the average of at least three independent 
experiments.
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4.2.6. Role of AP-1 in human IL-5 promoter activation in HSB-2 cells
Since AP-1 can significantly transactivate the human IL-5 promoter in HSB-2 
cells, one might expect that dominant negative AP-1 would reduce the normal 
induction of the human IL-5 promoter in response to PMA/cAMP/ionophore 
stimulation. The dominant negative AP-1 used in these experiments was made by 
fusing an acidic amphipathic extension to the N-terminus of the c-Jun and c-Fos 
leucine zipper domain (Olive et al., 1997). The acidic extension of c-Jun and c-Fos 
interacts with the basic region of c-Jun or c-Fos forming a coiled-coil extension of the 
leucine zipper and thus prevents the basic region of wild-type c-Jun and c-Fos 
binding to DNA.
Dominant negative AP-1 (DN-AP-1) expression plasmid constructs were 
cotransfected together with the -1.2khIL-5Luc reporter construct into HSB-2 cells. 
The transfected cells were treated with PMA/cAMP/ionophore. The repression of IL- 
5 promoter activity by DN-AP-1 was very significant, and it was also dose-dependent 
(Fig.4.10) confirming a role for AP-1 in normal human IL-5 gene induction.
4.3. Discussion
The regulation of IL-5 gene induction during T cell activation is a complex 
process that is controlled primarily at the level of transcription (Naora et ah, 1994b). 
To investigate the molecular mechanisms involved in the regulation of the human IL- 
5 gene in activated T cells, the proximal region of this promoter was examined in 
detail. There is a shortage of suitable human T cell lines which show normal 
inducible expression of the IL-5 gene. For example, human IL-5 gene transcription 
has been studied in the human Jurkat cell line which does not express IL-5
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Fig. 4.10 Effect of dominant negative AP-1 on human IL-5 promoter 
expression. HSB-2 cells were cotransfected with the -1.2khIL-5Luc 
construct and plasmids expressing dominant negative c-Fos and c-Jun. 
Transfected cells were treated with PMA/cAMP/ionophore and luciferase 
activity was measured (see Materials and Methods).The results represent 
the average of at least three independent experiments.
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(Blumenthal et al., 1999), mouse EL-4 cells (Gruart-Gouilleux et al., 1995) and the 
human T-cell leukemia cell line ATL-16T (Yamagata et al., 1997 ) which expresses 
IL-5 constitutively. The human HSB-2 T cell line shows inducible expression of IL-5 
(Rolfe et al., 1997). The expression characteristics of the IL-5 gene in HSB-2 cells are 
similar to those in normal T cells (Rolfe et al., 1997). These characteristics include 
the inducible expression of IL-5 by PMA/ionophore stimulation and repression of IL- 
5 expression by CsA and FK506 (Rolfe et al., 1997), but detailed transcriptional 
studies with this cell line have not been possible because of the lack of a sensitive 
transient expression assay for IL-5 reporter constructs. In this study the sensitive 
luciferase reporter gene was used to establish a transient transfection system in the 
human HSB-2 cell line. This system provides a new model for studying human IL-5 
gene regulation and has allowed detailed transactivation and mutational studies to be 
carried out in the present work.
It is surprising that the flanking regions of the human and mouse genes share 
such limited homology. The region -80 to -20 is highly conserved (Fig.4a), but 
upstream and 3' regions give little indication of common elements that might be 
involved in the specific regulation of the gene. The conserved proximal region of IL- 
5 promoter contains potential binding sites for a number of transcription factors 
particularly AP-1, GATA and Ets/NFAT (Mizuta et al., 1988; Campbell et al., 1988; 
Zhang et al., 1997). The AP-1 and Ets/NFAT-binding sites together constitute an 
element called the consensus lymphokine element zero (CLEO) found in several 
cytokine genes including IL-3, IL-4, IL-5, and GM-CSF (Arai et al., 1990; Nimer, et 
al., 1990). This element plays a critical role in the regulation of the GM-CSF gene
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(Miyatake et al., 1991; Nimer, et al., 1988; Wang et al., 1994 ). The CLEO element 
also has a binding site for Oct (Thomas et al., 1999).
4.3.1. Activation of the human IL-5 gene in response to stimulation
The human IL-5 luciferase reporter gene was inducibly expressed 6-fold by 
stimulation with PMA/cAMP/ionophore in HSB-2 cells. The activation of the IL-5 
promoter by PMA/cAMP was synergistically enhanced by ionophore, suggesting that 
expression of human IL-5 depends not only on PKA and PKC activation but also on 
an increase of intracellular Ca2+ in HSB-2 T cells. In D10W cells, IL-5 gene 
expression can be efficiently induced by PMA and cAMP alone (Chapter 3), 
indicating that slightly different signaling pathways are linked in induction of IL-5 
gene expression in the two cell lines. Site-directed mutagenesis studies showed that 
inducible expression of the human IL-5 gene can be severely impaired by mutation of 
the binding sites for AP-1, Ets/NFAT and GATA in the proximal region of human 
IL-5 promoter, indicating that these binding sites are indispensible for IL-5 gene 
activation in HSB-2 cells as is the case for the mouse IL-5 promoter in D10W cells. It 
appears therefore that the core enhancers in the mouse and human IL-5 promoters are 
very similar.
4.3.2. Involvement of transcription factors in human IL-5 gene 
activation
Although the mutational studies showed that activation of human IL-5 gene 
expression in HSB-2 T cells required the AP-1, Ets/NFAT and GATA sites, 
transactivation studies were necessary to determine the transcription factors that
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functioned at these sites. The -1.2khIL-5Luc construct is only induced 6-fold by 
PMA/cAMP/ionophore in HSB-2 cells but dramatic transactivations were achieved 
with expression constructs. AP-1, GATA-3 and Etsl could transactivate the human 
IL-5 promoter 80-fold, 100-fold and 15-fold respectively, in the absence of 
stimulation. Thus in HSB-2 cells, the amount of AP-1 and GATA-3 in particular 
appear to be limiting the expression of the IL-5 promoter. The differences in the 
signaling pathways linked to IL-5 promoter induction in HSB-2 cells as compared to 
mouse D10W cells were also evident in the transactivation studies. In D10W cells, 
PMA was a very weak inducer relative to cAMP and the combination of PMA/'cAMP 
enhanced IL-5 transactivation 2-10 times the levels achieved with cAMP alone. In 
contrast, in HSB-2 cells, PMA was 2-3 fold more effective as a stimulus than cAMP 
or ionophore alone. The combination of PMA/cAMP/ionophore increased 
transactivation 2-20 times that achieved with PMA. Despite the apparent differences 
in the pathways leading to gene activation, the transcription factors involved and the 
absolute dependence on the AP-1, Ets/NFAT and GAT A sites were the same in the 
mouse and human systems. The transactivation data with the human IL-5 promoter 
strongly supported the findings with the mouse IL-5 promoter (Chapter 3) but was 
sufficiently different to give added verification of some aspects. For example, the 
evidence for the involvement of Etsl in mouse IL-5 gene expression largely rested on 
the unique ability of Etsl compared with Elfi, NFATp and NFATc to synergize with 
AP-1. In the human IL-5 promoter, Etsl was much more active in transactivation 
than the other three factors potentially able to interact at the Ets/NFAT site. In 
addition, GATA-3 transactivation was very high with the human IL-5 promoter and 
strong evidence of cooperativity between GATA-3 and AP-1 and Etsl was obtained 
in the transactivation studies. These results provide further support for the suggestion
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(Chapter 3) that a higher order enhanceosome type complex may be involved in IL-5 
gene regulation.
Although as discussed above some previous studies have not supported the 
involvement of the CLEO element and adjacent GATA site in the proximal promoter 
region in human IL-5 expression, there is strong support for their role in expression 
of the mouse IL-5 gene (see Chapter 1). Given the strong conservation of the IL-5 
proximal promoter region between human and mouse, it seems unlikely that the 
human IL-5 promoter would not be similarly regulated to the mouse promoter. The 
present work indicates that induction of the human IL-5 gene in HSB-2 cells involves 
cooperation between GATA-3, AP-1 and Etsl binding in the proximal promoter 
region in an analogous way to induction of mouse IL-5 gene expression in the Th2 
clone D10W. Support for a role for the GATA and CLEO elements in human IL-5 
gene expression has been provided by Yamagata et al., (1995, 1997). Thomas et al., 
(1999) also showed a role for CLEO in the course of their studies on Oct involvement 
at the CLEO site. A role for Oct was not examined in the present studies but it is 
possible that Oct cooperates with GATA-3, AP-1 and Etsl in human IL-5 gene 
induction and further investigation of the role of Oct factors would be an interesting 
topic for future research.
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Chapter 5 Role of Mitogen-activated Protein Kinase 
Signaling Pathways in the Regulation of Interleukin-5
Gene Expression
5.1. Introduction
Signal transduction via mitogen-activated protein (MAP) kinases plays a key 
role in a variety of cellular responses, including growth factor-induced proliferation, 
differentiation and cell death. Recently, several parallel MAP kinase signal 
transduction pathways have been defined in mammalian cells (Whitmarsh and Davis, 
1996; Ip and Davis, 1998). These pathways include the extracellular signal related 
kinase (ERK) (Boulton et al., 1990, 1991), c-Jun N-terminal kinases (JNK, also 
known as SAPK) (Kyriakis, 1994), and p38 MAP kinase (Han et al., 1994; Lee et al., 
1994b; Rouse et al., 1994). These MAP kinases are activated by phosphorylation on 
Thr and Tyr by dual-specificity MAP kinase kinases (Raingeaud et al., 1995). The 
MAP kinase groups are functionally independent and are implicated in different 
biological processes (Whitmarsh and Davis, 1996; Ip and Davis, 1998).
5.1.1. Cellular biology of MAP kinase pathway
The ERK is associated with proliferation and growth factors, while JNK and 
p38 are induced by stress responses and cytokines and can mediate differentiation and 
cell death. Several studies have described the participation of JNK and p38 MAP 
kinase in inflammation (Ip and Davis, 1998). It is likely that these kinases can also 
regulate the immune response. Three JNK genes have been identified in mammalian 
cells: JNK1, JNK2 and JNK3 (Ip and Davis, 1998). In addition, several isoforms
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generated by alternative splicing of transcripts derived from these genes have been 
identified in humans (Gupta et al., 1996). JNK1 and JNK2 are widely expressed in 
several tissues, whereas JNK3 is selectively expressed in brain, testis and heart. The 
p38 MAP kinase gene was cloned following the purification of a 38 kDa protein that 
was phosphorylated on tyrosine in response to hyperosmolarity and endotoxic 
lipopolysaccharide. Human p38 MAP kinase homologues were identified as the 
targets of pyridinyl imidazole compounds, which inhibit the production of pro- 
inflammatory cytokines (IL-1, TNF-a) in stimulated macrophages (Han et al., 1994; 
Lee et al., 1994b; Rouse et al., 1994).
MAPKs are activated by other kinases functioning in a kinase cascade. Both 
JNK and p38 MAP kinase are activated by phosphorylation on threonine and tyrosine 
residues within the kinase subdomain VIII by dual-specificity MAP kinase kinases 
(MKK). The p38 MAP kinase is a selective target for pyridinyl imidazole drugs (Lee 
et al., 1994b). These drugs appear to act by inhibiting p38 MAP kinase activity 
through competition with ATP at the ATP-binding pocket (Tong et al., 1997; Wilson 
et al., 1997; Young et al., 1997). These compounds are candidate drugs for the 
treatment of arthritis, bone resorption and endotoxin shock (Griswold et al., 1988; 
Badger et al., 1996).
Two MAPK kinases, MKK4 and MKK7, have been found to be the primary 
activators of JNK (Derijard et al., 1995; Toumier et al., 1997). The p38 MAP kinase 
is activated by MKK3, MKK4 and MKK6 (Stein et al., 1996; Derijard et al., 1995; 
Han et al., 1996; Raingeaud et al., 1996;). The direct upstream kinase of ERK is 
MEK, which is regulated via phosphorylation by Raf (Daum et al., 1994 ). One of the 
JNK kinase activators (Fänger et al., 1997) is the mixed lineage kinase 3 (MLK3)
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also known as the SH3 domain-containing proline-rich kinase (SPRK) (Rana et ah, 
1996).
JNK and p38 differ from ERK in that they are predominantly regulated by 
cellular stress inducers and proinflammatory cytokines (Kyriakis et ah, 1994; 
Raingeaud et ah, 1995). JNK is activated by SEK (SEK, also know as MKK4) as well 
as by the recently identified kinase MKK7 (Fänger et ah, 1997). The activation of 
JNK is further controlled by a putative scaffold protein, JNK-interacting protein 1 
(JIP-1), which binds to JNK and several other components of the JNK pathway 
(Whitmarsh et ah, 1998). Overexpression of JIP-1 or the JNK-binding domain of JIP- 
1 leads to the cytoplasmic retention of JNK and the inhibition of JNK-dependent gene 
expression (Dickens et ah, 1997) MAPK kinase 6 (MKK6) functions as an activating 
kinase for all known p38 isoforms (Han et ah, 1996; Raingeaud et al, 1996; Enslen et 
al, 1998).
5.1.2. MAP kinase signal transduction during T cell activation
MAP kinase pathways play a critical role in the activation of T cells during the 
immune response. Several studies have shown the involvement of the ERK pathway 
in the positive selection of T cells in the thymus and in T-cell activation (Alberola-Ila 
et ah, 1995; Swan et ah, 1995). It has also been reported that JNK is activated during 
T-cell activation, where this molecule appears to play a role in integrating signals 
initiated at the TCR complex and the co-stimulatory molecule CD28 (Rincon and 
Flavell, 1994; Su et ah, 1994). TCR ligation or TPA treatment is sufficient to 
maximally induce ERK activity, JNK and p38 activation requires a costimulatory 
signal such as CD28 ligand binding or ionomycin cotreatment, respectively (Dickens
102
Chapter 5 MAP Kinase Pathways in IL-5 Expression
et al., 1997; Su et al., 1994; Hoffmeyer et al., 1998). More recently, it has been shown 
that IL-2 and IL-7 activate both JNK and p38 kinases (Crawley et al., 1997).
A commonly used approach to determine the involvement of MAP kinase 
pathways is the use of inhibitors. Selective inhibitors of two of the MAP kinase 
pathways are available. PD98059 inhibits MEK1 and MEK2 activation with an IC50 
of 5-10 pM and 50 pM respectively (Egerton et al., 1998) and is thus an inhibitor of 
the ERK pathway. SB203580 inhibits p38 MAP kinase (IC50, 0.6pM). It is active on 
the p38a and ß isoforms but not p38y and 8 (Hale et al., 1999). This is a potential 
difficulty for T cell studies as both the a  and 8 isoforms have been reported to be 
highly expressed in T cells (Jiang et al., 1997). Other approaches are the use of 
dominant negative expression constructs but in general these are often not highly 
effective (Hoffmeyer et al., 1999; Egerton et al., 1998). More effective have been 
positive activation constructs to induce individual MAP kinase pathway (Hoffmeyer 
et al., 1999).
The role of the three MAP kinase pathways in cytokine production by T cells 
has received comparatively little attention. In relation to the induction of IL-5 
expression, stimulation mediated by the MAP kinase pathway could be achieved by 
phosphorylation of one or more of the relevant transcription factors within their 
activation domains or via the increased expression of one or more of the transcription 
factors or coactivators. For example, the basal levels of AP-1 proteins in T cells are 
generally low and T cell activation results in induction of Jun and Fos. JNK is 
believed to phosphorylate newly synthesized c-Jun and p38 MAP kinase can induce 
c-Fos and c-Jun levels (Karin, 1995)
103
Chapter 5 MAP Kinase Pathways in IL-5 Expression
SB203580 has been used to show a role for p38 MAP kinase in IL-5 expression 
in human T cells (Mori et al., 1999) and in the mouse T cell clone D10.G4.1 (Chen et 
al., 2000). Involvement of the ERK pathway in IL-5 expression in mouse T cells was 
demonstrated using PD98059 (Egerton et al., 1998). However, the relative 
importance of the MAP kinase pathways and their effectiveness in stimulating IL-5 
expression in the absence of other stimuli has not yet been tested. This was 
investigated in the present work using activated expression constructs
5.2. Results
5.2.1. Activation of MAP kinase pathways in D10W cells
A transient transfection system was previously established to study the 
inducible activation of the mouse IL-5 gene in D10W cells (Chapter 3). Efficient 
induction of the -1170mIL-5Luc reporter gene was achieved by stimulation with 
PMA/cAMP. In the present work, this system was used to investigate the role of the 
ERK, JNK and p38 MAP kinase pathways in the induction of IL-5 transcription. 
Three expression plasmids previously shown to specifically stimulate the individual 
MAP kinase pathways were used for this study: (1) a constitutively active kinase 
mutant of Raf (Raf-BXB-CX) which serves as a specific ERK activator (Hoffmeyer 
et al., 1998); (2) MLK3, which when overexpressed results in a strong activation of 
JNK without affecting ERK and p38 MAP kinase activities; and (3) an activated 
mutant of MKK6 (MKK6E) which serves as a specific activator of p38 (Hoffmeyer et 
al., 1998). A p4 x AP-l/Ets promoter construct, which carries four copies of a 
combined AP-l/Ets binding from the polyoma virus enhancer in front of a luciferase 
gene, was used as a control. This enhancer element has previously been shown to be
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responesive to constitutively active Raf in NIH3T3 cells (Bruder et al., 1992). It is 
also induced by MLK3 and MKK6E in the human T cell line A3.01 (Hoffmeyer et 
al., 1999). The results of the present work show that the transfection of Raf-BXB-CX 
also had a significant stimulatory effect on the transcriptional activity of the p4 x AP- 
1/Ets promoter in D10W cells. However, MLK3 induced the expression of this 
reporter construct to a lesser extent and MKK6E alone showed no significant effect 
on the promoter activity in D10W cells (Fig.5.1). The promoter activity induced by 
Raf or MLK3 in D10W cells was concentration-dependent (Fig.5.1). Combining Raf- 
BXB-CX with either MKK6E or MLK3 did not synergistically enhance the promoter 
activity (data not shown). However, the combination of Raf-BXB-CX, MKK6E and 
MLK3 resulted in over 30-fold induction of the p4 x AP-l/Ets construct which is 
double that achieved with Raf activation alone (Fig.5.2). Thus the p4 x AP-l/Ets 
promoter was a good indicator of ERK activation and therefore could be used to test 
the efficacy of the inhibitor PD98059 in D10W cells. A previous study using mouse 
T cells showed that a concentration of 100 pM PD98059 was required for near 
complete inhibition of the ERK pathway (Egerton et al., 1998). Therefore, the effect 
of concentrations of PD98059 of up to 120 pM were tested on Raf-stimulated p4 x 
AP-l/Ets expression. Surprisingly, there was no effect unless 20 pM SB203580 was 
also included (data not shown). The stimulation by Raf/MLK3/MKK6E was also 
significantly decreased by the same combination of PD98059/SB203580 (Fig.5.2).
5.2.2. Ability of MAP kinase pathways to induce IL-5 gene 
expression in D10W cells
The effect of activation of the MAP kinase pathways on IL-5 gene expression 
in D10W cells was then investigated. The -1170mIL-5Luc construct was
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Fig. 5.1 Effect of the MAP kinase pathway activators Raf-BXB-CX, MLK3 
and MKK6E on the induction of the p4 x AP-l/Ets promoter construct in 
D10W cells. The p4 x AP-l/Ets promoter construct was cotransfected alone with 
o r5o r l0pgo f  Raf-BXB-CX, MLK3, or MKK6E expression plasmids into 
D10W cells. At 20 hour posttransfection, cells were harvested, and luciferase 
activity was measured (see Materials and Methods). The results represent the 
average of at least three independent experiments.
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Fig. 5.2 Effect of MAP kinase inhibitors on the activation of the 
p4 x AP-l/Ets promoter construct in D10W cells. The p4 x AP-l/Ets 
promoter construct was cotransfected alone or with 5 pg of Raf-BXB-CX, 
MLK3 and MKK6E expression plasmids into D10W cells. Cells were 
left untreated (-) or treated with PMA/cAMP and PD98059 (120pM)/ 
SB203580 (20pM) (PD/SB) as indicated. Luciferase activity was 
measured (see Materials and Methods). The results represent the average 
of at least three independent experiments.
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cotransfected with each of the MAP-kinase-stimulating expression constructs into 
D10W cells. As shown in Fig.5.3, expression of activated Raf gave up to 13-fold 
induction of IL-5 promoter activity in a dose-dependent manner. MLK3 gave up to 3- 
fold induction but MKK6E had smaller effect. The stimulation of all three kinase 
pathways together approximately doubled induction compared to stimulation by Raf 
alone (Fig.5.4). These results suggest that the activation of mouse IL-5 gene in D10W 
cells can be effectively induced by activation of the MEK/ERK pathway and to a 
lesser extent by stimulating the JNK pathway. Activation of the p38 MAP kinase 
pathway gave very slight induction of IL-5 expression. The results with the - 
1170mIL-5Luc construct were very similar to the effects on expression of the p4 x 
AP-l/Ets promoter suggesting that the stimulatory effects of the MAP kinase 
pathways may be exerted via the AP-l/Ets region of the IL-5 promoter.
It was of interest to see if PD98059, a specific inhibitor of the MEK/ERK 
pathway, could block the Raf-mediated stimulation of IL-5 transcription. In 
agreement with the results obtained with the p4 x AP-l/Ets promoter, Raf-induced 
IL-5 activity was not inhibited by PD98059 alone even at relatively high 
concentrations (120 pM) (Fig.5.5). However, Raf/MLK3/MKK6E-induced 
transcriptional activity of the IL-5 gene was significantly reduced by the combination 
of PD98059/SB203580 in D10W cells (Fig. 5.4).
The effects of PD98059 and SB203580 on induction of the IL-5 promoter in 
response to PMA/cAMP were also tested. The -1170mIL-5Luc reporter gene 
construct was transfected into D10W cells and the cells stimulated with PMA/cAMP 
in the presence and absence of PD98059 or SB203580. As shown in Fig.5.6, 
transcriptional activity of mouse IL-5 promoter was strongly induced in D10W cells
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Fig. 5.3 Effect of expression of Raf-BXB-CX, MLK3, and MKK6E 
on the induction of the -1170mIL5Luc reporter construct in D10W cells.
The-1170mIL5Luc construct was transfected alone or with 5 or 10pg of 
Raf-BXB-CX, MLK3 or MKK6E expression plasmids into D10W cells. 
At 20 hour posttransfection, cells were harvested and luciferase activity 
was measured (see Materials and Methods). The results represent the 
average of at least three independent experiments.
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Fig. 5.4 Effect of expression of Raf-BXB-CX, MLK3 and MKK6E 
on the induction of the -1170mIL5Luc reporter construct in D10W cells.
The -1170mIL5Luc construct was transfected alone or in combination with 
5 pg of Raf-BXB-CX, MLK3, or MKK6E expression plasmids into D10W 
cells as indicated. Where inhibitors were used, cells were treated with 120 
pM PD98059 (PD) and 20 pM SB203580 (SB) immediately after 
transfection. Luciferase activity was measured (see Materials and Methods). 
The results represent the average of at least three independent experiments.
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following PMA/cAMP stimulation. Neither PD98059 nor SB203580 alone was able 
to block PMA/cAMP-induced IL-5 activity in D10W cells. However, in keeping with 
the above results, when relatively high concentrations of PD98059 and SB203580 
were added together, a significant inhibitory effect was observed (Fig.5.6).
5.2.3. Enhanced activation of IL-5 transcription by each MAP kinase 
pathway in response to PMA and cAMP stimulation.
Since PMA/cAMP is a strong inducer of IL-5 gene expression, it was of interest 
to test the effects of PMA and cAMP in combination with stimulation of the ERK, 
JNK and p38 pathways on the induction of the IL-5 promoter. As shown in Fig.5.7, 
when transfected cells were treated with PMA and cAMP, very strong induction of 
the IL-5 promoter by Raf, MLK3 and MKK6E was observed. The highest stimulation 
was achieved with MKK6E (over 1300-fold). These results indicate that the MAP 
kinase pathways are being effectively stimulated by the expression constructs used 
and that stimulation of each MAP kinase pathway gives considerable stimulation of 
IL-5 expression. These high levels of stimulation require activation by PMA/cAMP 
and are very much greater than the stimulation obtained when all three MAP kinase 
pathways are stimulated together (Fig.5.6). This suggests that PMA/cAMP 
stimulation must activate an additional pathway or pathways important for IL-5 
expression.
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Fig. 5.5 Effect of different concentrations of PD98059 on the activation of 
the -1170mIL5Luc reporter construct induced by Raf in D10W cells. The
-1170mIL5Luc construct was transfected alone or with 5 pg of the Raf-BXB-CX 
expression plasmid into D10W cells. Transfected cells were treated immediately 
after transfection with different amounts ofPD98059 as indicated. Cells were 
harvested and luciferase activity was measured (see Materials and Methods). The 
results represent the average of at least three independent experiments.
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Fig. 5.5 Effect of different concentrations of PD98059 on the activation of 
the -1170mIL5Luc reporter construct induced by Raf in D10W cells. The
-1170mIL5Luc construct was transfected alone or with 5 fig of the Raf-BXB-CX 
expression plasmid into D10W cells. Transfected cells were treated immediately 
after transfection with different amounts ofPD98059as indicated. Cells were 
harvested and luciferase activity was measured (see Materials and Methods). The 
results represent the average of at least three independent experiments.
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Fig. 5.7 Effect of expression of Raf-BXB-CX, MLK3 and MKK6E on 
induction of the -1170mIL5Luc reporter construct in response to PMA/cAMP 
in D10W cells. The-1170mIL5Luc construct was cotransfected with 5 fag of 
Raf-BXB-CX, MLK3, or MKK6E expression plasmids into D10W cells. At 20 
hours posttransfection, cells were treated with PMA/cAMP for 9 hours. Luciferase 
activity was measured (see Materials and Methods). The results represent the 
average of at least three independent experiments.
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5.2.4. Role of the putative transcription factor binding sites in MAP 
kinase-mediated IL-5 activity
In the work described in Chapter 3, it was shown that the AP-1, Ets and GATA 
elements in the proximal promoter region were essential for IL-5 expression. To 
determine whether the stimulation of IL-5 expression mediated by activation of the 
MAP kinase pathways was dependent on these binding sites, wild-type and mutant - 
1170mIL-5Luc constructs were transfected together with expression vectors for Raf- 
BXB-CX, MLK3 or MKK6E into D10W cells. Mutation of each of the three 
transcription factor binding sites greatly reduced the induction of IL-5 expression
mediated by each MAP kinase pathway (Fig.5.8).
1
5.2.5. Effect of MAP kinases on distal and proximal IL-5 promoter 
activity in D10W cells
To study whether the effect of each MAP kinase pathway on IL-5 activation in 
response to PMA/cAMP treatment also requires upstream promoter elements, the 
proximal promoter construct -88mIL-5Luc was compared with -1170mIL-5Luc. 
These constructs were transfected together with expression constructs for Raf, MLK3 
or MKK6E into D10W cells. The transfected cells were treated with or without 
PMA/cAMP. The results showed that the -88mIL-5Luc reporter gene construct was 
also strongly stimulated by each expression construct in response to PMA/cAMP 
stimulation (Fig.5.9). It is therefore reasonable to conclude that the major effects of 
the MAP kinase pathways involve the proximal promoter region to -88 and that there 
is no obligatory involvement of elements further upstream.
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Fig.5.8 Effect of Mutation of the transcription factor binding sites on 
Raf-, MLK3- or MKK6E-mediated IL-5 transcription activity in D10W 
cells. The structures of the mutant mouse IL-5 promoter constructs are shown 
schematically. The indicated mutant constructs were cotransfected with 
expression plasmids for Raf-BXB-CX, MLK3 and MKK6E into D10W cells. 
Luciferase activity was measured (see Materials and Methods). Results represent 
the average of three independent experiments.
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
it
2200
■  -88mIL-5Luc 
□  -1 170mIL-5Luc
1650 -
1100 -
550 -
PMA/cAMP
Raf MLK3 MKK6E
Fig. 5.9 A reporter construct carrying only the proximal promoter region 
of the IL-5 gene shows strong stimulation by expression of Raf-BXB-CX, 
MLK3, or MKK6E in response to PMA/cAMP stimulation in D10W cells.
The indicated promoter constructs were cotransfected with either Raf-BXB-CX, 
MLK3, or MKK6E expression plasmids into D10W cells. At 20 hours 
posttransfection, cells were either left untreated (-) or treated (+) with 
PMA/cAMP. Luciferase activity was measured (see Materials and Methods). 
The results represent the average of at least three independent experiments.
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5.3. Discussion
In this Chapter, the involvement of MAP kinase pathways in IL-5 promoter 
activation in D10W cells was studied. Three expression constructs were used to 
specifically activate the ERK, JNK or p38 MAP kinase pathways. A reporter system 
(p4 x AP-l/Ets) shown in a human T cell line to be responsive to activation of each of 
the MAP kinase pathways was used as a control. This reporter had the additional 
advantage of being closely related to the IL-5 promoter which also carries an essential 
AP-l/Ets site. Raf-BXB-CX, a constitutively active kinase mutant, which lacks the 
N-terminal negative regulatory domain and contains the C-terminal membrane 
targeting 17 amino acids of Ki-Ras fused to the kinase domain of c-Raf (Hoffmeyer 
et al., 1998) was used to activate the ERK pathway. Overexpression of MLK3 was 
used to activate JNK without affecting ERK and p38 activities. MKK6E which is a 
constitutively active mutant of MKK6 with two serines involved in the activation of 
the kinase replaced by glutamic acid (Raingeaud et al., 1996) was used to activate 
p38. The expression constructs used have been verified by others as specific 
activators of ERK, JNK, and p38 (Hoffmeyer et al., 1998, 1999). Recent inhibitor 
studies have indicated involvement of the ERK and p38 MAP kinase pathway in IL-5 
expression (Egerton et al., 1998; Mori et al., 1999; Chen et al., 2000). The present 
work has shown for the first time that activation of the ERK pathway, in the absence 
of other stimulation, is sufficient to induce IL-5 transcription (Fig.5.3). The activation 
of JNK also induced IL-5 expression but to a lesser extent. The effects of the - 
1170mIL-5Luc construct were closely similar to the induction of the p4X AP-l/Ets 
promoter (Fig.5.1) which was used as a control. This suggests that the stimulatory 
effects of the MAP kinase pathways are being mediated via the AP-l/Ets element in
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the IL-5 promoter. This could involve elevation of AP-1 levels as the studies 
described in Chapter 3 demonstrated that overexpression of AP-1 is sufficient to 
induce IL-5 transcription and/or activation of AP-1 and Etsl by phosphorylation, c- 
Jun is known to be phosphorylated by JNK (Karin, 1995) and Etsl can be 
phosphorylated by ERK (Rabault et al., 1996). Ras is know to activate Etsl and Ets2 
and to induce transcription through AP-l/Ets composite element (Wasylyk et al., 
1997; Patton et al., 1998).
The ability of each of the three MAP kinases to strongly stimulate IL-5 
expression was shown when transfected cells were treated with PMA/cAMP. The 
Raf-induced IL-5 activation was increased over 1000-fold with PMA/cAMP 
stimulation and overproduction of MLK3 and MKK6E in cells stimulated with 
PMA/cAMP resulted in 800-fold and 1300-fold induction of the IL-5 activity over 
basal levels. The impressive stimulation by the MAP kinases were dependent on the 
GATA, AP-1 and Ets sites in the proximal promoter region and did not require the 
upstream promoter region of the IL-5 gene. The results with IL-5 are somewhat 
similar to the role of MAP kinases in T cell expression of TNFa (Hoffmeyer et al.,
1999) where activation of each pathway is sufficient to induce expression and it 
appears that the three MAP kinase pathways cooperate to induce TNFa expression 
(Hoffmeyer et al., 1999). In the case of IL-5 expressionin D10W cells such 
cooperation could also occur. A role for MEK and p38 in IL-5 expression are 
supported by other studies (Egerton et al., 1998; Mori et al., 1999; Chen et al., 2000). 
cAMP can stimulated activation of p38 kinase in D10.G4.1 which can result in 
increased phosphorylation of GATA-3 and increased expression of IL-5 (Chen et al.,
2000) . Currently, there is no additional evidence supporting a role for JNK in IL-5
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expression although its well studied role in AP-1 activation (Karin, 1995) makes its 
involvement likely. It is clear from the present work, however, that activation of the 
three MAP kinase pathways alone is not sufficient to achieve optimal transcription of 
IL-5. PMA/cAMP stimulation provides an important additional signal or signals.
The MAP kinase inhibitor results in these studies were unexpected. PD98059 
would normally be expected to inhibit ERK activation on its own without the 
requirement for SB203580. One possible explanation could be that SB203580 has 
been shown to be a specific inhibitor of p38 MAP kinase only at low concentrations 
and to additionally inhibit the ERK pathway at the concentration used in this work 
(20 pM). Perhaps both PD98059 and SB203580 are required to effectively inhibit 
ERK in D10W cells. There was not sufficient time to investigate this further by direct 
measurements of MAP kinase inhibition.
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6.1. Discussion
The present work has concentrated on functional studies of the transcription 
factors involved in binding to the proximal region of the IL-5 promoter and in 
inducing gene expression. This aspect has not received much attention in previous 
studies. In particular, it has been unclear whether Ets or NFAT family members 
function together with AP-1 at the CLEO site. Transient transfection systems have 
been established in mouse and human cell lines which are good models for IL-5 
expression in normal T lymphocytes. D10W cells are a closer model of mouse Th2 
iymphocytes than the widely used mouse thymoma EL-4 and HSB-2 cells provide a 
generally available system for human IL-5 expression studies.
The importance of the proximal promoter region for IL-5 gene induction was 
supported by previous studies in this laboratory of the mouse IL-5 gene in a normal 
chromatin environment (Bourke et al., 1995; Tan, 1998; Young et al., 1999). The 
results indicate that the proximal promoter region to -88 is responsible for Th2- 
specific expression and gene induction (Tan, 1998; Young et ah, 1999). However, 
there appears to be elements further upstream which are also important in IL-5 
expression such as in the repression by dexamethasone (Tan, 1998; Young et ah, 
1999). For this reason, in the present work, the -1170mIL-5Luc and -1.2khIL-5Luc 
reporter constructs were used which carry approximately 1200 bp of upstream 
sequence and, where required, mutations were made in elements in the proximal 
promoter region of these constructs. An obligatory role for the GATA, AP-1 and 
Ets/NFAT sites in the proximal IL-5 promoter in human and mouse was
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demonstrated. Comparison with a construct truncated to -88 allowed verification that 
there was no obligatory involvement of upstream elements in mouse IL-5 gene 
induction and transactivation.
The mouse and human transactivation studies provide complementary data that 
supports an obligatory role of the proximal AP-1, Ets/NFAT and GATA sites in 
promoter induction and indicate cooperative interactions between AP-1 (c-Fos/c-Jun), 
Etsl and GATA-3. Very high levels of transactivation and synergism were achieved 
in some cases in these studies but mutation of the GATA, AP-1 and Ets/NFAT sites 
showed that these sites played a critical role in the transactivations observed.
The signaling pathways linked to IL-5 gene induction were somewhat different 
in D10W and HSB-2 cells. In D10W, PMA alone was a very weak inducer of IL-5 
expression in comparison to cAMP but the two agents strongly synergized in gene 
induction. In HSB-2 cells, PMA alone was more effective than cAMP or Ca2+ 
ionophore as an inducer but the three stimuli synergized to give the most effective IL- 
5 induction. In both cells, elevation of AP-1 levels using expression constructs for c- 
Fos and c-Jun resulted in strong induction of IL-5 expression in the absence of 
stimulation. DNA binding studies have shown that AP-1 binding to the CLEO 
element of the mouse IL-5 promoter is strongly induced by stimulation (Siegel et al., 
1995; Karlen et al., 1996; Zhang et al., 1997; Tan, 1998; Young et al., 1999) and the 
transactivation results suggest that elevation of AP-1 levels is important in normal IL- 
5 gene induction. Gene activation involving upregulation of AP-1 has also been 
reported in other cases. Stimulation of expression of AP-1 accompanies the activation 
of the AP-1 transcriptional complex by insulin (Griffiths et al., 1998) and the cAMP
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response of the dopamine-ß hydroxylase gene is mediated via AP-1 (Swanson et al., 
1998).
In HSB-2 cells, elevation of GATA-3 levels also resulted in strong IL-5 gene 
induction without stimulation. Thus in HSB-2 cells, in contrast to D10W cells, the 
levels of GATA-3 in unstimulated cells appear to limit IL-5 expression. GATA-3 
levels may be elevated to some extent by stimulation as part of the IL-5 induction 
process. On the other hand, low GATA-3 levels may explain why the IL-5 gene is 
less effectively induced in HSB-2 than in D10W. Comparison of the effectiveness of 
GATA-3 and GATA-4 in both mouse and human IL-5 induction showed that they 
were of comparable activity. Since GATA-3 is normally expressed in T cells, it 
would be involved in IL-5 expression in normal T lymphocytes.
The transactivation studies also showed strong cooperative effects between AP- 
1, Etsl and GATA-3. In D10W cells there was strong synergy between Etsl and AP- 
1 and in HSB-2 strong synergistic effects were seen between all three factors. This 
suggests that the three factors may be part of a higher order complex analogous to the 
enhanceosome of the IFN-ß promoter (Yie et al., 1997). The preliminary indication of 
binding sites and a role for HMGI(Y) in the proximal mouse IL-5 promoter suggest 
that this architectural transcription factor could be also be involved. No indications 
are yet available as to possible coactivators involved in IL-5 gene expression.
The unique ability of Etsl to synergize with AP-1 in D10W cells and with AP-1 
and GATA-3 in HSB-2 cells provides evidence that this factor, rather than Elfi, 
NFATc or NFATp, functions at the Ets/NFAT site in the CLEO element. 
Recombinant Etsl bound to this site but only weakly in EMSA experiments
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(Fig.3.12). It is possible that in vivo other proteins in the postulated higher order 
complex promote Etsl binding. A recent study showed that the proteins involved in 
formation of the constitutive complexes with the CLEO element in EL-4 cells belong 
to the octamer transcription factor family and this finding was confirmed in primary 
mouse T cells (Salerno et al., 2001). The functional activity of octamer factors 
binding to the mouse IL-5 CLEO element was supported by ectopic expression of 
Octl and Oct2 with a mouse IL-5 reporter gene construct. Both octamer factors had 
small positive effects on mouse IL-5 reporter gene activity with Octl having the 
greatest impact (Salerno et al., 2001). Oct2 binding to a region between -94 to -64 in 
the IL-2 promoter has been shown to have a positive effect on the expression of this 
gene. The close association between Oct2 and AP-1 in this segment of the gene was 
crucial for the optimal induction of IL-2 promoter in T cells (Kamp et ah, 1990; 
Pfeuffer et ah, 1994). The association between Octl, Oct2, AP-1 and NFAT proteins 
in IL-4 promoter region has also been shown to be essential for the overall activity of 
this promoter in T cells (Li-Weber et al., 1998). The octamer transcription factors 
have also been reported to bind to the human IL-5 CLEO element (Thomas et ah, 
1999). It would be of interest to establish if Octl or Oct2 could cooperate with AP-1, 
Etsl or GATA-3 in the transient transfection systems described in this work.
The MAP kinase studies described in Chapter 5 support the possibility that the 
three MAP kinase pathways cooperate in IL-5 gene induction. Activation of the ERK 
pathway and to a lesser extent the JNK pathway was sufficient to induce IL-5 
expression without stimulation. This activation appeared to be mediated via the CLEO 
element as an analogous p4 x AP-l/Ets enhancer construct was similarly induced. 
Simultaneous activation of all three MAP kinase pathways did not give maximal IL-5
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expression in the absence of stimulation. However, when D10W cells were stimulated 
with PMA/cAMP, activation of each MAP kinase pathway resulted in very high 
expression levels indicating that activation of another singaling pathway (or 
pathways), in addition to the MAP kinase pathways, is required for optimal IL-5 
expression. The impressive MAP kinase stimulations were also observed with a 
construct truncated to -88 and were dependent on the proximal GATA, AP-1 and 
Ets/NFAT sites indicating that they were mediated through the proximal promoter 
region.
Overall, the work described in this thesis supports the concept that the proximal 
promoter region of the mouse and human IL-5 genes is the major element regulating 
inducible gene expression. Th2 specificity appears to be largely due to the essential 
involvement of GATA-3, a Th2-specific transcription factor (Zhang et al., 1997, 
1998, 1999; Zheng and Flavell, 1997) but obligatory involvement of AP-1 and Etsl is 
also required. The three MAP kinase pathways may cooperate in gene induction via 
the proximal promoter elements in stimulated cells. ERK activation alone is sufficient 
to induce gene expression via the AP-l/Ets site. Upregulation of AP-1 is an important 
part of normal gene induction and is sufficient to induce the IL-5 gene. Activation of 
the three transcription factors by phosphorylation is probably also involved. The 
impressive synergistic interactions between AP-1, Etsl and GATA-3 suggest a higher 
order complex possibly involving HMGI(Y) and one or more coactivators whose 
activity could be modulated by regulatory elements elsewhere in the IL-5 gene.
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